ORGANOMETALLIC CHEMISTRY OF GOLD, PALLADIUM AND IRIDIUM COMPLEXES BEARING N-HETEROCYCLIC AND/OR ACYCLIC DIAMINO CARBENES by HARESH S/O SIVARAM
 ORGANOMETALLIC CHEMISTRY OF GOLD, PALLADIUM, 
AND IRIDIUM COMPLEXES BEARING N-HETEROCYCLIC 








HARESH S/O SIVARAM 








A THESIS SUBMITTED FOR THE DEGREE OF 
MASTER OF SCIENCE 
DEPARTMENT OF CHEMISTRY 





My two-year M. Sc. journey has undoubtedly been a very challenging one. However, 
it has also been a fulfilling and enriching experience. I am extremely grateful for all the 
support rendered to me by various people, and I wish to acknowledge their efforts. 
I would like to first and foremost thank my family for their undying support 
throughout the course of my education. Thank you to my mother, for showing me that if you 
put your heart and mind to something, you can and will achieve it. And to my father, for 
reminding me that no one in this world owes you a living, and if you want to get anywhere in 
life, it has to be by your own sheer hard work. I am also immensely grateful to my sister, for 
having been one of my greatest sources of inspiration. 
I am also indebted to my supervisor, A/P Huynh Han Vinh. He has taught me a 
tremendous amount of Chemistry, and many life lessons. His perspectives on scientific 
research and teaching are immensely refreshing and thought provoking. He has challenged me 
each day to extend the limits of my own capabilities, and in doing so has made me a much 
better person. 
I am thankful for my past and present lab-mates – Dr Han Yuan, Dr Yuan Dan, Teng 
Qiaoqiao, Jan Christopher Bernhammer, Guo Shuai, and Jackie Tan – for all their help, and 
the many discussions on my work. The many light-hearted moments we shared greatly 
reduced the stress of lab work. I would like to particularly thank Jan and Jackie, for their 
assistance in the computational and cytotoxicity studies, respectively. 
I definitely owe a great deal to my friends, for all their encouragement. I am especially 
grateful to my best friend and brother, Zhang Jinfeng. He has constantly motivated me, and at 
the same time helped me to get my mind off work whenever I needed a break. 
A big thank you to Prof Koh Lip Lin (X-ray Diffraction Lab), Ms Tan Geok Kheng 
(X-ray Diffraction Lab), Ms Hong Yimian (X-ray Diffraction Lab), Madam Han Yanhui 
(NMR Spectroscopy Lab), and all other technical and support staff at the NUS Department of 
Chemistry’s CMMAC for their invaluable assistance. 
And finally, I would like to express my heartfelt gratitude to the Ministry of Education 
(Singapore), for having sponsored my graduate studies at NUS through the MOE Masters 
Sponsorship. 
 
Table of Contents 
 
Summary .................................................................................................................................... I 
Compounds Synthesized in this Work .................................................................................. III 
List of Tables ............................................................................................................................ V 
List of Schemes ....................................................................................................................... VI 
List of Figures ....................................................................................................................... VII 
List of Abbreviations .............................................................................................................. IX 
1. Introduction ....................................................................................................................... 1 
1.1. Definition and nature of carbenes ................................................................................. 1 
1.2. N-heterocyclic carbenes: synthesis and properties ....................................................... 3 
1.3. Determination of the donor strength of carbenes ......................................................... 6 
1.4. Preparation and applications of transition metal carbene complexes ........................... 9 
2. Gold Complexes Bearing a Non-classical Pyrazole-derived NHC Ligand, and their 
Cytotoxic Activities ................................................................................................................. 14 
2.1. Ligand precursor and donor strength of the FPyr ligand ............................................ 14 
2.1.1. Synthesis and characterization of ligand precursor ............................................. 14 
2.1.2. Determination of the donor strength of the FPyr ligand ...................................... 15 
2.2. Syntheses and characterizations of gold(I) NHC complexes ..................................... 17 
2.2.1. Syntheses and characterizations of gold(I) monocarbene complexes ................. 17 
2.2.2. Syntheses and characterizations of gold(I) hetero- and homoleptic complexes .. 19 
2.3. Cytotoxicity study of selected gold(I) NHC complexes ............................................. 25 
2.4. Syntheses and characterizations of gold(III) NHC complexes ................................... 28 
2.5. Cytotoxicity study of gold(III) NHC complexes ........................................................ 31 
3. Gold Monometallic and Gold/Palladium Hetero-bimetallic Complexes Featuring 
Template-synthesized Carbenes: Syntheses, Characterization, Properties, and 
Reactivities .............................................................................................................................. 33 
3.1. Template-directed syntheses and characterization of gold(I) hetero-bis(carbene) 
complexes ............................................................................................................................. 33 
3.1.1. Gold(I) hetero-bis(carbene) complex featuring an ADC and a benzimidazole-
derived NHC ..................................................................................................................... 33 
3.1.2. Gold(I) hetero-bis(carbene) complexes featuring tetrazole-derived NHCs ........ 36 
3.2. Indirect determination of the donor strength of carbenes ........................................... 44 
3.3. Computational study of tetrazolato complexes .......................................................... 46 
3.4. Syntheses and characterization of Au/Pd hetero-bimetallic complexes .................... 50 
3.4.1. Reactivity of tetrazolato complexes with dimeric [PdBr2(iPr2-bimy)]2 – 
Syntheses of Au(I)/Pd(II) hetero-bimetallic complexes .................................................. 50 
3.4.2. Synthesis of a Au(III)/Pd(II) hetero-bimetallic complex .................................... 56 
3.5. Electrochemical studies of gold(I) and gold(III) tetrazolato and Au/Pd hetero-
bimetallic complexes............................................................................................................ 58 
3.6. Electronic properties of Au/Pd hetero-bimetallic complexes .................................... 63 
4. Syntheses, Characterization, and Properties of Iridium NHC Complexes ............... 66 
4.1. Syntheses and characterization of iridium(I) NHC complexes .................................. 66 
4.2. Determination of ligand donor strength using CO-stretch method ............................ 71 
4.3. Electronic properties of iridium(I) NHC complexes .................................................. 73 
4.4. Electrochemical studies of iridium(I) NHC complexes ............................................. 76 
4.5. Reactivity of iridium(I) NHC complex with isocyanide ............................................ 79 
5. Conclusion........................................................................................................................ 84 
Experimental Section ............................................................................................................. 90 
Selected X-ray Crystallographic Data ................................................................................ 118 
Appendix ............................................................................................................................... 123 
References ............................................................................................................................. 128 
Summary  I 
Summary 
This dissertation focuses on the organometallic chemistry of gold, palladium, and 
iridium complexes that bear a N-heterocyclic carbene (NHC) and/or an acyclic diamino 
carbene (ADC). The findings of this research are presented in three chapters. 
Chapter 2 introduces a new non-classical NHC, FPyr, which was found to be the 
strongest donating ligand measured using our group's 13C NMR spectroscopic method. The 
gold(I) complex [AuCl(FPyr)] (2) was synthesized using the silver carbene transfer method, 
and converted to its bromido and iodido analogues [AuBr(FPyr)] (3) and [AuI(FPyr)] (4) via 
ligand substitution reactions. The spectroscopic and structural properties of 1–3 have been 
studied. Complex 2 was also used as a precursor for the syntheses of several gold(I) 
heteroleptic complexes of the type [Au(FPyr)(L)]PF6, where L is either a benzimidazole-
derived NHC (5–12) or a non-NHC co-ligand (13–15). The gold(I) homo-bis(carbene) 
complex [Au(FPyr)2]PF6 (16) was synthesized using a two-fold one-pot silver carbene 
transfer method. Selected gold(I) complexes were also oxidized to their respective gold(III) 
analogues. The in vitro cytotoxicities of the gold(I) and gold(III) complexes have been 
investigated using the NCI-H1666 non-small cell lung cancer cell line. Most of the complexes 
perform better than cisplatin, and there is also evidence for some unique structure-activity 
relationships. 
Chapter 3 explores template-directed synthetic routes towards the formation of less 
conventional carbenes. The gold(I) hetero-bis(carbene) complex [Au(ADC)(iPr2-bimy)]BF4 
(21) was synthesized from the template complex [Au(CN-Xyl)(iPr2-bimy)]BF4 (20). In 
addition, gold(I) tetrazolato complexes of the type [Au(CN4-
tBu)(L)] (25: L = FPyr, 26: L = 
iPr2-bimy, and 27: L = ADC) were synthesized from their respective template gold(I) azido 
complexes. Complexes 26 and 27 were further reacted with HBF4, forming the gold(I) hetero-
bis(carbene) complexes [Au(iPr2-bimy)(
tBu-tzy)]BF4 (28) and [Au(ADC)(
tBu-tzy)]BF4 (29), 
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which bear the protic tetrazolin-5-ylidene ligand. Computational studies have also been used 
to confirm that the CN4-
tBu ligand in complexes 25–27 is in fact an anionic NHC. Thus, 
complexes 25–27 were investigated as metalloligands, by way of reaction with the dimeric 
Pd(II) complex [PdBr2(
iPr2-bimy)]2 (I), resulting in the formation of Au(I)/Pd(II) hetero-
bimetallic complexes of the type [(L)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (30: L = 
FPyr, 31: L = iPr2-bimy, and 32: L = ADC). The Au(III)/Pd(II) hetero-bimetallic complex 
[(iPr2-bimy)AuBr2(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (34) was also prepared. Selected 
gold(I) and gold(III) mono- and hetero-bimetallic complexes have been further investigated 
using cyclic voltammetry and UV-Vis absorption spectroscopy. 
Chapter 4 presents iridium NHC complexes that bear the iPr2-bimy ligand. The 
iridium(I) complex [IrCl(COD)(iPr2-bimy)] (35) was prepared using the silver carbene 
transfer method, and was used as a precursor for the synthesis of the cationic complex 
[Ir(COD)(iPr2-bimy)(PPh3)]PF6 (36), as well as the dicarbonyl complex [IrCl(CO)2(
iPr2-
bimy)] (37). The electronic and electrochemical properties of complexes 35 and 36 have been 
studied using UV-Vis absorption spectroscopy and cyclic voltammetry. Complex 37 was 
analyzed using FTIR spectroscopy, and the determined CO stretching frequencies were used 
to determine the TEP of the iPr2-bimy ligand. The reaction of complex 35 with CN-
tBu and 
KPF6 results in the formation of the iridium(I) complex [Ir(CN-
tBu)3(
iPr2-bimy)]PF6 (38). 
Complex 38 was observed to undergo an oxidative addition reaction with chloroform, forming 
the iridium(III) complex [Ir(CHCl2)Cl(CN-
tBu)3(
iPr2-bimy)]PF6 (39). 
The new compounds synthesized in this work are depicted in a following section (see 
Compounds Synthesized in this Work). 
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1. Introduction 
1.1. Definition and nature of carbenes 
The IUPAC defines a carbene as an electrically neutral R’RC: species in which the 
carbon is covalently bonded to two univalent groups of any kind or a divalent group, and 
bears two non-bonding electrons.1 The carbene carbon atom is therefore electron deficient, 
with only six valence electrons. The geometry about the carbene carbon can be either linear or 
bent, depending on the nature of the hybridization. An sp-hybridized carbene carbon atom, 
which features two non-bonding and energetically degenerate p orbitals (px and py), would 
result in a linear geometry (Figure 1.1). 
 
 
Figure 1.1. Possible geometries of a carbene carbon atom, and the nature of their respective 
frontier orbitals. 
 
On the other hand, an sp2-hybridized carbene center would adopt a bent structure 
about the carbon atom. The degeneracy of the two non-bonding p orbitals is lost when the 
carbene carbon adopts an sp2-hybridization. The py orbital remains largely unaffected, and is 
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denoted as pπ, while the px orbital is stabilized as it acquires some s character, and is denoted 
as  (Figure 1.1). The linear, sp-hybridized carbene is an extreme case and is rare, while the 
bent sp2-hybridized carbene is far more prevalent. 
The sp2-hybridized carbene carbon can adopt one of four possible electronic 
configurations, and exist in a singlet or triplet ground state (Figure 1.2).2 The two non-
bonding electrons on the carbene carbon atom can each occupy one of the frontier orbitals 
(1pπ1) with either parallel (triplet 3B1) or opposing spin (singlet 1B1). The non-bonding 
electrons could also both occupy the same frontier orbital (2pπ0 or 0pπ2) with opposing spin 
(singlet 1A1), with the 2pπ0 configuration being more stable than 0pπ2. 
 
 
Figure 1.2. Possible electronic configurations and spin multiplicities of the sp2-hybridized 
carbene carbon. 
 
The electronic configuration adopted by the carbene carbon is dependent on the 
relative energies of the  and pπ orbitals. If the energy gap between the two frontier orbitals is 
greater than 2 eV, a singlet ground state can possibly be stabilized. However, if the energy 
gap is less than 1.5 eV, a triplet ground state is favoured.3 The ground state spin multiplicity 
of the carbene determines its properties and reactivities.4 A singlet carbene, for example, 
features one filled and one empty frontier orbital, and can thus exhibit both nucleophilic and 
electrophilic properties. A triplet carbene, on the other hand, features two singly occupied 
frontier orbitals, and can thus be considered as a diradical species. The steric and electronic 
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properties of the substituents on the carbene carbon atom can affect the relative energies of 
the  and pπ orbitals, and in this way the electronic properties of the carbene can be tuned. The 
singlet spin state is usually associated with Fischer type carbenes,5 while the triplet spin state 
is associated with Schrock type carbenes.6 
1.2. N-heterocyclic carbenes: synthesis and properties 
N-heterocyclic carbenes (NHCs) are a type of Fischer carbene, in which the carbene 
carbon is incorporated into a heterocyclic ring with one or more nitrogen atoms. Discussion 
on NHCs was initiated in 1962 when Wanzlick reported the α-elimination of chloroform from 
the corresponding imidazole adduct.7 Unfortunately, the proposed imidazolidin-2-ylidene 
could not be isolated as it dimerized to form the corresponding enetetraamine. Attempts to 
isolate free carbenes derived from 1,3-disubstituted imidazolium salts were also unsuccessful, 
although the formation of the free carbenes was supported by trapping them as transition 
metal complexes.8 The first free, stable NHC was isolated and reported by Arduengo et al. in 
1991.9 It was formed by the deprotonation of the corresponding imidazolium salt using 




Scheme 1.1. Arduengo’s synthesis of the first stable NHC. 
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It was initially thought that the stability of the carbene isolated by Arduengo and co-
workers was due to the steric hindrance of the two bulky adamantyl substituents. However, 
this notion was dispelled in 1992 when Arduengo reported a spectroscopically characterized 
1,3,4,5-tetramethylimidazolin-2-ylidene as a stable solid that has only methyl groups as N-
substituents.10 The stability of such isolated NHCs has therefore been attributed to mesomeric 
and inductive effects of the nitrogen atoms, which aid in stabilizing the NHC.2a In this so-
called “push-pull-effect”, the +M effect “pushes” the lone pair of electrons on the nitrogen 
atoms into the empty pπ orbital of the carbene carbon. This alleviates the carbon atom’s 
electron deficiency, and consequently increases the relative energy of the pπ orbital. 
Moreover, the –I effect of the electron withdrawing nitrogen atoms “pulls” electron density 
away from the carbene carbon, stabilizing the  orbital as a result. These two effects, in 
combination, increase the energy gap between the two frontier orbitals, and therefore stabilize 
the singlet ground state. 
Following the successful isolation of the free carbene by Arduengo et al., there have 
been numerous other reports detailing various methods through which free carbenes can be 
isolated.11 Such methods have led to the isolation of a wide range of NHCs.2a The majority of 
these NHCs can be classified into three types, namely imidazolin-2-ylidene, benzimidazolin-
2-ylidene, and imidazolidin-2-ylidene (Figure 1.3). These NHCs, also referred to as classical 
NHCs, feature a carbene carbon that is adjacent to two nitrogen atoms. It is interesting to note 
that the benzannulated benzimidazolin-2-ylidene represents a sort of mid-point between the 
unsaturated imidazolin-2-ylidene and the saturated imidazolidin-2-ylidene. This is evidenced 
by the characteristics and reactivity of benzimidazolin-2-ylidenes. First, the 13C NMR 
spectroscopic chemical shift range for the C2 carbon atom in benzimidazole-derived NHCs 
falls in between the typical ranges for imidazolin-2-ylidenes and imidazolidin-2-ylidenes. 
This is also the case with the range of N1–C2–N3 bond angles in benzimidazolin-2-
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ylidenes.11f,12 In terms of reactivities, saturated imidazolidin-2-ylidenes and benzannulated 
benzimidazolin-2-ylidenes are relatively unstable and tend to dimerize, especially if the N-
substituents are less bulky.11f,12,13 Unsaturated imidazolin-2-ylidenes, on the other hand, are 




Figure 1.3. Comparison of the three major classical NHCs. 
 
Benzimidazolin-2-ylidenes are therefore highly fascinating NHCs, as they seem to 
combine features unique to imdazolin-2-ylidenes and imidazolidin-2-ylidenes. Despite this, 
most of the work done on metal NHC complexes has focused on the non-annulated NHCs. 
Our group has thus been actively exploring the chemistry of metal NHC complexes bearing 
benzimidazole-derived NHCs, and parts of the work reported in this thesis will also consider 
such NHCs. 
Despite the growing research interest in NHCs, the study of these ligands has also 
been predominantly focused on classical NHCs, such as those shown in Figure 1.3. 
Experimental and theoretical studies have shown that the superior activity of NHCs in 
organometallics and organocatalysis is due to its strong innate σ-donating ability and 
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nucleophilicity as compared to that of phosphines.15 In this regard, tuning of the electronic 
properties and donor strength of the NHCs can be achieved by varying the back-bone as well 
as the N-substituents. Interest has thus grown in studying the synthesis of strongly donating 
carbenes and their metal complexes. For example, incorporating the carbene carbon adjacent 
to fewer heteroatoms is one manner in which a stronger donating NHC can be prepared.16 In 
light of this, our group has reported a wide range of non-classical NHCs which feature a 
carbene carbon atom that is adjacent to only one, or even no nitrogen atoms (Figure 1.4).17 As 
an extension of the work already done by our group, we have developed a new non-classical 
pyrazole-derived NHC, 1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]indazolin-11-ylidene 
(FPyr). Palladium and gold complexes featuring this new ligand have been developed, and the 
findings of our work with FPyr will be presented in Chapters 2 and 3. 
 
 
Figure 1.4. Representations of non-classical NHCs developed by our group. 
 
1.3. Determination of the donor strength of carbenes 
With the introduction of newer, more unconventional carbenes, it has become 
increasingly important to establish a method to determine the relative donating abilities of 
such ligands. It is common knowledge that the donating ability of a ligand has tremendous 
influence on the stability and reactivities of its metal complexes. At present, the most well-
known method of determining ligand donor strength is the Tolman’s Electronic Parameter 
(TEP).18 This methodology is based on complexes of the type [Ni(CO)3L], whereby the 
donating ability of the ligand L is correlated to the CO stretching frequency. However, this 
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method requires the handling of the highly dangerous [Ni(CO)4]. Thus, recognizing the 
inherent dangers of Tolman’s nickel(II) system, variants based on complexes of the type 
[MX(CO)2(L)], where M = Rh(I) or Ir(I), and X = Cl or Br, have been developed. The Rh(I) 
and Ir(I) systems have also been correlated to the TEP, allowing for direct comparison of new 
ligands with those already found on the TEP scale.19 Then again, the Rh(I) and Ir(I) systems 
have their disadvantages. They make use of relatively costly metals, and involve the handling 
of highly toxic carbon monoxide gas. Furthermore, the very principle of correlation with CO 
stretching frequencies has its shortcomings, and inconsistent results have been obtained in 
many cases. Further discussion on this matter is presented in Chapter 4. 
The solution to the problems encountered with the TEP system had to therefore 
involve a complete shift in paradigm in terms of how ligand donor strength is measured. In 
response, our group has introduced a new methodology for determining relative donor 





Such complexes can be easily synthesized by cleavage of the Pd(II) dimeric complex 
[PdBr2(
iPr2-bimy)]2 (I) (Scheme 1.2).  
 
 
Scheme 1.2. Synthesis of complexes of the type trans-[PdBr2(
iPr2-bimy)(L)]. 
 
When the ligand L is changed, it is to be expected that the chemical shift of the 
carbene carbon atom in the iPr2-bimy ligand would be affected. This has been shown to be the 
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case, wherein stronger donating ligands situated trans to the iPr2-bimy ligand result in a 
downfield shift of the resonance due to the carbene carbon atom. On the other hand, weaker 
donating ligands result in a highfield shift of the resonance of the same carbon atom. In this 
way, the relative donating abilities of various ligands can be studied by correlation to the 
chemical shift of the iPr2-bimy ligand’s carbene carbon atom. Our group has already studied a 




Figure 1.5. Relative donating abilities of Werner-type and organometallic ligands on the 13C 
NMR spectroscopic scale. 
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It is especially noteworthy that the 13C NMR spectroscopic method is able to discern 
between very closely related NHCs that feature the same backbone and differ only in terms of 
N-substituents. This is indeed an advantage of this method over the TEP system, since the 
latter has been shown to be less sensitive to small changes in ligand structure. Furthermore, 
the method introduced by our group is safer than the CO-stretch method, in that it does not 
require the use of toxic chemicals. The synthesis of the required Pd(II) complex is also 
straightforward, and the complexes can be fully recovered following NMR spectroscopic 
analysis and employed for other uses. 
We will therefore be using the 13C NMR spectroscopic methodology to determine the 
donor strength of the new FPyr ligand in Chapter 2. In addition, the method will be employed 
in Chapter 3, where we will consider the donating abilities of three new gold-based 
metalloligands. 
1.4. Preparation and applications of transition metal carbene complexes 
The synthesis of transition metal carbene complexes can be achieved via a variety of 
routes. These include the reaction of a free NHC with a suitable metal complex, in situ 
deprotonation of azolium salts under suitable conditions,8,21 insertion of transition metals into 
electron rich C=C bonds,22 transmetalation reaction of Ag‒NHC complexes,23 metal-template 
assisted synthesis from isocyanide complexes,24 and oxidative addition of an azolium salt to a 
low-valent metal complex.25 
The transmetalation reaction, in particular, is widely used given its ease and 
versatility, since it can be carried out without having to exclude moisture and air. In such 
reactions, silver(I) oxide (Ag2O) is used as a base to deprotonate the azolium salt and first 
form a Ag‒NHC complex. Owing to the weak Ag‒C bond, the NHC can then be transferred 
to another metal centre via the use of a suitable metal precursor. This simple and 
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straightforward method has also been employed as part of the synthesis strategy in this thesis, 
particularly in Chapters 2 and 4. 
However, despite the wide success of the silver carbene transfer method, it is not 
without its fair share of limitations and disadvantages. For one, it requires a relatively acidic 
azolium salt, and that in itself limits the range of carbenes the method is able to generate. 
Furthermore, with the use of a metal compound as a base, the method is relatively costly. 
Although the metal salts generated as by-products from the reaction can be recycled, such 
processes are tedious and not widely adopted on a laboratory scale. As such, it is not 
surprising that other methods of carbene generation are gradually regaining popularity. One 
such methodology is the metal-mediated template-directed synthetic route. Part of the 
growing interest in this synthetic method stems from its ability to generate both acyclic and 
cyclic carbenes (Scheme 1.3). 
 
 
Scheme 1.3. Metal-mediated template-directed synthesis of (a) acyclic and (b) cyclic 
carbenes. 
 
As depicted in Scheme 1.3, the metal-mediated synthetic route allows for the 
development of acyclic diamino carbenes (ADCs), which are closely related to NHCs.26 
Although developed as early as 1915 by Tschugajeff and co-workers, ADCs were not, at that 
time, recognized as carbenes.24a It was only in 1971 that Badley et al. identified ADCs as 
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carbenes,27 and the first stable ADC was prepared by Alder and co-workers in 1996,28 shortly 
after the isolation of the first stable NHC. While similar to NHCs in terms of electronic 
stabilization, ADCs are generally considered to be stronger donating ligands as compared to 
NHCs. ADCs are therefore able to increase electron density on the metal center to a greater 
extent than NHCs. This also makes metal ADC complexes more suited for transition metal 
catalyzed reactions that proceed via oxidative addition mechanisms. Moreover, ADCs offer 
unique steric properties that are not found in cyclic systems. For one, they allow for possible 
rotation of both the substituents attached to the carbene carbon about the Ccarbene–NR2 bonds. 
Furthermore, without a rigid ring structure, ADCs possess larger N–Ccarbene–N bond angles, 
and are thus able to bring N-substituents closer to the metal center in transition metal 
complexes. This latter property allows ADCs to provide steric protection to the metal center, 
while at the same time favouring reductive elimination processes, which are usually the final 
stage of many cross-coupling reactions. 
The metal-mediated template-directed synthetic route also allows for the preparation 
of metal NHC complexes that bear a tetrazole-derived carbene. Beck and co-workers first 
reported the strategy of reacting a metal azido complex with isocyanides, resulting in the 
formation of metal tetrazolato complexes.29 This [3+2] cycloaddition reaction is fairly 
straightforward and regiospecific, and does not require harsh conditions. Template-directed 
synthesis of metal tetrazolato complexes is also very useful, since it conveniently bypasses the 
otherwise long and tedious organic synthesis of substituted tetrazoles. The handling of organic 
tetrazoles also presents a safety concern, since such nitrogen rich compounds are known to be 
explosive. The tetrazolato ligand can be further alkylated or protonated, resulting in the 
formation of a tetrazolin-5-ylidene. The tetrazolato ligand is also in itself very intriguing, as it 
can be considered to be an anionic NHC. A detailed discussion of this notion will be 
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presented in Chapter 3, alongside examples of metal-mediated template-directed syntheses of 
ADCs and tetrazole-derived NHCs. 
Just as the preparation of metal NHC and ADC complexes has gained speed over the 
last several years, so has the variety of uses such complexes have been applied to. One major 
area of application of metal carbene complexes is undoubtedly organometallic catalysis.30 
Carbene complexes are now being widely used in processes that were once dominated by 
metal phosphine compounds. This shift to carbene complexes is in part fuelled by the superior 
properties of carbene ligands. They are known to be strong σ-donors and weak π-acceptors,31 
and are thus similar to tertiary phosphines. However, carbenes are far more Lewis basic than 
even trialkylphosphines, and have also been shown to be stronger donating ligands. 
Furthermore, unlike metal phosphine complexes, carbene bearing analogues have increased 
stability, and are less prone to oxidative degradation. As such, metal carbene complexes have 
been applied as catalysts in a wide range of organic transformations. Most notable are olefin 
metathesis catalyzed by Ru NHC complexes, C–C and C–N cross-coupling reactions 
catalyzed by Pd NHC complexes, hydrosilylation reactions catalyzed by Pt NHC complexes, 
and hydrogenation and transfer hydrogenation reactions catalyzed by Rh and Ir NHC 
complexes. Perhaps the most famous example of a metal NHC complex used as an 
organometallic catalyst is Grubbs’ 2nd generation catalyst for olefin metathesis (Figure 1.6).  
 
 
Figure 1.6. 1st and 2nd generation Grubbs’ catalysts. 
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The development of this catalyst was in part responsible for the awarding of the 2005 
Nobel Prize in Chemistry to Grubbs, Chauvin, and Schrock.32 The replacement of one 
tricyclohexylphosphine ligand in Grubbs’ 1st generation catalyst with an NHC greatly 
increased the catalytic efficiency of the complex, proving the potential of NHCs as a viable 
alternative to phosphines in such transition metal catalysts. 
Apart from organometallic catalysis, metal carbene complexes are also being widely 
applied in medicinal chemistry.33 Many in the anti-microbial and anti-tumour research 
communities have been drawn towards the stability of metal carbene complexes. Also alluring 
is the ease with which the hydro- and lipophilic properties of NHCs can be tuned, simply by 
varying the N-substituents. A fine balance between the two properties has been shown to be a 
critical consideration for the superior bio-activity of such metal carbene complexes. Among 
the metal centers being explored in medicinal chemistry, gold features very prominently, in 
part due to the success of auranofin. This gold(I) mixed phosphine thioglucose complex, 
which is an anti-rheumatic drug, has also shown potential as an anti-cancer agent. Research 
has also shown that the cytotoxic mechanism of action of gold complexes is distinctively 
different from that of the more established platinum complexes, such as cisplatin, making 
them a viable alternative in cancer therapeutics.34 In terms of gold NHC complexes, only 
mono- and homo-bis(carbene) complexes featuring imidazolin-2-ylidenes or imidazolidin-2-
ylidenes have been widely explored for their bio-activity. Complexes bearing benzimidazolin-
2-ylidenes have very rarely been studied, and those featuring non-classical NHCs have been 
left out of investigations altogether. Heteroleptic complexes have also been overlooked in 
such studies. As such, our group has embarked on preliminary studies of the cytotoxic 
activities of gold NHC complexes that bear benzimidazole-derived NHCs and the non-
classical NHC FPyr. Cationic heteroleptic complexes have also been a focus of our work, and 
the findings of our research are presented in Chapter 2. 
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2. Gold Complexes Bearing a Non-classical Pyrazole-derived 
NHC Ligand, and their Cytotoxic Activities 
The main body of work dealing with NHC chemistry has focused primarily on 
classical NHCs, where the carbene carbon is adjacent to two nitrogen atoms. Thus, the 
development of new, non-classical NHCs that feature decreased heteroatom stabilization is 
fast gaining interest among researchers. This interest is also spurred by the knowledge that 
non-classical NHCs are stronger -donors as compared to classical NHCs. As our 
contribution to this field, we sought to develop a new pyrazole-derived NHC ligand, FPyr 
(1,2,3,4,6,7,8,9-octahydropyridazino[1,2-a]indazolin-11-ylidene). Our initial work with this 
new ligand was focused on gold complexes for the purpose of cytotoxicity studies. 
Heteroleptic complexes were of particular interest since their cytotoxic activities have not 
been widely studied. 
2.1. Ligand precursor and donor strength of the FPyr ligand 
2.1.1. Synthesis and characterization of ligand precursor  
The ligand precursor for the new pyrazole-derived FPyr ligand, FPyrHBr (A), was 
synthesized straightforwardly from 4,5,6,7-tetrahydro-1H-indazole (Scheme 2.1), in a manner 
similar to the synthesis of a previously reported indazolium salt.17j  
 
 
Scheme 2.1. Synthesis of non-classical NHC ligand precursor, FPyrHBr (A). 
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Following N-deprotonation of the starting material, two stepwise nucleophilic 
substitution reactions occur with 1,4-dibromobutane, resulting in the cyclized product, which 
was obtained as an off-white powder in a reasonable yield of 67%. Salt A is slightly 
hygroscopic and readily dissolves in water and other polar organic solvents such as acetone, 
acetonitrile, CH2Cl2, and chloroform. It is insoluble in less polar solvents such as ethyl 
acetate, diethyl ether, and hexane. The formation of salt A was confirmed by its 1H NMR 
spectrum, where a characteristic downfield signal is observed as a singlet at 8.29 ppm, 
corresponding to the acidic NCH proton. Two triplets observed at 4.56 and 4.32 ppm for the 
two sets of NCH2 protons also support the successful reaction. In the MS (ESI) spectrum of 
the compound, a base peak is noted at m/z = 177 for the [M – Br]+ fragment. 
2.1.2. Determination of the donor strength of the FPyr ligand 
With the appropriate ligand precursor for the FPyr ligand at hand, we sought to study 
the donor strength of this new, non-classical NHC ligand using the 13C NMR spectroscopic 
methodology developed by our group (vide supra).20 The required complex [PdBr2(
iPr2-
bimy)(FPyr)] (1) was synthesized from the dimeric Pd(II) complex [PdBr2(
iPr2-bimy)]2 (I) in 
a one-pot reaction, using the silver carbene transfer method developed by Lin and co-workers 




Scheme 2.2. Synthesis of palladium(II) hetero-bis(carbene) complex [PdBr2(
iPr2-
bimy)(FPyr)] (1). 
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While complex 1 was characterized using various spectroscopic and spectrometric 
methods, the key focus was the chemical shift of the carbene carbon of the iPr2-bimy ligand in 
the 13C NMR spectrum. The carbon atom in question was observed to resonate at 184.0 ppm. 
Placing this alongside all the other ligands that have already been scaled according to our 
group’s methodology, it is truly noteworthy that the FPyr ligand stands as the strongest 
donating ligand thus far, surpassing all other classical and non-classical NHC ligands on this 
scale (Figure 2.1). The presence of only one electronegative nitrogen atom adjacent to the 
carbene carbon, as well as electron-donating alicyclic rings on two sides of the pyrazole 




Figure 2.1. Relative position of the FPyr ligand on the unified 13C NMR spectroscopic scale 
depicting the donor abilities of NHCs and phosphines. 
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2.2. Syntheses and characterizations of gold(I) NHC complexes 
2.2.1. Syntheses and characterizations of gold(I) monocarbene complexes  
The gold(I) chlorido monocarbene complex [AuCl(FPyr)] (2) was synthesized via the 
silver carbene transfer method.23 Salt A was first reacted with Ag2O in CH2Cl2, following 
which the reaction mixture was filtered directly into a solution of [AuCl(SC4H8)] in CH2Cl2 
(Scheme 2.3). The immediate precipitation of AgBr during the second step indicated the 




Scheme 2.3. Synthesis of gold(I) chlorido monocarbene complex [AuCl(FPyr)] (2). 
 
Complex 2 was obtained as a white powder in a good yield of 84%, and is soluble in 
most polar organic solvents such as DMSO, acetone, acetonitrile, CH2Cl2, and chloroform. 
The formation of complex 2 was confirmed by 1H NMR spectroscopy, where the absence of 
the downfield singlet due to the acidic NCH proton in the precursor salt was noted, indicating 
successful salt deprotonation. The coordination of the FPyr ligand to the gold metal center 
was confirmed through the complex’s 13C NMR spectrum, where a signal at 167.8 ppm is 
observed for the carbene carbon. 
Our group had previously reported an interesting phenomenon, where a complex of 
the type [AuI(NHC)] underwent auto-ionization via ligand disproportionation in the solid 
state to afford the polynuclear cation [Au3I2(NHC)4)]
+ and anion [Au3I4(NHC)2]
–.17j 
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Therefore, in an effort to explore the structural diversity of complexes of the type 
[AuX(FPyr)], the bromido and iodido analogues of complex 2 were synthesized via salt 
metathesis reactions with LiBr and NaI respectively, in acetone (Scheme 2.4). The resulting 
complexes [AuBr(FPyr)] (3) and [AuI(FPyr)] (4) were obtained as white powders in very 
good yields of 92% and 95% respectively. 
 
 
Scheme 2.4. Syntheses of gold(I) bromido and iodido monocarbene complexes [AuBr(FPyr)] 
(3) and [AuI(FPyr)] (4). 
 
The solubilities of complexes 3 and 4 are similar to that of complex 2, and their 
successful formation could be confirmed using 13C NMR spectroscopy as a diagnostic tool. 
The chemical shifts of the carbene carbon atoms in complexes 3 and 4, at 171.7 ppm and 
178.7 ppm, respectively, are distinctively different from that of complex 2 (cf. 167.8 ppm). 
This reflects the increasing donating ability of the halido ligands in the order Cl < Br < I, 
which in turn decreases the Lewis acidity of the gold(I) metal center. Consequently, a 
downfield shift of the carbene carbon signal is observed.17j,35,36 In this manner, 13C NMR 
spectroscopy can be used to differentiate the complexes from one another, given that the 1H 
NMR spectra of 2–4 are nearly identical, and all three complexes show the same base peak at 
m/z = 549 in their MS (ESI) spectra, corresponding to the [M – X + FPyr]+ fragment. 
The formation of complexes 2–4 was unambiguously confirmed by X-ray diffraction 
analyses, using crystals of the compounds obtained via slow evaporation of solutions in 
CH2Cl2 layered with hexane. All three complexes adopt a linear geometry about the gold(I) 
center, with all bond lengths and distances within the range observed for similar complexes 
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(Figure 2.2).17j It is however noteworthy that the iodido complex 4 did not undergo auto-
ionization via ligand disproportionation as per our previous report. The seemingly selective 
occurrence of this phenomenon requires further study. 
 
 
Figure 2.2. Molecular structures of complexes 2–4 showing 50% probability ellipsoids; 
hydrogen atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: 2: Au1–C1 
1.980(7), Au1–Cl1 2.3248(18); C1–Au1–Cl1 178.6(2); 3: Au1–C1 1.996(7), Au1–Br1 
2.4062(9); C1–Au1–Br1 178.98(19); 4: Au1–C1 2.004(8), Au1–I1 2.5645(7); C1–Au1–I1 
178.7(2). 
 
2.2.2. Syntheses and characterizations of gold(I) hetero- and homoleptic complexes  
Complex 2 serves as a useful precursor for the synthesis of a range of cationic gold(I) 
hetero-bis(carbene) complexes, wherein the NHC ligands trans to the FPyr ligand are derived 
from disubstituted benzimidazolium salts. Complex 2 was reacted with an equivalent of a 
benzimidazolium salt in the presence of K2CO3, forming complexes 5–12 as white powders in 
good yields of 72–82% (Scheme 2.5). 2 can also be used for the synthesis of cationic gold(I) 
heteroleptic complexes in which the ligand trans to the FPyr ligand is a neutral, non-NHC 
donor. Complexes 13–15 are examples of such compounds, and were synthesized by reacting 
2 with an equivalent of the appropriate pro-ligand in the presence of excess KPF6 (Scheme 
2.5). 13–15 were obtained as white powders in good yields of 77–94%. Complexes 5–15 are 
soluble in most polar organic solvents, and insoluble in less polar solvents such as hexane and 
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diethyl ether. It is worth noting that 14 represents the first gold-NHC complex to bear the 
triphenylphosphite ligand. 
 
Scheme 2.5. Syntheses of cationic gold(I) heteroleptic complexes of the type [Au(FPyr)(RR’-
bimy)]PF6 (5–12) and [Au(FPyr)(L)]PF6 (13–15). 
 
Unfortunately, the methodology adopted for the synthesis of complexes 5–12 could 
not be extended to the synthesis of the homo-bis(carbene) complex [Au(FPyr)2]PF6 (16). 
Pyrazolium based salts have been shown to be less acidic as compared to benzimidazolium 
salts, rendering K2CO3 too weak a base for the purpose of deprotonation of the former.
17j 
Thus, a one-pot two-fold silver carbene transfer method was employed for the synthesis of 
complex 16 (Scheme 2.6), akin to the procedure used previously for the synthesis of a gold(I) 
homo-bis(carbene) complex bearing two indazolin-3-ylidene ligands.17j The 
hexafluorophosphate analogue of salt A, FPyrHPF6 (B), which is necessary for this reaction 
was easily obtained via anion exchange of A with KPF6 in acetone. Complex 16 was obtained 
as an off-white powder with a yield of 62%, and is soluble in most polar organic solvents. 
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Scheme 2.6. Synthesis of the cationic gold(I) homo-bis(carbene) complex [Au(FPyr)2]PF6 
(16). 
 
Complexes 5–16 were characterized using MS (ESI) and multinuclei NMR 
spectroscopies. The MS (ESI) spectra of 5–15 were particularly useful in confirming the 
formation of the compounds, given that the base peak observed in all cases correspond to the 
[M – PF6]+ fragment. 1H NMR spectroscopy corroborated the successful formation of 
complexes 5–15, whereby signals from both ligands are observed in the respective spectra. 
Moreover, the 1H NMR spectra of 5–15 did not show any evidence of rearrangement to form 
homoleptic complexes; a phenomenon that has been reported for other gold(I) hetero-
bis(carbene) complexes that bear two different 1,3-disubstituted benzimidazolin-2-ylidenes.37 
The stronger donating ability of the FPyr ligand, as compared to the benzimidazolin-2-
ylidenes, leads to a stronger Au–Ccarbene bond. Thus, rearrangement reactions that proceed via 
ligand detachment mechanisms would not be favorable for complexes bearing the FPyr NHC. 
Unfortunately, MS (ESI) and 1H NMR spectroscopy proved to be less effective in 
confirming the formation of complex 16, since the spectra from both methods of analysis 
were almost indistinguishable from the gold(I) halido monocarbene complexes, which is to be 
expected.17j 13C NMR spectroscopy was thus used as the diagnostic tool to confirm the 
formation of complex 16, since the chemical shift of the carbene carbon atoms in 16 would be 
expected to be significantly different from that of 2–4 (vide infra). As for complexes 5–12, the 
13C NMR spectra correspondingly featured two downfield signals as a result of the presence 
of two carbene carbon atoms in the molecules. 2D-HMBC NMR spectroscopic analysis was 
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conducted on complex 5 to correctly assign these two signals to their respective carbon atoms 
(Figure 2.3). The relative position of the signals in complex 5 was then used as reference for 
the assignment of signals in complexes 6–12. The chemical shift(s) of the carbene carbon 
atom(s) in complexes 5–16 are tabulated in Table 2.1. 
 
Figure 2.3. Section of the 2D-HMBC NMR spectrum of complex 5. 
Table 2.1. Chemical shift(s) of the carbene carbon atom(s) in complexes of the type 
[Au(FPyr)(L)]PF6 (5–16)a 
Complex L FPyr RR’-bimy 
5 iPr2-bimy 179.6 192.5 
6 (CHPh2)2-bimy 178.8 197.8 
7 (iPr2)(CHPh2)-bimy 179.2 195.1 
8 (CH2Ph)2-bimy 179.9 195.7 
9 iBu2-bimy 180.2 194.8 
10 n-Pr2-bimy 180.0 194.8 
11 Et2-bimy 180.7 194.1 
12 (2-propenyl)2-bimy 179.9 196.0 
13 PPh3 182.4 – 
14 P(OPh)3 179.6
b – 
15 DMAP 161.0 – 
16 FPyr 184.6 – 
a All 13C NMR spectra were measured in CDCl3, except for complexes 10, 12 and 15, which were 
measured in CD3CN due to poor solubility in chloroform. 
b Doublet, 2J(C,P) = 178 Hz. 
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Considering the chemical shift of the FPyr carbene carbon, it is overt that as compared 
to the gold(I) chlorido monocarbene complex 2 (cf. 167.8 ppm), the FPyr carbene carbon in 
complexes 5–14, and 16, resonate at a much more downfield region, ranging from 178.8–
184.6 ppm. This is due to the replacement of the chlorido co-ligand in 2 with a stronger 
donating ligand situated trans to the FPyr ligand in the mentioned complexes, leading to the 
observed downfield shift of the signal.17j,20,36 On the other hand, complex 15, with its DMAP 
co-ligand, shows a more upfield FPyr carbene carbon resonance as compared to 2, which is 
the result of DMAP being a weaker donating ligand as compared to the chlorido ligand. 
The changes in the chemical shift of the FPyr carbene carbon also reveal other 
interesting, albeit unexpected, findings. For example, when focusing on the relevant data for 
hetero-bis(carbene) complexes 5–12, it is noteworthy that no real correlation can be drawn 
between the chemical shift of the FPyr carbene carbon and the N-substituents of the RR’-
bimy ligands, where the latter would inadvertently influence the overall donating ability of 
said RR’-bimy ligands. This is unlike the 13C NMR spectroscopic methodology reported by 
our group (vide supra), wherein even small changes to the N-substituents of various NHCs are 
shown to affect the donating ability of the ligands, and can be detected by the iPr2-bimy probe 
in complexes of the type [PdBr2(
iPr2-bimy)(NHC)]. Therefore, the data presented in this work 
seems to suggest that the Au(I) system is less sensitive than the Pd(II) system when it comes 
to detecting small changes in donor strength. Furthermore, while the Pd(II) system is able to 
confirm the stronger donating ability of NHCs as compared to phosphines, the Au(I) system 
studied in this work suggests the reverse, with the FPyr carbene carbon in 
[Au(FPyr)(PPh3)]PF6 (13) resonating at 182.4 ppm, which is significantly more downfield as 
compared to the hetero-bis(carbene) complexes 5–12. This may be due to some unique 
interactions that the phosphorus donor in PPh3 has with the electron-rich gold(I) metal center, 
and warrants further investigation. 
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Figure 2.4. Molecular structures of complexes 5, 8·CHCl3, 9 and 12–14 showing 50% 
probability ellipsoids; hydrogen atoms, PF6
– anions, and solvent molecules (if any) are 
omitted for clarity. Selected bond lengths [Å] and angles [°]: 5: Au1–C1 2.024(5), Au1–C14 
2.026(5); C1–Au1–C14 177.2(2); 8·CHCl3: Au1–C1 2.017(5), Au1–C22 2.015(5); C1–Au1–
C22 177.7(2); 9: Au1–C1 2.027(5), Au1–C16 2.013(5); C1–Au1–C16 174.85(19); 12: Au1–
C1 2.020(3), Au1–C14 2.018(3); C1–Au1–C14 176.81(12); 13: Au1–C1 2.035(6), Au1–P1 
2.2843(17); C1–Au1–P1 175.43(17); 14: Au1–C1 2.030(6), Au1–P1 2.2426(18); C1–Au1–P1 
177.17(18). 
 
Chapter 2  25 
Single crystals suitable for X-ray diffraction analysis were obtained for complexes 5, 
8, 9 and 12–14 via slow diffusion of diethyl ether into solutions of the compounds in either 
chloroform or CH2Cl2. The determined molecular structures were as expected, with all 
complexes adopting a linear geometry about the gold(I) metal center (Figure 2.4). Apart from 
complex 8, which crystallized as the chloroform solvate, all other complexes crystallized 
unsolvated. It is interesting to note that unlike 8, where both the benzyl N-substituents are 
arranged in an anti arrangement across the benzimidazole plane, the N-substituents in 9 and 
12 are arranged in a syn arrangement, which is a result of achieving optimum packing in the 
unit cell. Two of the carbon atoms (C29 and C30) in the alicyclic ring of the FPyr ligand in 8 
were also disordered into two positions, with an occupancy ratio of 50:50. The molecular 
structure of complex 14 is particularly interesting, in that two of the phenyl rings of the 
P(OPh)3 ligand are pointed towards the gold metal center. The remaining one is pointed away 
as a result of the close proximity of a PF6
– anion. The potential steric shielding of the metal 
center accorded by the phenyl rings is unique to this ligand, and could prove beneficial for the 
overall stability of the complex. Furthermore, it is worth noting that none of the complexes 
showed evidence for intermolecular aurophilic interactions in the solid-state.38 
2.3. Cytotoxicity study of selected gold(I) NHC complexes  
As a preliminary investigation into the cytotoxic properties of the newly developed 
gold(I) NHC complexes, complexes 2 and 5–16 were studied through a cell proliferation 
assay conducted on the NCI-H1666 non-small cell lung cancer cell line. IC50 values for each 
complex were obtained from best-fit dose-response curves (see Appendix), and the values are 
tabulated in Table 2.2. Although the cytotoxicity of cisplatin on this cell line has been 
reported,39 we have determined its IC50 value again under the same experimental conditions 
for a more valid comparison. 
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Table 2.2. Cytotoxicity of [AuCl(FPyr)] (2), complexes of the type [Au(FPyr)(L)]PF6 (5–16), 
and cisplatin in the NCI-H1666 cell line, expressed as IC50 values (M)a 
Complex L IC50 (M) 
2 – 8.97 ± 0.87 
5 iPr2-bimy 0.241 ± 0.01 
6 (CHPh2)2-bimy 0.346 ± 0.03 
7 (iPr2)(CHPh2)-bimy 2.01 ± 0.20 
8 (CH2Ph)2-bimy 0.720 ± 0.18 
9 iBu2-bimy 0.964 ± 0.06 
10 n-Pr2-bimy 1.91 ± 0.40 
11 Et2-bimy 0.747 ± 0.08 
12 (2-propenyl)2-bimy 5.10 ± 0.10 
13 PPh3 2.15 ± 0.22 
14 P(OPh)3 3.04 ± 0.27 
15 DMAP > 10 
16 FPyr 2.35 ± 0.07 
Cisplatin – 2.51 ± 0.11 
a IC50 values were determined from best-fit dose-response curves on the basis of three independent 
experiments. 
 
The cytotoxicity data highlights several interesting features. First, the cationic 
complexes in general show better activity as compared to the neutral gold(I) chlorido 
monocarbene complex 2, with complex 15 being an exception (vide infra). This finding 
agrees with what has been previously referred to as delocalized lipophilic cations (DLCs), 
which have the ability to readily pass through the lipid membrane of mitochondria and 
accumulate within the mitochondria as a result of the large mitochondrial membrane potential, 
eventually leading to mitochondria-induced apoptosis.40 The neutral monocarbene complex, 
while having a certain degree of lipophilic properties, lacks an overall cationic character, 
which seems necessary for targeting mitochondria. 
It is also interesting that most of the gold(I) hetero-bis(carbene) complexes 5–12 
perform better than the gold(I) homo-bis(carbene) complex 16. This seems to indicate some 
form of ligand detachment process in the mechanism of action of such cationic complexes. 
The vacant site that ensues as a result of ligand detachment could be used for binding with 
donor atoms on target proteins, such as the selenol groups in thioredoxin reductase that is 
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found in both cytoplasm and mitochondria, the inhibition of which has been shown to lead to 
apoptosis of cancer cells.34,40a–f The FPyr ligand is a better -donor and is expected to be more 
strongly bound to the gold center as compared to ligands of the type RR’-bimy. Thus, the 
former is far less labile as compared to the latter, and any biological activation of the 
complexes via ligand detachment is more likely for complexes bearing the benzimidazolin-2-
ylidenes. The lability of the RR’-bimy type ligands could be further enhanced in the gold(I) 
hetero-bis(carbene) complexes, where the presence of the FPyr ligand could potentially have a 
significant trans effect on the benzimidazole-derived NHC ligand. However, complex 12 
seems to be an anomaly in this series, and this could be due to the nucleophilic and reactive 
olefin groups present in the complex. Such reactive groups may cause the compound to 
undergo transformations in vitro, ultimately deactivating the complex. 
Unfortunately, no consistent trend is observed when correlating the nature and length 
of the N-substituents on the benzimidazole derived NHC and the activities of complexes 5–
12. However, it is worth nothing that complexes 5 and 6, which both bear symmetrically 
substituted benzimidazolin-2-ylidenes, with both N-substituents being 2 carbon atoms, show 
superior performance as compared to complexes that bear benzimidazole-derived NHCs with 
either asymmetric N-substituents (i.e. complex 7), or 1 carbon atom N-substituents (i.e. 
complexes 8–12). This does suggest some form of structure-activity relationship, although 
further studies would be necessary to better understand the relative performance. 
While the presence of a labile ligand seems necessary for the superior activity of these 
gold(I) complexes, it is apparently also important that the ligand trans to the FPyr ligand is 
not too weakly bound to the metal center. Evidence for this is found when considering 
complexes 13–15. As we progress from the stronger donating PPh3 to the much weaker 
donating DMAP, there is an increase in the IC50 values. It is therefore very possible that in the 
case of complex 15, for example, the DMAP ligand detaches from the complex cation prior to 
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penetrating into the mitochondria. This could potentially deactivate the compound even 
before it reaches its target site, leading to poor activity. Therefore, a fine balancing of these 
various properties is necessary for the development of an optimum complex. In any case, the 
general equivalent, if not better, performance of these gold(I) NHC complexes as compared to 
the benchmark cisplatin is very promising, and further studies could be done to better 
understand the mode of action of these complexes. 
2.4. Syntheses and characterizations of gold(III) NHC complexes 
Following the cytotoxicity study of the gold(I) NHC complexes, we sought to 
investigate the relative performance of gold(III) analogues of selected complexes. For this 
purpose, complexes 2, 5 and 16 were chosen as representatives of mono-, hetero-bis-, and 
homo-bis(carbene) complexes. The three complexes were oxidized to their gold(III) 
derivatives, [AuCl3(FPyr)] (17), [AuCl2(FPyr)(
iPr2-bimy)]PF6 (18), and [AuCl2(FPyr)2]PF6 
(19) respectively, via oxidative addition reactions with PhICl2, which is a useful and safer 
alternative to elemental Cl2. The reactions, carried out in CH2Cl2 at ambient temperature, 
yielded the desired products in very good yields of 90–98% (Scheme 2.7). While complex 18 
showed solubility similar to that of its gold(I) precursor complex, complexes 17 and 19 did 
not, being only slightly soluble in chloroform. Furthermore, unlike the white or off-white 
gold(I) complexes, the gold(III) species were pale to bright yellow. 
While 1H NMR spectroscopic analysis of complexes 17–19 did not reveal much 
differences when compared to their respective gold(I) precursors, the 13C NMR spectra of the 
three complexes showed significant upfield shifts of the resonances due to the carbene carbon 
atom(s). In complexes 17 and 19, the carbene carbon of the FPyr ligand resonates at 134.9 and 
155.4 ppm, respectively. As for 18, the carbene carbon atoms of the FPyr and iPr2-bimy 
ligands resonate at 151.2 and 168.5 ppm, respectively. This upfield shift can be attributed to 
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the increase in the Lewis acidity of the gold metal center when transiting from the +1 to the 
+3 oxidation state.17j,36 
 
 
Scheme 2.7. Syntheses of gold(III) NHC complexes [AuCl3(FPyr)] (17), [AuCl2(FPyr)(
iPr2-
bimy)]PF6 (18), and [AuCl2(FPyr)2]PF6 (19). 
 
It is also worth mentioning that the 13C NMR signal due to the isopropyl methine 
carbon of the iPr2-bimy ligand in complex 18 could not be resolved, despite a high sample 
concentration and extended acquisition time. In order to probe this unexpected observation, a 
2D-HMQC NMR spectroscopic analysis was conducted, which suggested a direct 
connectivity between the isopropyl methine proton, resonating at 5.34 ppm in the 1H NMR 
spectrum, and the carbon atom in question, which should have a 13C NMR signal at ~55 ppm 
(Figure 2.5). The apparent signal suppression could be due to the unhindered rotation of the 
iPr2-bimy ligand about the Au–C bond at ambient temperature, which results in the 
equivalence of the isopropyl methine carbon atoms on the 13C NMR time scale, causing signal 
coalescence. This premise was confirmed by a variable temperature (VT) 13C NMR 
spectroscopic analysis of 18 (Figure 2.6). 
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Figure 2.5. Section of the 2D-HMQC NMR spectrum of complex 18. 
 
 
Figure 2.6. Section of the low temperature-variable temperature (VT) 13C NMR spectrum of 
complex 18. 
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At 263 K, two distinct resonances at 55.9 and 54.8 ppm were noted, corresponding to 
the two inequivalent methine carbon atoms of the isopropyl groups, as a result of thermally 
arrested rotation of the iPr2-bimy ligand about the Au–C bond. At temperatures lower than 
243 K, signal suppression is once again observed, possibly due to poor solubility of the 
complex at such low temperatures. On the other hand, no significant changes were observed 
in the 1H NMR spectra across the various temperatures (see Appendix). It is also noteworthy 
that such a phenomenon was not observed in its gold(I) precursor complex 5. This suggests 
that the increased steric crowding in complex 18, due to the square planar geometry about the 
metal center, affects the rotation of the two NHC ligands about their respective Au–C bonds. 
2.5. Cytotoxicity study of gold(III) NHC complexes  
As per the study of gold(I) NHC complexes, the cytotoxic activities of 17–19 were 
investigated through a cell proliferation assay conducted on the NCI-H1666 non-small cell 
lung cancer cell line. IC50 values for each complex were obtained from best-fit dose-response 
curves (see Appendix). Complex 17 shows very low cytotoxic activity, with an IC50 value 
greater than 10 M. 18 and 19, on the other hand, are appreciably active, with IC50 values of 
0.210 (± 0.04) and 1.46 (± 0.09) M, respectively. The trend in terms of activity that was 
observed for the gold(I) NHC complexes (vide supra) holds true for the gold(III) analogous 
presented here. The cationic complexes 18 and 19 perform far better than the neutral complex 
17, and the hetero-bis(carbene) complex 18 is superior to the homo-bis(carbene) complex 19. 
It is also interesting to note the lack of significant differences in the relative performance of 
the gold(III) complexes and their respective gold(I) analogues. This could be due to the redox 
activities that occur in the cellular environment, favoring one oxidation state over the other.41 
However, the study reported in this work still represents only a preliminary investigation of 
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these gold-NHC complexes, and further inquiry into the mode of action of these compounds 
would be necessary for a better understanding of their performance. 
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3. Gold Monometallic and Gold/Palladium Hetero-bimetallic 
Complexes Featuring Template-synthesized Carbenes: Syntheses, 
Characterization, Properties, and Reactivities 
Template-directed synthetic routes leading to the formation of carbenes are slowly 
making a comeback. They allow for the development of less conventional carbenes such as 
acyclic diamino carbenes (ADCs) and tetrazole-derived NHCs. These unconventional yet 
highly interesting carbenes possess unique steric and electronic properties that ultimately 
influence the reactivities of their metal complexes. Metal-mediated template-directed 
synthesis is also fairly regiospecific, leading to high, if not near quantitative yields of desired 
products. In a bid to explore such template-directed synthetic routes, our group has embarked 
on the syntheses of gold hetero-bis(carbene) complexes bearing an ADC and/or a tetrazole-
derived NHC. The properties and reactivities of these complexes have also been studied. 
3.1. Template-directed syntheses and characterization of gold(I) hetero-
bis(carbene) complexes 
3.1.1. Gold(I) hetero-bis(carbene) complex featuring an ADC and a benzimidazole-
derived NHC 
Our group has previously reported the synthesis of the gold(I) chlorido monocarbene 
complex, [AuCl(iPr2-bimy)] (II).
36 Complex II can be used as a precursor for the generation 
of a gold(I) hetero-bis(carbene) complex bearing both the benzimidazolin-2-ylidene and an 
ADC (Scheme 3.1). The chlorido ligand in [AuCl(iPr2-bimy)] can be replaced by 2,6-
dimethylphenylisocyanide (CN-Xyl), with the use of AgBF4 as a halide abstracting agent, 
affording the cationic complex [Au(CN-Xyl)(iPr2-bimy)]BF4 (20) as a white powder in a very 
good yield of 95%. The CN-Xyl ligand’s electrophilic carbon that is bound to the gold(I) 
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metal center is susceptible to nucleophilic attack, and thus reaction of 20 with an excess of 
HNEt2 forms the desired complex [Au(ADC)(
iPr2-bimy)]BF4 (21), where ADC refers to 
(diethylamino)(2,6-dimethylphenylamine)methylidene. Complex 21 was obtained as a white 
powder with a yield of 97%, and is soluble in most polar organic solvents such as chloroform, 
CH2Cl2, acetonitrile and DMSO. 
 
 
Scheme 3.1. Synthesis of gold(I) hetero-bis(carbene) complex [Au(ADC)(iPr2-bimy)]BF4 
(21), via [Au(CN-Xyl)(iPr2-bimy)]BF4 (20). 
 
The 1H and 13C NMR spectra of complex 21 confirmed the successful formation of the 
compound, displaying signals from both ligands. In the 1H NMR spectrum, a broad downfield 
singlet is observed at 8.30 ppm, assignable to the NH proton of the ADC. Two multiplets are 
also observed at 3.95 and 3.68 ppm, attributable to the two sets of NCH2 protons of the Et 
groups. On the other hand, the methyl groups of the Et substituents appear as a single broad 
multiplet at 1.39 ppm. The unequal character of the Et groups is also reflected in the 13C NMR 
spectrum of the complex, where two sets of signals are observed for both the NCH2 (53.0 and 
42.8 ppm) and methyl groups (16.0 and 13.0 ppm). The inequivalence of the two Et groups is 
probably due to sterically hindered rotation about the C–NEt2 bond. 
Interestingly, despite the asymmetric structure of the complex, only one multiplet due 
to the NCH protons of the iPr2-bimy ligand is observed in the 
1H NMR spectrum of 21, at 4.69 
ppm. This suggests the free rotation of both carbene ligands about their respective Au–Ccarbene 
bonds. However, it is also noted that the doublet due to the isopropyl methyl protons of the 
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iPr2-bimy ligand is shifted upfield to 1.53 ppm, compared to its precursor complex 20 (cf. 1.82 
ppm). A similar upfield shift is also observed in the 13C NMR spectrum of 21, where the 
isopropyl methyl groups resonate at 22.5 ppm, as compared to 23.1 ppm in complex 20. Thus, 
despite the free rotation of both ligands, the isopropyl methyl groups are still influenced by 
the additional shielding effect due to the inward facing phenyl ring of the ADC (vide infra). 
Similar shielding effects have been observed for Pd(II) NHC complexes that have been 
reported by our group.42 
Furthermore, in the 13C NMR spectrum of complex 21, two downfield signals at 203.5 
and 188.7 ppm are observed, attributed to the carbene carbon atoms of the ADC and iPr2-bimy 
ligands, respectively. The resonance of the latter is shifted downfield when compared to the 
precursor complex 20 (cf. 181.0 ppm), clearly indicating the stronger donating ability of the 
ADC as compared to CN-Xyl. Moreover, MS (ESI) supports the NMR spectroscopic data, 
with a base peak noted at m/z = 503, corresponding to the [M – BF4]+ fragment. 
 
 
Figure 3.1. Molecular structure of complex 21 showing 50% probability ellipsoids; hydrogen 
atoms and BF4
– anion are omitted for clarity. Selected bond lengths [Å] and angles [°]: Au1–
C1 2.029(6), Au1–C14 2.056(7); C1–Au1–C14 178.5(3), N1–C1–N2 107.2(6), N3–C14–N4 
119.6(6). 
 
Single crystals of complex 21 suitable for X-ray diffraction analysis were obtained via 
slow evaporation of a solution of the compound in CH2Cl2, layered with hexane. The solid-
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state molecular structure of 21 is as expected, with a linear geometry adopted about the 
gold(I) metal center (Figure 3.1). The inward orientation of the phenyl ring on the ADC may 
seem counter-intuitive. However, similar orientations have been observed for other ADCs 
which bear aryl substituents,26 and is the result of steric repulsion between the bulky phenyl 
ring and Et substituents on the ADC. While the varied orientation of the isopropyl substituents 
on the iPr2-bimy ligand is peculiar, this may simply be the result of achieving optimum 
packing in the unit cell. These substituents would be freely rotating in the solution state as 
evidenced by the NMR spectroscopic data (vide supra). In addition, the larger N–C–N angle 
in the ADC ligand (119.6(6)°) as compared to the iPr2-bimy ligand (107.2(6)°) also supports 
the notion that ADCs are able to bring N-substituents within closer proximity to the metal 
center as opposed to NHCs.26 
3.1.2. Gold(I) hetero-bis(carbene) complexes featuring tetrazole-derived NHCs 
Gold(I) hetero-bis(carbene) complexes featuring FPyr (vide supra), iPr2-bimy, or 
ADC, as well as a tetrazole-derived NHC, can be straightforwardly synthesized starting with 
the appropriate gold(I) chlorido monocarbene complexes. [AuCl(FPyr)] (2), [AuCl(iPr2-
bimy)] (II), and [AuCl(ADC)] (III), which was synthesized according to a previously 
reported procedure,43 were converted to their azido analogues, [Au(N3)(FPyr)] (22), 
[Au(N3)(
iPr2-bimy)] (23), and [Au(N3)(ADC)] (24), via two step ligand substitution reactions 
(Scheme 3.2), similar to the procedure reported by Baker et al.35 Complexes 22–24 were 
obtained as white powders in very good yields of > 90%. The azido complexes have 
solubilities similar to their chlorido precursors, readily dissolving in polar organic solvents 
such as CHCl3, CH2Cl2, acetonitrile and DMSO. 
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Scheme 3.2. Syntheses of gold(I) azido monocarbene complexes [Au(N3)(FPyr)] (22), 
[Au(N3)(
iPr2-bimy)] (23), and [Au(N3)(ADC)] (24). 
 
The gold(I) azido monocarbene complexes 22–24 show 1H NMR spectra that are 
similar to their respective chlorido precursors. In the 13C NMR spectra, however, an upfield 
shift of the carbene carbon resonance is noted when compared to the chlorido analogues. The 
carbene carbon atoms in 22–24 resonate at 165.8, 174.7, and 191.2 ppm, respectively (cf. 
167.8 (vide supra), 175.8,36 and 192.343 ppm for the respective chlorido analogues). This 
reflects the slightly weaker donating ability of the azido ligand as compared to the chlorido 
ligand.35 
The molecular structures of the gold(I) azido complexes 22–24 could be confirmed by 
X-ray diffraction analyses. Single crystals of the complexes were obtained from solutions of 
the compounds in CH2Cl2, layered with either hexane or toluene. The determined molecular 
structures were as expected, with all three complexes adopting a linear geometry about the 
gold(I) metal center (Figure 3.2). It should be noted that the asymmetric unit for complex 24 
contains two independent molecules of the compound, of which only one is depicted in Figure 
3.2. There is also evidence for intermolecular hydrogen bonding in the solid-state structure of 
complex 24. These interactions occur between either the nitrogen atom bound to the gold(I) 
metal center or the terminal nitrogen atom of the azido ligand, and the hydrogen atom of the 
NH moiety in the ADC. The intermolecular hydrogen bonding results in a unique wave-like 
arrangement of the molecules (Figure 3.3). 
38  Chapter 3 
 
Figure 3.2. Molecular structures of complexes 22–24 showing 50% probability ellipsoids; 
hydrogen atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: 22: Au1–C1 
1.988(5), Au1–N3 2.060(5); C1–Au1–N3 176.9(2); 23: Au1–C1 1.966(11), Au1–N3 
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The gold(I) azido monocarbene complexes 22–24 were then subjected to [3+2] 
cycloaddition reactions with tert-butyl isocyanide (Scheme 3.3), following the methodology 
reported by Raubenheimer and co-workers.44 This resulted in the formation of the tetrazolato 
complexes [Au(CN4-
tBu)(FPyr)] (25), [Au(CN4-
tBu)(iPr2-bimy)] (26), and [Au(CN4-
tBu)(ADC)] (27), where CN4-
tBu refers to the 1-(tert-butyl)tetrazolato ligand. Complexes 25–
27 were also obtained as white powders, with good yields of 84–89%. Furthermore, unlike 
their precursor complexes, they are soluble in most polar organic solvents, as well as less 
polar solvents such as ethyl acetate and THF. 
 
 
Scheme 3.3. Syntheses of gold(I) tetrazolato complexes [Au(CN4-
tBu)(FPyr)] (25), [Au(CN4-
tBu)(iPr2-bimy)] (26), and [Au(CN4-
tBu)(ADC)] (27). 
 
The 1H and 13C NMR spectra of the gold(I) tetrazolato complexes 25–27 confirmed 
the successful formation of the respective compounds. A characteristic singlet at around 1.9 
ppm in the 1H NMR spectra of complexes 25 and 26 is indicative of the formation of the CN4-
tBu ligand. The tert-butyl substituent in complex 27, however, resonates more upfield at 1.32 
ppm. This drastic shift may be due to the phenyl ring of the ADC ligand pointing towards the 
tBu substituent (vide infra), thus providing additional electronic shielding.42 It is interesting to 
note that despite the asymmetric nature of complex 26, the NCH protons of the iPr2-bimy 
ligand resonate as a multiplet at 5.55 ppm, and the methyl protons of the same ligand resonate 
as a single doublet at 1.77 ppm. Similarly, in the 13C NMR spectrum of 26, only one signal 
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each is observed for the NCH (54.5 ppm) and methyl (22.6 ppm) groups of the iPr2-bimy 
ligand. This indicates the free rotation of both the CN4-
tBu and iPr2-bimy ligands about their 
respective Au–C bonds, resulting in the equivalence of both the iPr substituents. Furthermore, 
in the 13C NMR spectra of 25–27, two downfield signals were noted assignable to the carbene 
carbon atom (184.2–206.2 ppm), and the carbon donor atom of the CN4-tBu ligand (178.9–
182.4 ppm). 
The molecular structures of complexes 26 and 27 could be confirmed by X-ray 
diffraction analyses. Suitable single crystals were obtained from solutions of the compounds 
in CH2Cl2, layered with either hexane or toluene. The determined solid-state structures of both 
complexes were as expected, with both compounds adopting a linear geometry about the 
gold(I) metal center (Figure 3.4). In the case of complex 26, the dihedral angle between the 
plane of the CN4-
tBu ligand and the plane of the iPr2-bimy ligand is 55.85. This orientation 
of the ligands allows for minimization of steric hindrance between the bulky alkyl 
substituents, while allowing for optimum packing in the unit cell. As for complex 27, it 
should be noted that the asymmetric unit features two independent molecules of the 
compound, of which only one is depicted in Figure 3.4. The dihedral angle between the plane 
of the CN4-
tBu ligand and the plane comprising the NCN moiety of the ADC is 48.19. While 
the syn orientation of the tert-butyl and Xyl substituents in complex 27 is fairly unexpected, 
such an orientation probably allows for more optimum packing in the unit cell, and also 
avoids the steric effects between the bulky N-substituent of the CN4-
tBu ligand and the Et 
substituents of the ADC. Furthermore, as was the case with the gold(I) azido complex 24, 
there is evidence for intermolecular hydrogen bonding in the solid-state structure of complex 
27. These interactions, which occur between the N4 nitrogen atom of the CN4-
tBu ligand and 
the hydrogen atom of the NH moiety in the ADC, result in a step-like molecular arrangement 
(Figure 3.5). 
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Figure 3.4. Molecular structures of complexes 26 and 27 showing 50% probability ellipsoids; 
hydrogen atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: 26: Au1–C1 
2.016(4), Au1–C14 2.016(4); C1–Au1–C14 178.57(16); 27: Au1–C1 2.046(6), Au1–C6 
2.042(6); C1–Au1–C6 178.1(2). 
 
 
Figure 3.5. Intermolecular hydrogen bonding in [Au(CN4-
tBu)(ADC)] (27), resulting in a 
step-like molecular arrangement. 
 
The CN4-
tBu ligand is unique, as it features a five-membered ring comprising four 
nitrogen atoms and one carbon atom. Therefore, while the carbon donor atom of the ligand is 
formerly negatively charged, this charge should be delocalized among the four 
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electronegative nitrogen atoms, and not localized on the carbon atom. This would potentially 
turn the carbon atom into a neutral donor, thus resulting in the CN4-
tBu ligand being a form of 
anionic NHC. Undoubtedly, this postulation would require further investigation (vide infra). 
The tetrazolato ligands in complexes 25–27 can be transformed into a tetrazolin-5-
ylidene via N-alkylation. However, as our group has previously shown,45 such reactions 
would require the use of strong alkylating reagents such as trimethyloxonium 
tetrafluoroborate (Me3OBF4). This would also necessitate the exclusion of air and moisture 
during the course of the reaction. We therefore chose to pursue the syntheses of gold(I) 
hetero-bis(carbene) complexes via a protonation route, instead of alkylation. Such reactions 
would be more straightforward, as they would not require harsh alkylating reagents, and can 
be conducted without excluding air and moisture. Moreover, while protic NHCs have been 
reported before,46 syntheses of such NHCs via direct protonation using HX still remain fairly 
uncommon. Complexes 26 and 27 were chosen as representative complexes, and protonation 
of their N4 nitrogen atoms in the tetrazole-ring using HBF4 allows for the isolation of the 
desired gold(I) hetero-bis(carbene) complexes [Au(iPr2-bimy)(
tBu-tzy)]BF4 (28), and 
[Au(ADC)(tBu-tzy)]BF4 (29), where 




Scheme 3.4. Syntheses of gold(I) hetero-bis(carbene) complexes [Au(iPr2-bimy)(
tBu-tzy)]BF4 
(28) and [Au(ADC)(tBu-tzy)]BF4 (29). 
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Both complexes were obtained as white powders with very good yields of 93% and 
97%, respectively, and are readily soluble in solvents such as THF, CHCl3, CH2Cl2, acetone, 
acetonitrile and DMSO. Complex 29 is a truly unique complex, in that it is, to the best of our 
knowledge, the first example of a fully template-synthesized gold(I) hetero-bis(carbene) 
complex. 
The 1H NMR spectra of the gold(I) tetrazolin-5-ylidene complexes 28 and 29 are 
essentially similar to that of their corresponding precursors, except for the presence of a 
downfield broad singlet at 14.85 and 14.52 ppm, respectively, due to the newly formed NH 
group at the N4 position of the tetrazole ring. When comparing the 13C NMR spectra of 28 
and 29 with their respective precursor complexes, a couple of interesting observations are 
made. First, the carbene carbon atom of the ligand situated trans to the tBu-tzy ligand in 28 
and 29 resonate upfield (185.6 and 201.3 ppm, respectively) as compared to 26 and 27 (192.1 
and 206.2 ppm, respectively). This indicates the stronger donating ability of the anionic CN4-
tBu ligand in the latter as opposed to the neutral tBu-tzy ligand in the former. Furthermore, the 
change in the chemical shift of the carbon donor atom in the tetrazole-based ligands is also 
noteworthy. The carbon donor of the CN4-
tBu ligand in 26 and 27 resonate at 179.0 and 178.9 
ppm, respectively, while the same atom in the tBu-tzy ligand in 28 and 29 resonate at 177.9 
and 177.7 ppm, respectively. The close proximity of the corresponding values seems to 
indicate some similarities in the nature of the carbon donors. This affirms the earlier 
mentioned possibility that the carbon donor in the CN4-
tBu ligand in 26 and 27 already 
possesses some carbene-like character, therefore making it an anionic NHC (vide infra). 
Single crystals of complex 29 suitable for X-ray diffraction analysis were obtained via 
slow evaporation of a solution of the compound in CH2Cl2, layered with hexane. The 
determined solid-state structure is as expected, with a linear geometry adopted about the 
gold(I) metal center (Figure 3.6). It should be noted that the asymmetric unit contains three 
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independent molecules of the compound, and only one of the unique molecules is depicted in 
Figure 3.6. Despite the close proximity of the molecules in the unit cell, there is no evidence 
for aurophilic interactions between them.38 The dihedral angle between the plane of the tBu-
tzy ligand and the plane comprising the NCN atoms of the ADC is 20.85. The ligands are 
therefore closer to co-planarity in this case as compared to the precursor complex 27. 
Moreover, as was the case for the precursor complex 27, a syn orientation of the tBu and Xyl 
substituents is noted for 29, and this likely allows for optimum packing in the unit cell. 
Furthermore, intramolecular hydrogen bonding between the NH moiety of the ADC ligand 
and a fluorine atom of an adjacent BF4
– anion is also noted. 
 
 
Figure 3.6. Molecular structure of complex 29 showing 50% probability ellipsoids; hydrogen 
atoms (except H4N) and BF4
– anion are omitted for clarity. Selected bond lengths [Å] and 
angles [°]: Au1–C1 2.009(7), Au1–C6 2.031(7); C1–Au1–C6 177.6(3). 
 
3.2. Indirect determination of the donor strength of carbenes 
Apart from the Pd(II)-based 13C NMR spectroscopic method for determining the 
relative donating abilities of ligands (vide supra), our group has also recently established a 
similar method using a Au(I) system, where complexes of the type [Au(iPr2-bimy)(L)]BF4 are 
studied. We have also performed a correlation of the Pd(II) and Au(I) scales, allowing for the 
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indirect determination of donor strengths on the Pd(II) scale.37 On the basis of several known 
examples, the correlation equation [Pd] = 1.19[Au] – 45.0 ppm is derived, where [Au] refers 
to the known chemical shift of the iPr2-bimy probe using the Au(I) system, and [Pd] refers to 
the corresponding value on the Pd(II) scale. With a linear regression coefficient R2 of 0.98, it 
is fair to conclude that there is a very good linear correlation between the Pd(II) and Au(I) 
systems. 
The correlation of the Pd(II) and Au(I) systems is especially useful for ligands which 
are fairly difficult to incorporate into the [PdBr2(
iPr2-bimy)(L)] complex. ADCs and 
tetrazolin-5-ylidenes have proven to be such ligands. For example, in a previous attempt at 
determining the donor strength of an ADC using the Pd(II) system, challenges were faced in 
completing the template-directed synthesis of the ADC.47 Cleavage of the dimeric 
[PdBr2(
iPr2-bimy)]2 complex with an isocyanide leads to the formation of a mixture of cis and 
trans configured complexes which could not be separated using chromatographic techniques. 
Reaction of the isomeric mixture with an amine for the formation of the ADC also resulted in 
a very small yield of the desired complex, and the formation of an unexpected organic 
product. The template-directed synthesis of a tetrazolin-5-ylidene complex is equally 
encumbered with problems, since the cleavage of the Pd(II) dimer with NaN3 also results in 
salt metathesis reactions, where the bromido ligands are replaced by azido ligands. 
Thus, using our group’s correlation method, we can elegantly circumvent the above-
mentioned problems. With complexes 21 and 28, both of the type [Au(iPr2-bimy)(L)]BF4, at 
hand, we could proceed to determine the corresponding values of the probe on the Pd(II) 
scale, and thus study the relative donor strengths of the ADC and tBu-tzy ligands. Based on 
the correlation equation, the ADC ligand would result in a probe value of 179.6 ppm, while 
the tBu-tzy ligand would cause the probe to resonate at 175.8 ppm. Placing these two ligands 
on the already established Pd(II) scale, we note that the ADC ligand appears to be a stronger 
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donor as compared to several other classical NHCs (Figures 3.7). This is not entirely 
surprising, since previous reports involving other ADCs have revealed a similar trend.26 
However, iPr2-bimy and 1,3-dibenzylimidazolidin-2-ylidene appear to be anomalies in this 
relationship (vide infra). The tBu-tzy ligand, on the other hand, turns out to be a weaker donor 
compared to the classical NHCs, and is also weaker than tricyclohexylphosphine (Figure 3.7). 




Figure 3.7. Relative positions of the ADC and tBu-tzy ligands on the unified 13C NMR 
spectroscopic scale depicting the donor abilities of NHCs and phosphines. 
 
3.3. Computational study of tetrazolato complexes 
It has been suggested that the CN4-
tBu ligand in complexes 25–27 could in fact be 
considered as an anionic NHC (vide supra). The concept of anionic NHCs is not unheard of, 
and has been reported in literature.48 An anionic NHC would be a formerly negatively charged 
ligand, but in which the charge is drawn away from the carbon donor atom by electronegative 
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heteroatoms on the ring. This essentially turns the carbon donor into a neutral one, with the 
negative charged localized or dispersed elsewhere in the ring. This should be the case with the 
CN4-
tBu ligand in complexes 25–27. Although the ligand is formerly negatively charged, with 
four electronegative nitrogen atoms in the ring, this charge would logically be distributed 
among the nitrogen atoms, and not localized on the carbon atom bound to the gold(I) center. 
In an effort to further investigate this possibility, computational studies were conducted to 
study the charge distribution in complexes 25–27 through natural population analyses (Figure 
3.8). In the case of complexes 26 and 27, single-point energy calculations were done using 
computationally unoptimized X-ray determined molecular structures. As for complex 25, 
single-point energy calculation was done following a structure optimization. 
 
 
Figure 3.8. Charge distribution in complexes 25–27, determined through natural population 
analyses. For the purpose of clarity, only selected charges are shown. 
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The computational assessment of complexes 25–27 reveals that the negative charge of 
the CN4-
tBu ligand is distributed among the nitrogen atoms, as predicted, leaving the carbon 
atom on the ring to act as neutral donor. It can also be observed that the nitrogen atoms at the 
N4 position have the largest negative charge, which explains why subsequent protonation of 
the complexes binds the proton to the N4 position as opposed to the N2 and N3 positions. In 
any case, the computationally predicted induction of negative charge away from the carbon 
atom, and subsequent distribution of negative charge across the nitrogen atoms of the 
tetrazole ring, supports the notion of the CN4-
tBu ligand behaving as an anionic NHC. 
However, the calculated distribution of charges in 25–27 reveals an unexpected, albeit 
interesting finding. The N4 nitrogen atom of 27 has the largest negative charge of –0.381, 
followed by –0.378 in 25, and finally –0.367 in 26. This is fairly counter-intuitive, since it 
would be expected that complex 25, bearing the stronger donating FPyr ligand (vide supra) 
trans to the CN4-
tBu ligand, would have the most negatively charged N4 nitrogen atom, 
followed by 26, which bears iPr2-bimy, and finally the ADC complex 27. This is because it 
would be expected that a stronger donating ligand situated trans to the CN4-
tBu ligand would 
decrease the Lewis acidity of the gold(I) metal center to a greater extent, thus placing a lower 
electronic demand on the tetrazolato ligand, and consequently allowing more negative charge 
to remain on the tetrazole ring.  
In order to study if this peculiar trend was only the case for charge distribution, or if it 
also applied to other computationally determined electronic properties of 25–27, an analysis 
of the relative HOMO energies of the three complexes was also conducted. The calculated 
contour plots of the HOMOs of the three complexes are depicted in Figure 3.9. 
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Figure 3.9. Contour plots of the HOMOs of complexes 25–27. 
 
The HOMOs of 25–27 are all predominantly situated on the CN4-tBu ligand, with 
some gold(I) metal center involvement in the cases of 25 and 26, and significant metal 
participation in the case of 27. A key finding in all three cases, however, is the significant 
lobe centered on the N4 nitrogen atom of the CN4-
tBu ligand, clearly indicating its propensity 
for electron donation and consequential binding to electrophilic centers. Furthermore, the 
HOMO energies of complexes 25–27 are found to be –5.89, –6.11, and –5.99 eV respectively, 
and the trend in terms of increasing HOMO energy is therefore 26 < 27 < 25. Comparing this 
to the trend in terms of increasing negative charge on the N4 nitrogen atom of the tetrazolato 
ligand (cf. 26 < 25 < 27), we note the dissonance between the two sets of data. This indicates 
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that the extent of charge localization on the N4 nitrogen atom of the CN4-
tBu ligand is not 
exactly correlated to the relative HOMO energies of complexes 25–27 as a whole. 
In an effort to further explore and understand the computational data’s disagreement 
with expectation, experimental methods were employed to study the relative donating abilities 
of complexes 25–27 as metalloligands. 
3.4. Syntheses and characterization of Au/Pd hetero-bimetallic complexes 
3.4.1. Reactivity of tetrazolato complexes with dimeric [PdBr2(iPr2-bimy)]2 – Syntheses 
of Au(I)/Pd(II) hetero-bimetallic complexes 
Given that the N4 nitrogen atom of the CN4-
tBu ligand in complexes 25–27 bear the 
largest negative charge in their respective tetrazole rings, we sought to explore if complexes 
25–27 could be used as metalloligands to cleave the dimeric Pd(II) complex [PdBr2(iPr2-
bimy)]2. The dimer cleavage reaction was straightforward, wherein one equivalent of 
complexes 25–27 was reacted with half an equivalent of the dimeric Pd(II) complex in 
CH2Cl2 (Scheme 3.5). The desired hetero-bimetallic products 30–32 were obtained as yellow 
powders in good yields of > 80%. All three complexes are soluble in polar organic solvents 
such as THF, chloroform, CH2Cl2, acetone, acetonitrile and DMSO, sparingly soluble in ethyl 
acetate, and insoluble in less polar solvents such as diethyl ether and hexane. 1H and 13C 
NMR spectroscopic analyses of 30–32 confirm the successful formation of the bimetallic 
complexes, with signals from both complex fragments present in the spectra. Furthermore, the 
MS (ESI) spectra of the complexes corroborates the NMR spectroscopic data, with the [M – 
Br]+ fragment observed in all three cases. It is especially noteworthy that, to the best of our 
knowledge, complexes 30–32 represent the first examples of bimetallic complexes which 
feature a bridging tetrazolato ligand, where the bridging mode is η1C:η1N. 
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(31), and [(ADC)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (32). 
 
Single crystals suitable for X-ray diffraction analysis were obtained for complexes 31 
and 32 via evaporation of a solution of the compound in CH2Cl2, layered with toluene or 
CCl4, respectively. The determined molecular structures were as expected, with the N4 
nitrogen atom of the CN4-
tBu ligand bound to the Pd(II) metal center, resulting in V-shaped 
hetero-bimetallic complexes (Figure 3.10).  
For complex 31, it is noteworthy that the dihedral angle between the CN4-
tBu plane 
and the plane of the iPr2-bimy ligand bound to the gold(I) metal center is close to 
orthogonality, at 88.80°. On the other hand, the dihedral angle between the CN4-
tBu plane and 
the plane of the iPr2-bimy ligand bound to the Pd(II) center is 33.67°. It is also interesting that 
the Br1–Pd1–Br2 angle deviates from linearity, at 174.17(2)°, and is bent towards the carbene 
carbon of the iPr2-bimy ligand. The Br1–C15 and Br2–C15 interatomic distances, at 3.068 and 
3.028 Å, respectively, are also well within the sum of the Van der Waals radii of carbon and 
bromine (~ 3.6 Å). There is therefore evidence to suggest possible lone pair donation from the 
bromine atoms to the empty p-orbital of the carbene carbon atom; an occurrence that has been 
reported previously.17j,49 
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Figure 3.10. Molecular structures of complexes 31 and 32·2CCl4·CH2Cl2 showing 50% 
probability ellipsoids; hydrogen atoms, iPr substituents, and solvent molecules (if any) are 
omitted for clarity. Selected bond lengths [Å] and angles [°]: 31: Au1–C1 2.007(5), Au1–C14 
2.028(4), Pd1–C15 1.957(4), Pd1–N3 2.073(3); C1–Au1–C14 178.60(18), C15–Pd1–N3 
176.85(17), Br1–Pd1–Br2 174.17(2); 32: Au1–C14 2.041(10), Au1–C15 2.054(9), Pd1–C1 
1.941(9), Pd1–N3 2.066(9); C14–Au1–C15 176.8(4), C1–Pd1–N3 177.0(4), Br1–Pd1–Br2 
172.67(5). 
 
Unlike 31, complex 32 crystallized in a solvated form, with two molecules of CCl4 
and one molecule of CH2Cl2 in the asymmetric unit. The molecular structure of 32 reveals the 
dihedral angle between the CN4-
tBu plane and the plane of the ADC ligand to be 55.92°. 
However, the dihedral angle between the CN4-
tBu plane and the plane of the iPr2-bimy ligand 
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is closer to co-planarity, at 14.38°. Also unlike 31, complex 32 does not feature a PdBr2 
moiety that is bent towards the carbene carbon atom of the iPr2-bimy ligand. This may be due 
to the steric hindrance exerted by the NEt2 group of the ADC ligand that is pointed towards 
the center of the molecule, which causes the two bromine atoms to bend away from the square 
plane around the Pd(II) metal center. 
Focusing on the 13C NMR spectra of the three complexes, we note that the chemical 
shift of the carbene carbon atom of the iPr2-bimy ligand attached to the Pd(II) center is 165.4 
ppm in 30, 164.8 ppm in 31, and 165.3 ppm in 32. Based on the knowledge that a stronger 
donating ligand trans to the iPr2-bimy ligand would lead to a more downfield shift of the 
carbene carbon atom in question, we are able to rank the relative donating abilities of the 
metalloligands 25–27 in the increasing order 26 < 27 < 25. 
A summary of the data collected thus far for the gold(I) tetrazolato complexes 25–27 
and the Au(I)/Pd(II) hetero-bimetallic complexes 30–32 is provided in Table 3.1. Comparing 
the 13C NMR spectroscopic trend of complexes 30–32 with the trend in terms of increasing 
negative charge on the N4 nitrogen atom of the tetrazolato ligand in 25–27 (cf. 26 < 25 < 27), 
we observe that complex 26, with the lowest negative charge on the N4 nitrogen atom, 
consequently leads to the weakest donor strength as noted in complex 31. However, while it is 
predicted that complex 27, which has the greatest negative charge on the N4 nitrogen atom, 
should be the strongest donor, this is not the case. The experimental data instead suggests that 
the metalloligand 25 is a stronger donor compared to 27. 
However, when we compare the experimental 13C NMR spectroscopic data with the 
calculated relative HOMO energies of complexes 25–27 (vide supra), we note the agreement 
of the two trends. Just as the experimental data allows for the ranking of the relative donating 
abilities of 25–27 in an increasing order 26 < 27 < 25, the relative HOMO energies of the 
three complexes are also ranked in increasing order similarly (vide supra). 
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Table 3.1. Summary of data for Au(I) tetrazolato complexes 25–27 and Au(I)/Pd(II) 
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Therefore, the disagreement between the computationally determined charge 
distribution and the experimental findings suggests that correlating charge density on the 
donor atom alone to the overall donating ability of a ligand may be invalid. Since the gold(I) 
monometallic complexes 25–27 are acting as metalloligands, the relative donating ability as 
determined using the 13C NMR spectroscopic method is in fact a measure of the donor 
strength of the metalloligand as a whole, and not just that of the N4 nitrogen atom. Therefore, 
as shown, it is more appropriate to correlate relative donor strength to the relative HOMO 
energies of the complexes. 
However, regardless of whether we consider the computational or the experimental 
data, a puzzling finding still lingers. We had established through the Au(I)/Pd(II) 13C NMR 
spectroscopic correlation methodology that ADC is a weaker donor as compared to iPr2-bimy 
(vide supra). Based on this, it is expected that complex 26, with an iPr2-bimy ligand bound to 
the gold(I) metal center, would be a stronger donating metalloligand, leading to a more 
downfield shift of the probe in complex 31. Instead, the probe in complex 32, which features 
the ADC complex 27, shows a more downfield probe signal. It may therefore be the case that 
the ADC ligand is in fact a stronger donating ligand as compared to iPr2-bimy, and the 
correlation methodology is only able to accurately describe relative donor strengths for NHC 
systems. Such a limitation to the methodology is in fact understandable since ADCs, with a 
wider N–Ccarbene–N bond angle, tend to bring N-substituents closer to the metal center. The 
resulting electronic shielding effect on the metal center may potentially affect the chemical 
shift of the probe, leading to deviation from what is expected. Nonetheless, these limitations 
allow for more in-depth appreciation of the fundamental workings of such systems, and 
studies are underway at our group to better understand these phenomena. 
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3.4.2. Synthesis of a Au(III)/Pd(II) hetero-bimetallic complex 
Following the work with Au(I)/Pd(II) hetero-bimetallic complexes, we sought to 
synthesize gold(III) analogues to better understand the effects a Au(III) metal center would 
have on the bimetallic complex as a whole. For this purpose, the gold(III) analogue of 
complex 31, [(iPr2-bimy)AuBr2(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (34), was chosen as 
a representative target product. In fact, there are two synthetic routes available for the 
synthesis of complex 34, both of which were attempted and proved feasible (Scheme 3.6).  
 
 
Scheme 3.6. Synthesis of Au(III)/Pd(II) hetero-bimetallic complex [(iPr2-bimy)AuBr2(µ-
η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (34) via either the intermediate gold(III) tetrazolato 
complex [AuBr2(CN4-
tBu)(iPr2-bimy)] (33), or direct oxidative addition to 31. 
 
The first route involves the oxidation of the gold(I) tetrazolato complex 26 to its 
gold(III) analogue, [AuBr2(CN4-
tBu)(iPr2-bimy)] (33), via reaction with elemental bromine, in 
CH2Cl2. This reaction proceeds cleanly, affording the product as a yellow powder in high 
yield of 91%. Subsequent dimer cleavage reaction of 33 with the Pd(II) dimeric complex 
[PdBr2(
iPr2-bimy)]2 affords the desired complex [(
iPr2-bimy)AuBr2(µ-η1C:η1N-(CN4-
tBu))PdBr2(
iPr2-bimy)] (34) in good yield of 84%. Alternatively, complex 34 can also be 
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obtained via direct oxidative addition of elemental bromine to the Au(I)/Pd(II) bimetallic 
complex 31. This straightforward reaction yields the desired product in high yield of 92%. 
Complex 34 was obtained as a yellow powder, and shows similar solubility properties to its 
gold(I) analogue 31. Given the successful formation of 34 via direct oxidative addition to 31, 
it may seem that the synthesis of 34 via 33 is unnecessarily tedious. However, the latter route 
allows for the possibility of synthesizing analogues of 34 which bear chlorido or iodido 
ligands on the gold(III) metal center; a possibility that may not be available in the former 
route due to potential halide scrambling. 
Complexes 33 and 34 have been characterized using multinuclei NMR spectroscopies. 
The spectra of both complexes are fairly similar to their respective gold(I) precursors, except 
for a noticeable change in the nature of the resonances of the isopropyl groups in the iPr2-
bimy ligand bound to the gold metal center. While the 1H and 13C NMR spectra of 26 and 31 
indicate both iPr substituents to be equivalent, this is not the case with 33 and 34, where two 
sets of signals are observed for the two iPr substituents. This may be due to hindered rotation 
of the iPr2-bimy ligand about the sterically encumbered gold(III) metal center (vide supra). 
The 13C NMR spectra of 33 and 34 also show a significant upfield shift of the carbon 
donor atoms bound to the gold metal center as compared to their respective gold(I) precursors. 
In the case of complex 33, for example, signals are observed at 165.8 and 149.2 ppm, 
corresponding to the carbon donor atoms of the iPr2-bimy and CN4-
tBu ligands, respectively 
(cf. 192.1 and 179.0 ppm, respectively, in 26). Similarly, for 34, the carbon donor atoms of 
the iPr2-bimy and CN4-
tBu ligands resonate at 161.8 and 152.6 ppm, respectively (cf. 190.5 
and 180.9 ppm, respectively, in 31). This upfield shift can be attributed to the increased Lewis 
acidity of the gold metal center in the +3 oxidation state.17j,36  
This increase in the Lewis acidity of the gold metal center is also responsible for the 
slight upfield shift in the resonance of the carbene carbon atom of the iPr2-bimy ligand bound 
58  Chapter 3 
to the Pd(II) center. The carbon atom in question resonates at 162.5 ppm, as compared to 
164.8 ppm in 31. This indicates the decreased donating ability of the gold(III) metalloligand 
33 when compared to its gold(I) precursor 26. The increase in the Lewis acidity of the gold 
metal center invariably places a greater electronic demand on its ligands, therefore making 
less electron density available for donation to the Pd(II) metal center. 
3.5. Electrochemical studies of gold(I) and gold(III) tetrazolato and Au/Pd 
hetero-bimetallic complexes 
The electrochemical properties of the gold(I) and gold(III) tetrazolato complexes (26 
and 33) and Au/Pd hetero-bimetallic complexes (31 and 34) were studied through cyclic 
voltammetry experiments. Cyclic voltammetry scans were performed in both scan directions, 
with scan rates of 0.1, 0.5, and 1.0 Vs-1 (Figures 3.11 – 3.14). 
Considering the cyclic voltammograms of the gold(I) complexes 26 (Figure 3.11) and 
31 (Figure 3.12), a few similar features can be noted. When considering the forward scan 
direction, no anodic peaks attributable to the oxidation of the gold(I) metal center are 
observed at positive potentials. At negative potentials, however, a peak is observed at about –
1.1 V, which can be assigned to the reduction of Au(I) to Au(0).50 Although a fairly well 
defined anodic peak can be observed at around –0.6 V during the return scan at 0.5 and 1.0 
Vs-1, the gold(I) reduction process is still essentially irreversible under these conditions. It is 
likely that the Au(0) species is unstable or precipitates out of the solution. The 
voltammograms of both 26 and 31 in the reverse scan direction are similar to that of the 
forward scan direction, particularly at negative potentials. At positive potentials, however, a 
noticeable anodic peak is observed at about 1.3 V for both 26 and 31. This may be due to the 
oxidative dissolution of the Au(0) formed during the initial reduction, which would have 
deposited on the electrode, to Au(I).51 
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Figure 3.11. Cyclic voltammograms of 1 mM solution of complex 26 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte) in (a) forward and (b) reverse scan directions, at scan 
rates of 0.1 (blue), 0.5 (green) and 1.0 Vs-1 (red). 
 
The voltammograms of 31 do, however, have other peaks not found in that of complex 
26. For instance, in both scan directions, a cathodic peak is observed at –1.8 V, which is due 
to the Pd(II)  Pd(0) reduction process.52 Similar to the Au(I)  Au(0) reduction, the 
reduction of Pd(II) is also irreversible under the experimental conditions. The Pd(0) species is 
expected to be unstable and/or precipitate from solution. It is also noteworthy that this 
cathodic peak becomes less well defined at higher scan rates, possibly due to it being a slow 
electron transfer process. Furthermore, although not very apparent, an anodic peak at about 
1.0 V is observed in the reverse scan direction, due to the oxidation of bromide ions produced 
Au(I)  Au(0) 
Au(I)  Au(0) 
Au(0)  Au(I) 
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during the Pd(II)  Pd(0) reduction process.53 Both the forward and reverse scan direction 
voltammograms of 31 also reveal an anodic peak at about 1.6 V (*). No such anodic peak was 
observed in the voltammograms of complex 26, and although the process leading to this peak 
is still unclear, it is postulated to be a gold(I) centered process (vide infra). 
 
 
Figure 3.12. Cyclic voltammograms of 1 mM solution of complex 31 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte) in (a) forward and (b) reverse scan directions, at scan 




Au(I)  Au(0) Pd(II)  Pd(0) 
Pd(II)  Pd(0) 
Au(I)  Au(0) 
Au(0)  Au(I) 
Br–  ½ Br2 
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Figure 3.13. Cyclic voltammograms of 1 mM solution of complex 33 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte) in (a) forward and (b) reverse scan directions, at scan 
rates of 0.1 (blue), 0.5 (green) and 1.0 Vs-1 (red). 
 
Direct comparison can also be drawn between the cyclic voltammograms of the 
gold(III) complexes 33 (Figure 3.13) and 34 (Figure 3.14). For both, the forward scan 
direction, at positive potentials, do not elucidate any anodic peaks. At negative potentials 
however, two distinct cathodic peaks are observed at about –0.4 and –1.1 V. These can be 
assigned to the Au(III)  Au(I) and Au(I)  Au(0) reduction processes respectively.51 A 
cathodic peak at –1.8 V is also observed for complex 34, due to the Pd(II)  Pd(0) reduction 
process. Again, these reduction processes appear to be irreversible under the experimental 
Au(I)  Au(0) 
Au(III)  Au(I) 
Au(I)  Au(0) 
Au(III)  Au(I) 
Au(0)  Au(I) Br
–  ½ Br2 
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Figure 3.14. Cyclic voltammograms of 1 mM solution of complex 34 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte) in (a) forward and (b) reverse scan directions, at scan 
rates of 0.1 (blue), 0.5 (green) and 1.0 Vs-1 (red). 
 
For both 33 and 34, the negative potential region of the reverse scan direction 
voltammograms is nearly identical to that of the forward scan direction. At positive potentials, 
however, two very close anodic peaks are observed at about 1.0 and 1.3 V, especially at 
higher scan rates of 0.5 and 1.0 Vs-1. These can be assigned, as per before, to the oxidation of 
bromide ions, and the oxidative dissolution of Au(0), respectively. As such, it is interesting to 
note that the anodic peak at 1.0 V is higher for the case of 34 as compared to 33. This reflects 
Pd(II)  Pd(0) 
Au(I)  Au(0) 
Au(III)  Au(I) 
Pd(II)  Pd(0) 
Au(I)  Au(0) 
Au(III)  Au(I) 
Br–  ½ Br2 Au(0)  Au(I) 
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the greater concentration of bromide ions being oxidized in the case of the former, where two 
reduction processes (Au(III)  Au(I) and Pd(II)  Pd(0)), as opposed to only one in 33 
(Au(III)  Au(I)), generate bromide ions. Moreover, the voltammograms of 34 in both scan 
directions do not show the anodic peak at 1.6 V, which was observed for 31. This lends 
credence to the proposal that the anodic peak at 1.6 V observed for 31 is a gold(I) metal 
centered process.  
The fact that the various redox processes described occur at about the same potentials 
in all four complexes is very intriguing. There is therefore the possibility that under applied 
voltage, the hetero-bimetallic complexes dissociate into the separate metal fragments, 
resulting in similar species being analyzed during the cyclic voltammetry experiments. While 
the cyclic voltammetry data presented here does not provide evidence for electronic 
communication between the two metal centers in 31 and 34, further experiments under a 
variety of conditions would have to be done to better study these systems. 
3.6. Electronic properties of Au/Pd hetero-bimetallic complexes 
The electronic properties of the Au/Pd hetero-bimetallic complexes 31 and 34 have 
been explored using UV-Vis absorption spectroscopy (Figure 3.15). The UV-Vis spectra of 
the two complexes shows intense absorption bands in the 220 – 300 nm region, attributable to 
intra-ligand aromatic π  π* transitions.36 The spectrum of 31 also shows a low intensity 
absorption band at about 362 nm. A similar band, albeit blue-shifted to about 333 nm, is also 
observed for complex 34. These low intensity absorption bands are probably due to HOMO–
LUMO transitions.  
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Figure 3.15. UV-Vis absorption spectra of 50 μM solutions of complexes 31 and 34 in 
CH2Cl2. 
 
In an effort to confirm the assignment of the low intensity absorption bands to 
HOMO–LUMO transitions, a single-point energy calculation was done for complex 31 as a 
representative compound. The calculation was done using the computationally unoptimized 
X-ray determined molecular structure. The calculated contour plots of the HOMO and LUMO 
of 31 are shown in Figure 3.16. 
 
 
Figure 3.16. Contour plots of the calculated HOMO and LUMO of complex 31. 
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The HOMO of 31 is exclusively based on the PdBr2 moiety, while the LUMO is 
predominantly centered on the iPr2-bimy ligand attached to the gold(I) metal center, with 
some metal involvement. The HOMO and LUMO energies for 31 are –5.07 and –1.66 eV, 
respectively. The calculated HOMO–LUMO transition is therefore 3.41 eV, which 
corresponds to a wavelength of 364 nm. The close agreement of the experimental and 
calculated wavelength values indicates that the observed absorption band at 362 nm is in fact 
a HOMO–LUMO transition. The nature of this transition is also particularly unique, as it 
features a metal to metalloligand charge transfer. While calculations were not performed for 
complex 34, it is fair to assume that the nature of the transition observed at about 333 nm in 
its case would probably be a similar HOMO–LUMO transition. These findings are indeed 
very promising for the possibility of electronic communication between the two metal centers 
in the Au/Pd hetero-bimetallic complexes. 
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4. Syntheses, Characterization, and Properties of Iridium NHC 
Complexes 
Iridium(I) NHC complexes have been applied to a wide variety of uses, especially in 
organometallic catalysis. Notably, they have been employed in catalytic reactions such as 
hydrosilylation, hydrogenation, and transfer hydrogenation. The catalytic activities of such 
iridium(I) complexes have also been found to be dependent on both steric and electronic 
properties of the NHC ligands. Most of the work done in this area has focused on imidazole- 
and imidazoline-derived NHCs, while examples with benzimidazolin-2-ylidenes remain 
relatively scarce. Thus, as our contribution to this field of research, we have embarked on the 
syntheses and characterization of iridium(I) NHC complexes bearing the benzimidazole-
derived iPr2-bimy ligand. The electronic and electrochemical properties, as well as reactivities 
of the complexes have also been investigated. 
4.1. Syntheses and characterization of iridium(I) NHC complexes 
Iridium(I) complexes bearing NHC ligands can be easily synthesized via the silver 
carbene transfer method, with a dimeric iridium complex as a precursor. In such a manner, the 
iridium(I) complex [IrCl(COD)(iPr2-bimy)] (35)
54 was synthesized using the azolium salt iPr2-
bimy·HBr, and the dimeric complex [Ir(-Cl)(COD)]2 (Scheme 4.1). 
 
 
Scheme 4.1. Synthesis of iridium(I) NHC complex [IrCl(COD)(iPr2-bimy)] (35). 
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Complex 35 was obtained as an intense yellow powder in a moderate yield of 63%. It 
is soluble in most common organic solvents except hexane and toluene. The 1H NMR 
spectrum of the compound confirmed its formation, given the presence of signals from both 
the iPr2-bimy and COD ligands. While the isopropyl NCH protons resonate as a multiplet at 
6.19 ppm, the protons of the methyl groups are inequivalent, resonating as two doublets at 
1.77 and 1.64 ppm. This is a reflection of the asymmetric nature of the coordination plane 
around the iridium(I) metal center. The unequal nature of the methyl groups is also observed 
in the 13C NMR spectrum of the complex, where two upfield resonances at 22.2 and 21.3 ppm 
are observed. Furthermore, the downfield signal observed at 190.3 ppm in the 13C NMR 
spectrum is characteristic of the carbene carbon atom bound to the Ir(I) metal center,55 and 
thus further supports the formation of complex 35. In the MS (ESI) spectrum of the 




Figure 4.1. Molecular structure of complex 35 showing 50% probability ellipsoids; hydrogen 
atoms are omitted for clarity. Selected bond lengths [Å] and angles [°]: Ir1–C1 2.029(5), Ir1–
Cl1 2.3802(12); C1–Ir1–Cl1 90.19(13), N1–C1–N2 107.0(4). 
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Single crystals of complex 35 suitable for X-ray diffraction analysis were obtained by 
evaporation of a solution of the compound in CH2Cl2, layered with hexane. The determined 
molecular structure is as expected, with a distorted square planar geometry adopted around 
the iridium(I) metal center (Figure 4.1). This is the result of -bonding between the metal 
center and the two olefin moieties of the COD ligand. The Ir1–C1 bond length of 2.029(5) Å 
is typical of such iridium(I) NHC complexes.55a–e,56 The C1–Ir1–Cl1 bond angle of 90.19(13) 
is also close to orthogonality, indicating the lack of significant steric repulsion between the 
ligands in the solid state. 
Reaction of the neutral complex 35 with PPh3 in the presence of KPF6 cleanly affords 
the cationic iridium(I) complex [Ir(COD)(iPr2-bimy)(PPh3)]PF6 (36) as a bright reddish-
orange powder in very good yield of 91% (Scheme 4.2). Complex 36 is also soluble in most 
common organic solvents except for hexane, toluene, and diethyl ether. It is interesting to note 
that the COD ligand is not displaced in this reaction, even with the use of an excess amount of 
PPh3. The COD ligand can, however, be displaced by carbon monoxide. Bubbling the gas into 
a solution of complex 35 in CH2Cl2 for a short duration affords the iridium(I) dicarbonyl 
complex [IrCl(CO)2(
iPr2-bimy)] (37)
54 as a pale yellow powder in good yield of 92% (Scheme 
4.2). Similar to the cationic complex 36, the dicarbonyl complex 37 is soluble in most polar 
organic solvents, and insoluble in hexane, toluene, and diethyl ether. 
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As would be expected, the 1H NMR spectra of both complexes are distinctly different 
from that of the precursor complex 35. The spectrum of complex 36, for example, features 
signals from the iPr2-bimy, PPh3, and COD ligands, confirming the successful formation of 
the compound. Similar to the case of complex 35, the isopropyl methyl protons in 36 are also 
inequivalent, resonating as two doublets at 1.74 and 0.85 ppm. Comparing these values to the 
chemical shifts observed for complex 35 (cf. 1.77 and 1.64 ppm), it is interesting to note the 
drastic upfield shift in the resonance of one set of methyl protons. These are probably the 
methyl groups closer to the PPh3 ligand in complex 36 (vide infra). The close proximity of 
phenyl rings facing the methyl groups in question would provide additional electronic 
shielding, which causes the observed upfield shift in resonance (vide supra).42 A similar 
observation is made in the 13C NMR spectrum of complex 36, where the affected methyl 
groups resonate at 19.4 ppm, as compared to 21.3 ppm in the case of 35. 
As for the 1H NMR spectrum of the dicarbonyl complex 37, the absence of signals due 
to COD is noted, confirming the displacement of the ligand by carbon monoxide. While the 
isopropyl methyl groups are once again observed to be unequal, they resonate close to each 
other. The two doublets are in fact overlapped, appearing as a pseudo triplet centered at 1.70 
ppm. Similarly, the two sets of methyl groups resonate fairly close to each other in the 13C 
NMR spectrum, with signals observed at 21.7 and 21.3 ppm. 
Furthermore, in the 13C NMR spectra of complexes 36 and 37, the carbene carbon 
atom is observed to resonate highfield shifted at 183.9 and 181.0 ppm, respectively. This is 
probably due to the fact that unlike the chlorido and COD ligands, both PPh3 and CO are good 
-acceptors, thereby reducing the electron density on the iridium(I) metal center. It should be 
noted that the carbene carbon signal for complex 36 appears as a doublet, due to 13C–31P 
coupling. The small coupling constant of 9.3 Hz is in agreement with the cis arrangement of 
the iPr2-bimy ligand vis-à-vis the PPh3 ligand.
55c The MS (ESI) spectra of 36 and 37 support 
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the NMR spectroscopic data, with base peaks noted at m/z = 765 and 423, respectively. These 
correspond to the [M – PF6]+ and [M – Cl – CO]+ fragments, respectively. 
Single crystals of complex 36 suitable for X-ray diffraction analysis were obtained by 
slow diffusion of diethyl ether into a solution of the compound in chloroform. The determined 
solid-state structure of the complex is as expected, and the compound crystallizes as the 
chloroform solvate (Figure 4.2). The distorted square planar geometry about the iridium(I) 
center is also retained. The Ir1–C1 (2.039(3) Å) and Ir1–P1 (2.3365(9) Å) bond lengths are 
also similar to reported iridium(I) mixed NHC phosphine complexes.55c Moreover, the larger 
C1–Ir1–P1 bond angle of 94.93(9) is testament to the increased steric bulk around the metal 
center. Two of the phenyl rings of the PPh3 ligand are also facing the 
iPr substituents on the 




Figure 4.2. Molecular structure of complex 36·CHCl3 showing 50% probability ellipsoids; 
hydrogen atoms, PF6
– anion, and CHCl3 solvent molecule are omitted for clarity. Selected 
bond lengths [Å] and angles [°]: Ir1–C1 2.039(3), Ir1–P1 2.3365(9); C1–Ir1–P1 94.93(9), 
N1–C1–N2 106.4(3). 
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4.2. Determination of ligand donor strength using CO-stretch method 
The iridium(I) dicarbonyl complex 37 is of particular interest as it is of the type 
[IrX(CO)2(L)], where X is Cl or Br, and L is any neutral ligand. Such complexes can be 
investigated using FTIR spectroscopy to determine relative donor strengths of the ligands L 
via correlation with the CO stretching frequencies. The CO stretching frequencies determined 
from the iridium(I) system can also be related to Tolman’s Electronic Parameter (TEP), which 
is based on nickel(II) complexes of the type [Ni(CO)3L], using correlation equations reported 
by others.19 In order to explore the donor strength of the iPr2-bimy ligand using the iridium(I) 
system, and by extension its TEP, the FTIR spectrum of complex 37 was recorded in the 
solution state in CH2Cl2 (see Appendix). Two carbonyl stretching bands were observed at 
1987 and 2068 cm-1, confirming the cis configuration of complex 37. When the average CO 
stretching frequency (2028 cm-1) is applied to the correlation equation developed by Nolan 
and co-workers (i.e. TEP (cm-1) = 0.847[vCO(average)] + 336 cm
-1),19b we obtain a TEP value 
of 2054 cm-1. 
Placing the calculated TEP value of the iPr2-bimy ligand alongside the other ligands 
reported by Nolan and co-workers, it is noted that iPr2-bimy is a stronger donating ligand as 
compared to phosphines, as well as NHCs such as TPT and IPrCl (Figure 4.3). This trend is 
not surprising, and is in agreement with the relative donor strengths determined using the 13C 
NMR spectroscopic methodology developed by our group.20 The iPr2-bimy ligand is, 
however, calculated to be a weaker donor as compared to several other NHCs (Figure 4.3). 
The stronger donating ability of ItBu, IAd, and ICy as compared to iPr2-bimy is 
understandable. The former three NHCs bear non-annulated backbones and electron-donating 
N-substituents. They will thus be expected to be stronger -donors as compared to the 
benzannulated iPr2-bimy. On the other hand, the stronger donating ability of IPr, SIPr, IMes, 
and SIMes as compared to iPr2-bimy is surprising. While the former four NHCs all possess 
72  Chapter 4 
non-annulated backbones, their aryl N-substituents are electron withdrawing, and they would 
thus be expected to be weaker donors as compared to iPr2-bimy. The expected trend is in fact 
observed when using our group’s 13C NMR spectroscopic method. 
 
 
Figure 4.3. NHCs studied by Nolan and co-workers, and their respective TEP values in cm-1. 
Underlined TEP values were obtained using the Ir(I)-Ni(II) correlation equation, while the 
others were directly determined using the Ni(II) system.19b 
 
There are thus two possible explanations for this unanticipated finding. Firstly, the 
Ir(I)-Ni(II) correlation equation may not be entirely accurate and thus cannot be applied to a 
variety of NHCs. This possibility can of course be studied by applying the correlation 
equation to a larger collection of NHCs. However, the second possible explanation, and 
perhaps the more important one, is that the correlation between ligand donating abilities and 
CO stretching frequencies is inept to some extent. While the method is useful for predicting 
relative donor strengths of two vastly different ligands (e.g. phosphines vs NHCs), it is 
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unhelpful when attempting to differentiate the donating abilities of closely related ligands, 
such as two NHCs that bear the same backbone and differ only slightly in terms of N-
substituents. In fact, the data presented by Nolan and co-workers belies the accuracy of the 
method. When we compare the TEP values of IPr (2051.5 cm-1) vs SIPr (2052.2 cm-1), or 
IMes (2050.7 cm-1) vs SIMes (2051.5 cm-1), the CO-stretch method predicts that the NHCs 
with unsaturated backbones are stronger donors as compared to those with saturated 
backbones. This is clearly counter-intuitive, since backbones with sp3 carbon atoms would 
possess a greater +I effect as compared to those with sp2 carbon atoms.20 The CO-stretch 
methodology is therefore not very useful for more accurate analyses of relative donating 
abilities. 
In this context, it is also worth noting that Ganter and co-workers have calculated the 
TEP value of the bromido analogue of complex 37, [IrBr(iPr2-bimy)(CO)2], using the same 
correlation equation, and found it to be 2056 cm-1.57 This, when compared to the calculated 
TEP value of the chlorido complex 37 (cf. 2054 cm-1), yet again disproves the accuracy of the 
CO-stretch method. The bromido analogue of 37 would clearly be expected to have a lower 
TEP value, given the bromido ligand’s stronger donating ability as compared to the chlorido 
ligand. 
4.3. Electronic properties of iridium(I) NHC complexes 
The electronic properties of complexes 35 and 36, both of which are intensely 
coloured, have been further investigated through UV-Vis absorption spectroscopy (Figure 
4.4). In the case of both complexes, intense absorption bands are observed in the 220–320 nm 
region, due to intra-ligand aromatic   * transitions.36 At higher wavelengths, however, 
both complexes show a series of four low intensity absorption bands, though the bands for 36 
are bathochromically shifted as compared to that of 35. In complex 35, these bands occur at 
364, 403, 418, and 480 nm, while for 36 they are observed at 387, 462, 478, and 559 nm.  
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Figure 4.4. UV-Vis absorption spectra of 50 M solutions of complexes 35 and 36 in CH2Cl2. 
 
The low intensity absorption bands, which all occur very close to or within the visible 
spectral window, are most likely due to MLCT or LMCT processes, or intra-metal electronic 
transitions. In order to better understand the nature of the electronic transitions that result in 
the observed absorption bands, single-point energy calculations were conducted on both 
complexes 35 and 36, using computationally unoptimized X-ray determined molecular 
structures. A main area of focus would undoubtedly be the HOMO–LUMO energy gaps, and 
thus the contour plots of the calculated HOMO and LUMO of 35 and 36 are presented in 
Figure 4.5. 
The HOMO of complex 35 is predominately metal centered, and resembles the metal’s 
dz
2 atomic orbital. The LUMO, on the other hand, is predominantly based on the iPr2-bimy 
ligand, with a small amount of metal participation. A HOMO–LUMO transition in this case 
would therefore clearly be a MLCT process. Similar to complex 35, the HOMO of 36 is also 
mainly metal based, resembling the dz
2 atomic orbital. However, unlike 35, the LUMO of 
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complex 36 is also largely metal centered, with some participation from the ligands. The 
HOMO–LUMO transition in this case would likely be a metal centered one. 
 
 
Figure 4.5. Contour plots of the calculated HOMO and LUMO of complexes 35 and 36. 
 
Unfortunately, the calculated HOMO–LUMO energy gaps for complexes 35 and 36 
do not agree very well with the experimental data. For instance, the HOMO and LUMO 
energies for complex 35 are –5.09 and –0.96 eV, respectively. Thus the HOMO–LUMO gap 
is 4.13 eV, which translates to a transition wavelength of 300 nm. Comparing the calculated 
HOMO–LUMO transition wavelength to the experimental data, we note that the closest 
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absorption band to the calculated value is the one at 364 nm. Similarly, for complex 36, the 
HOMO and LUMO energies are –8.22 and –4.30 eV, respectively. Therefore, with a HOMO–
LUMO energy gap of 3.92 eV, a transition would be expected at 316 nm. However, the 
closest experimentally observed transition is at 387 nm. 
Considering both sets of data, it is undeniable that the deviation between the 
calculated and experimental values is significantly large. Given that the computational data 
did not improve significantly with different basis sets, it is possible that gas phase models 
alone are not an accurate description of the electronic transitions. Instead, solvent models that 
account for solvent interactions with the molecules would have to be employed. However, 
there are a couple of interesting factors when comparing the computational and experimental 
data. First, we note that akin to the experimental findings, the computational data also predicts 
a bathochromic shift in the HOMO–LUMO transition wavelength of complex 36. 
Furthermore, the calculated extent of the bathochromic shift (i.e. 16 nm), is fairly close to the 
experimentally observed red-shift of 23 nm. Therefore, while the absolute values obtained via 
calculation do not agree with the experimental data, there is still agreement in terms of trend. 
Unfortunately, the computational studies are still unable to account for the three other low 
energy absorption bands observed in the UV-Vis spectra of both complexes. These bands 
could, therefore, be the result of other metal-based transitions. 
4.4. Electrochemical studies of iridium(I) NHC complexes 
The electrochemical properties of complexes 35 and 36 have been explored using 
cyclic voltammetry experiments. Unfortunately, very few reports of CV studies on iridium(I) 
NHC complexes exist in the literature.58 Nonetheless, the reported CV experiments usually 
focus on the iridium(I)-centered one-electron oxidation process (Ir(I)  Ir(II)) at positive 
potentials. The reversibility of the oxidation process is also a main area of concern. As such, 
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the CVs of complexes 35 and 36 were measured in the forward scan direction at positive 
potentials, with scan rates of 0.1, 0.5, and 1.0 Vs-1. 
 
 
Figure 4.6. Cyclic voltammograms of 1 mM solution of complex 35 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte), at scan rates of 0.1 (blue), 0.5 (green) and 1.0 Vs
-1 (red). 
 
The CV of complex 35 (Figure 4.6) reveals an anodic peak at about 1.0 V, which can 
be assigned to the Ir(I)  Ir(II) oxidation. While there is a cathodic peak observed during the 
return scan at about 0.9 V, the ratio of the anodic and cathodic currents for all scan rates is not 
equal to one, and thus the process is irreversible. It is also interesting to note that with 
increasing scan rates, the positions of the anodic and cathodic peaks shift. This behaviour is 
characteristic of a slow electron-transfer process. 
The CV of complex 36 (Figure 4.7), on the other hand, offers more interesting 
insights. An anodic peak is noted at about 1.4 V due to the oxidation of Ir(I) to Ir(II), and 
during the return scan, a cathodic peak is observed at about 1.3 V. As it is with complex 35, 
the peaks shift with increasing scan rates, indicating a slow electron-transfer process. 
Furthermore, it is noteworthy that in the case of complex 36, the ratio of the anodic and 
cathodic currents is ≈ 1 at all scan rates. While this fulfils one of the requirements for 
Ir(I)  Ir(II) 
Ir(II)  Ir(I) 
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determining a redox process as reversible, the ∆E (i.e. Epoxi – Epred) is larger than 58 mV at all 
scan rates, suggesting an irreversible process. However, given that the ∆E increases with 
increasing scan rate, the redox process is most likely a quasi-reversible one. This finding 
offers the possibility of developing similar cationic iridium(I) NHC complexes, and thus 
tuning the reversibility of the iridium(I) redox process. 
 
 
Figure 4.7. Cyclic voltammograms of 1 mM solution of complex 36 in CH2Cl2 (0.1 M 
Bu4NPF6 as background electrolyte), at scan rates of 0.1 (blue), 0.5 (green) and 1.0 Vs
-1 (red). 
 
Complex 36 varies from its precursor complex 35 in that the chlorido ligand in the 
latter is replaced by a stronger donating PPh3 ligand. As such, it would be expected that 
complex 36, with a more electron-rich metal center, should result in a lower oxidation 
potential as compared to 35. However, given the difference in overall charge of the 
complexes, where 35 is neutral and 36 is cationic, such a simplistic treatment of the situation 
would be invalid. Here, the computational analyses of complexes 35 and 36 (vide supra) 
seamlessly explain the relative oxidation potentials. Complex 36 is calculated to possess an 
energetically more stable HOMO (–8.22 eV) as compared to complex 35 (–5.09 eV). As such, 
Ir(I)  Ir(II) 
Ir(II)  Ir(I) 
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the computational studies corroborate the oxidation potentials determined by CV, where 36 
has a higher oxidation potential (1.4 V) as compared to 35 (1.0 V). 
4.5. Reactivity of iridium(I) NHC complex with isocyanide 
With the iridium(I) chlorido monocarbene complex 35 at hand, we sought to 
synthesize an iridium(I) hetero-bis(carbene) complex bearing both the iPr2-bimy NHC, as well 
as a template-synthesized ADC. For this purpose, 35 was reacted with an equivalent of tert-
butyl isocyanide (CN-tBu), in the presence of an excess of KPF6, in acetone. The objective 
was to replace the chlorido ligand with the CN-tBu ligand, thus creating the metal-bound 
electrophilic reactive site necessary for subsequent attack of an amine, and consequential 
generation of the ADC. Unfortunately, the reaction did not proceed cleanly, and 1H NMR 
spectroscopic analysis of the crude product revealed the presence of multiple compounds. 
Interestingly, however, there was spectroscopic evidence to suggest the displacement of the 
COD ligand. Therefore, there are two competing ligand substitution reactions in the presence 
of CN-tBu. Given this unexpected outcome, we repeated the reaction as per before, except 
now with the use of three equivalents of CN-tBu (Scheme 4.3). Under these conditions, the 
reaction proceeds straightforwardly, with both the chlorido and COD ligands being replaced, 
affording the cationic iridium(I) NHC complex [Ir(CN-tBu)3(
iPr2-bimy)]PF6 (38) as a 
yellowish-brown powder in a moderate yield of 62%. 
 
 
Scheme 4.3. Synthesis of iridium(I) NHC complex [Ir(CN-tBu)3(
iPr2-bimy)]PF6 (38). 
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The 1H NMR spectrum of the complex is particularly useful in confirming its 
formation, given the absence of signals due to COD, as well as the presence of two upfield 
singlets at 1.40 and 1.54 ppm, corresponding to the methyl groups of the cis and trans 
configured CN-tBu ligands, respectively. In the 13C NMR spectrum, the resonance due to the 
carbene carbon atom is noted at 179.1 ppm, which is shifted upfield as compared to 35. 
Furthermore, the MS (ESI) spectrum of the compound shows a base peak at m/z = 644, 
corresponding to the [M – PF6]+ fragment. 
The NMR spectroscopy experiments for complex 38 were conducted in CDCl3. In an 
effort to obtain crystals of the complex for X-ray diffraction analysis, the bright yellow NMR 
sample solution was left to stand overnight to allow for the slow evaporation of the solvent. It 
was therefore very surprising to find, after 24 h, that the solution had turned pale yellow. 
After another 24 h, the solution had turned almost colourless. This drastic change in the 
colour of the solution was greatly intriguing, and NMR spectroscopic analysis of the 
colourless solution formed after 48 h offered some insights into the phenomenon (Figure 4.8). 
The differences between the initial and 48 h 1H NMR spectra are overt. In particular, 
we note the upfield shift of the isopropyl NCH signal, from a well-defined multiplet centered 
at 5.78 ppm, to a broad signal at 5.49 ppm. On the other hand, both the singlets due to the CN-
tBu methyl groups are shifted downfield to 1.62 and 1.72 ppm. More noticeably, the signal 
due to the isopropyl methyl groups changes from being one doublet in the initial spectrum to 
two doublets after 48 h, indicating that the two iPr substituents are in different chemical 
environments. The changes in the 13C NMR spectrum are equally noteworthy. In particular, 
the resonance due to the carbene carbon atom shifts significantly upfield to 154.1 ppm, and 
the single resonance observed for the isopropyl methyl groups becomes two signals after 48 h.  
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Figure 4.8. Initial and after 48 h (a) 1H and (b) 13C NMR spectra for complex 38. 
 
The large upfield shift of the carbene carbon atom is characteristic of an increase in 
the oxidation state of the metal center. Iridium(I) complexes are known to activate small 
molecules and undergo oxidative addition reactions. In fact, there are reports which discuss 
the oxidative addition of halo compounds to iridium(I) complexes via C–X activation.59 It is 
therefore very likely that the extended exposure of complex 38 to CDCl3 allowed for the 
oxidative addition of the solvent to the complex, forming the iridium(III) NHC complex 
[Ir(CDCl2)Cl(CN-
tBu)3(
iPr2-bimy)]PF6. Unfortunately, this could not be entirely confirmed by 
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13C NMR spectroscopy, as the signal due to the CDCl2 ligand could not be resolved despite 
extended analysis time. However, MS (ESI) was able to unequivocally confirm the 
postulation, wherein the spectrum of the colourless solution obtained after 48 h features only 
one peak at m/z = 763, corresponding to the [M – PF6]+ fragment. 
We therefore attempted to selectively synthesize the oxidatively added product 
[Ir(CHCl2)Cl(CN-
tBu)3(
iPr2-bimy)]PF6 (39), by allowing a solution of complex 38 in CHCl3 
to stand for 48 h (Scheme 4.4). As was the case with CDCl3, the initial intense yellow solution 
of complex 38 turned colourless after 48 h. 
 
 





1H NMR spectroscopic analysis of complex 39 confirmed the oxidative addition 
reaction, wherein a singlet was observed at 6.27 ppm due to the proton in the CHCl2 ligand. 
All other signals in the 1H NMR spectrum, as well as the 13C NMR spectrum, were as per the 
oxidative addition of CDCl3. Furthermore, no signals were observed at high field regions < 0 
ppm in the 1H NMR spectrum, firmly ruling out the possibility of C–H activation in this 
reaction. MS (ESI) was able to confirm the successful oxidative addition reaction, with a 
single peak observed in the spectrum at m/z = 762, corresponding to the [M – PF6]+ fragment. 
As shown in Scheme 4.3, there are three possible isomers of complex 39. The 
meridional arrangement of the CN-tBu ligands is certain, since only two singlets, due to the 
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tBu methyl groups, are observed in the 1H NMR spectrum. While it is spectroscopically 
impossible to determine which of the three isomers is present, it is evident that only one of the 
isomers forms selectively, since only one set of signals due to the iPr2-bimy and CHCl2 
ligands is observed. Unfortunately, attempts to obtain single-crystals of the complex for X-ray 
diffraction analysis proved futile, despite the use of various solvent systems. We are therefore 
unable to unambiguously confirm the molecular structure of complex 39. 
It should also be noted that when the reaction is attempted at an elevated temperature 
of 70 C, the change in the colour of the solution from bright yellow to colourless occurs 
within 2 h. However, 1H NMR spectroscopic analysis of the crude product reveals a mixture 
of two compounds. The major product is the same as that formed when the reaction is done 
over 48 h at ambient temperature. The minor product is probably one of the other two possible 
isomers, which forms as a result of rearrangement of the major product at the elevated 
temperature. 
It is interesting to note that no such oxidative addition reaction is observed when a 
solution of [IrCl(COD)(iPr2-bimy)] (35) in CDCl3 is either left to stand at ambient 
temperature or heated. The difference in reactivity is not entirely surprising, since the 
presence of three strongly donating CN-tBu ligands in complex 38 greatly lower the Lewis 
acidity of the iridium(I) metal center. This, coupled with the low oxidation state of the metal 
center, makes it highly favourable for complex 38 to undergo oxidative addition reactions. In 
any case, the ease with which the iridium(III) complex 39 can be synthesized provides for the 
possibility of exploring further reactivities and properties of similar iridium(III) complexes. 
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5. Conclusion 
In this thesis, we have explored the organometallic chemistry of gold, palladium, and 
iridium complexes bearing an N-heterocyclic carbene (NHC) and/or an acyclic diamino 
carbene (ADC). 
In Chapter 2, we introduced the new non-classical pyrazole-derived NHC, FPyr. The 
donating ability of this new ligand was determined using the 13C NMR spectroscopic method 
established by our group, and it was found to be the strongest donating ligand studied thus far 
using this method. The gold(I) monocarbene complex [AuCl(FPyr)] (2) was synthesized using 
the silver carbene transfer method, and reaction of complex 2 with LiBr or NaI afforded the 
bromido and iodido analogues, [AuBr(FPyr)] (3) and [AuI(FPyr)] (4). Structural analyses of 
complexes 2–4 revealed them to be discrete monocarbene complexes in the solid-state. 
Reaction of complex 2 with a 1,3-disubstituted benzimidazolium salt in the presence of 
K2CO3 afforded gold(I) hetero-bis(carbene) complexes of the type [Au(FPyr)(RR'-bimy)]PF6 
(5–12). Complexes of the type [Au(FPyr)(L)]PF6 (13–15), where L is a non-NHC co-ligand, 
were synthesized from complex 2 via reaction with the appropriate pro-ligand in the presence 
of KPF6. On the other hand, the gold(I) homo-bis(carbene) complex [Au(FPyr)2]PF6 (16) was 
synthesized via a two-fold one-pot silver carbene transfer reaction. 
The cytotoxic properties of complexes 2 and 5–16 were investigated using the NCI-
H1666 non-small cell lung cancer cell line. Most complexes were found to be more active 
than cisplatin, with the cationic complexes showing superior performance. This was in 
agreement with the concept of delocalized lipophilic cations (DLCs) having better bio-activity 
than neutral molecules. Unfortunately, no correlation could be made between the various N-
substituents on the benzimidazole-derived NHCs in complexes 5–12, and their relative 
cytotoxic activities. However, it was evident that complexes [Au(FPyr)(iPr2-bimy)]PF6 (5) 
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and [Au(CHPh2)2(FPyr)]PF6 (6), which both bear symmetrically substituted benzimidazolin-
2-ylidenes, where both N-substituents are 2° carbon atoms, have especially high 
cytotoxicities. This indicates some form of structure-activity relationship, and warrants further 
investigation. 
Furthermore, the selected gold(I) complexes [AuCl(FPyr)] (2), [Au(FPyr)(iPr2-
bimy)]PF6 (5), and [Au(FPyr)2]PF6 (16) were oxidized to their respective gold(III) analogues 
[AuCl3(FPyr)] (17), [AuCl2(FPyr)(
iPr2-bimy)]PF6 (18), and [AuCl2(FPyr)]PF6 (19) using 
PhICl2. Complexes 17–19 were also investigated for their cytotoxic activities using the same 
cell line. The comparative study revealed no significant difference between the performance 
of the gold(I) and gold(III) complexes, suggesting intracellular redox processes that prefer one 
oxidation state over the other. Based on these preliminary findings, further cytotoxicity assays 
could be conducted with a variety of cancer and healthy cell lines. Investigation of the 
physiochemical and pharmacokinetic properties of the complexes would also provide a more 
holistic understanding of their bio-activities. 
Metal-mediated template-directed synthetic routes towards the formation of ADCs and 
tetrazole-derived NHCs were explored in Chapter 3. The gold(I) hetero-bis(carbene) complex 
[Au(ADC)(iPr2-bimy)]BF4 (21) was obtained by reacting the cationic template complex 
[Au(CN-Xyl)(iPr2-bimy)]BF4 (20) with HNEt2. Similarly, metal-mediated synthesis of gold(I) 
tetrazolato complexes of the type [Au(CN4-
tBu)(L)] (25: L = FPyr, 26: L = iPr2-bimy, and 27: 
L = ADC) was achieved by reacting the template gold(I) azido complexes of the type 
[Au(N3)(L)] (22: L = FPyr, 23: L = 
iPr2-bimy, and 24: L = ADC) with CN-
tBu in a [3+2] 
cycloaddition reaction. Complexes 26 and 27 were chosen as representative compounds and 
further reacted with HBF4, generating complexes [Au(
iPr2-bimy)(
tBu-tzy)]BF4 (28) and 
[Au(ADC)(tBu-tzy)]BF4 (29), which both bear the protic tetrazolin-5-ylidene ligand. With 
complexes 21 and 28, both of the type [Au(iPr2-bimy)(L)]BF4, at hand, we indirectly 
86  Conclusion 
determined the relative donating abilities of the ADC and tBu-tzy ligands on the Pd(II) scale, 
using the Au(I)-Pd(II) correlation equation recently developed by our group. The ADC was 
found to be a stronger donating ligand as compared to most other classical NHCs. The tBu-tzy 
ligand, on the other hand, was found to be a weaker donor as compared to classical NHCs, 
and is also weaker than tricyclohexylphosphine. 
Computational analyses were also conducted for complexes 25–27, and these 
confirmed the tetrazolato ligand to be an anionic NHC where the negative charge of the ligand 
is distributed among the four nitrogen atoms of the tetrazole ring, and not localized on the 
carbon donor atom. The three complexes were therefore used as metalloligands to cleave the 
Pd(II) dimeric compound [PdBr2(
iPr2-bimy)]2 (I), generating Au(I)/Pd(II) hetero-bimetallic 
complexes of the type [(L)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (30: L = FPyr, 31: L = 
iPr2-bimy, and 32: L = ADC). Complexes 30–32 were used to determine the relative donating 
abilities of the metalloligands 25–27, and the donating abilities were found to be in the 
increasing order 26 < 27 < 25. Comparison of this trend with the computational data acquired 
for complexes 25–27 showed that relative donor strengths of the metalloligands could only be 
correlated to relative HOMO energies of the respective complexes, and not to the relative 
charge on the N4 nitrogen atom of the tetrazole ring. The comparative study also surfaced 
some limitations of the Au(I)-Pd(II) correlation method for determining relative donor 
strengths. 
The gold(III) analogue of complex 31, [(iPr2-bimy)AuBr2(µ-η1C:η1N-(CN4-
tBu))PdBr2(
iPr2-bimy)] (34), was prepared by two synthetic routes. Complex 34 was obtained 
by direct oxidation of complex 31 with Br2. It was also generated when the gold(III) analogue 
of complex 26, [AuBr2(CN4-
tBu)(iPr2-bimy)] (33), was reacted with the Pd(II) dimeric 
complex I. The gold monometallic complexes 26 and 33, and their respective Au/Pd hetero-
bimetallic complexes 31 and 34, were further investigated using cyclic voltammetry. Mainly 
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metal-centered redox processes were observed, with none of them being reversible. This was 
attributed to the instability of the Au(0) and Pd(0) species generated during the experiments. 
There was also no evidence for electronic communication between the two metal centers in 
complexes 31 and 34. It was noted that the redox processes for all four complexes occurred at 
about the same potential values, indicating the possibility of complex dissociation during the 
experiment, resulting in the formation of similar species. 
The electronic properties of the Au/Pd hetero-bimetallic complexes 31 and 34 were 
also studied using UV-Vis absorption spectroscopy. Complex 31 showed a low intensity 
absorption band at 362 nm, while complex 34 showed a similar band at about 333 nm. 
Computational analysis of complex 31 was able to confirm that the absorption band was due 
to the HOMO–LUMO transition, which was revealed to be a Pd-metal to Au-metalloligand 
transition. Further investigations could therefore be done to study the possibility of electronic 
communication between the metal centers. For example, CV experiments could be conducted 
under a variety of conditions to better understand the electrochemical behaviour of these 
hetero-bimetallic systems. Moreover, the electronic properties of these complexes could be 
tuned by varying the ligands, or even the metal centers. 
Chapter 4 discussed the syntheses and characterization of a few iridium NHC 
complexes that bear the iPr2-bimy ligand. The Ir(I) chlorido monocarbene complex 
[IrCl(COD)(iPr2-bimy)] (35) was synthesized using the silver carbene transfer method. 
Complex 35 was converted to the cationic Ir(I) complex [Ir(COD)(iPr2-bimy)(PPh3)]PF6 (36), 
by reacting with PPh3 in the presence of KPF6. Complex 35 was also used a precursor for the 
preparation of the iridium(I) dicarbonyl complex [IrCl(CO)2(
iPr2-bimy)] (37), via reaction 
with carbon monoxide gas. Complex 37 was studied using FTIR spectroscopy, and the 
average CO stretching frequency was correlated to the TEP. The calculated TEP value of the 
iPr2-bimy ligand was also compared with those of other ligands already on the TEP scale. The 
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comparison highlighted inconsistencies in the determined relative donating abilities of the 
ligands, and showed the limitations of the CO-stretch method. 
Complexes 35 and 36 were also further investigated using UV-Vis absorption 
spectroscopy and cyclic voltammetry. The UV-Vis absorption spectra of the two complexes 
revealed a series of four low intensity absorption bands that are close to or within the visible 
spectral window. The absorption bands of complex 36 were also observed to be 
bathochromically shifted as compared to 35. Unfortunately, computational analyses of 
complexes 35 and 36 could not unambiguously ascribe any one of the absorption bands to the 
HOMO–LUMO transition, although they were able to corroborate the red-shift observed for 
complex 36. Solvent models could be included in future computational studies to account for 
solvent-molecule interactions. In terms of CV, complex 35 showed an irreversible Ir(I)  
Ir(II) process at all scan rates. Complex 36, on the other hand, presented a quasi-reversible 
Ir(I)  Ir(II) redox process, with the ∆E increasing with increasing scan rate. This is 
characteristic of a slow-electron transfer process. Thus, future work with such complexes 
could involve the tuning of the electronic properties by varying the ligands. 
An attempt was also made at using complex 35 as a precursor for the synthesis of a 
iridium(I) hetero-bis(carbene) complex bearing both the iPr2-bimy ligand and an ADC. 
However, reaction of 35 with an equivalent of CN-tBu produced a mixture of products, with 
evidence for competing ligand substitution reactions between the chlorido and COD ligands. 
Complex 35 was therefore reacted with three equivalents of CN-tBu. This reaction cleanly 
afforded the iridium(I) complex [Ir(CN-tBu)3(
iPr2-bimy)]PF6 (38). When the bright yellow 
solution of complex 38 was allowed to stand in CDCl3 for crystallization, the solution was 
observed to turn colourless after 48 h. MS (ESI) and NMR spectroscopic analyses of the 
colourless solution confirmed the oxidative addition of CDCl3 to complex 38, forming the 
iridium(III) complex [Ir(CDCl2)Cl(CN-
tBu)3(
iPr2-bimy)]PF6. A solution of complex 38 in 
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CHCl3 was thus allowed to stand for 48 h, forming the iridium(III) complex 
[Ir(CHCl2)Cl(CN-
tBu)3(
iPr2-bimy)]PF6 (39). NMR spectroscopic analyses of complex 39 
confirmed the oxidative addition reaction, and ruled out the possibility of C–H activation. 
This unique and straightforward reaction could be employed for the synthesis of a variety of 
iridium(III) complexes, which can be further studied for their catalytic properties in organic 
transformations. 
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General considerations 
All operations were performed without taking precautions to exclude air and moisture, 
and all solvents and chemicals were used as received. 1H, 13C, 19F and 31P NMR spectra were 
recorded on a Bruker ACF 300 spectrometer or a Bruker AMX 500 spectrometer. 2D-HMBC 
and HMQC NMR spectra were recorded on a Bruker DRX 500 spectrometer. The chemical 
shifts (δ) were internally referenced to the residual solvent signals relative to tetramethylsilane 
(1H and 13C), or externally to CF3CO2H (
19F) and 85% H3PO4 (
31P). ESI mass spectra were 
measured using a Finnigan LCQ spectrometer. Elemental analyses were performed on an 
Elementar Vario Micro Cube elemental analyzer at the Department of Chemistry, National 
University of Singapore. UV-Vis absorption spectra were recorded on a Shimadzu UV-
1650PC spectrophotometer. FTIR spectra were recorded on a Shimadzu IRAffinity-1 
spectrophotometer. The azolium salts 1,3-diisopropyl benzimidazolium bromide,49c 1,3-
dibenzhydrylbenzimidazolium bromide,60 1,3-dibenzylbenzimidazolium bromide,60 1,3-
diisobutylbenzimidazolium bromide,60 1,3-dipropylbenzimidazolium bromide,61 1,3-
diethylbenzimidazolium bromide,62 and 1,3-di(2-propenyl)benzimidazolium bromide63 were 
synthesized according to literature procedures, albeit with slight modifications. 1-benzhydryl-
3-isopropylbenzimidazolium bromide was synthesized from 1-benzhydrylbenzimidazole, and 
the procedures for the syntheses of both are reported in this section. All azolium salts, 
including salt A, were converted to their hexafluorophosphate analogues via salt metathesis 





36 and [AuCl(ADC)] 
(III)43 were synthesized as previously reported. [AuCl(SC4H8)] was synthesized as a 
combination of two independent procedures, where HAuCl4 was first synthesized
66 and 
subsequently reduced to the desired [AuCl(SC4H8)] complex.
67 
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1-benzhydrylbenzimidazole. Benzimidazole (1.18 g, 10 mmol) was 
suspended in CH3CN (20 mL). NaOH (1.60 mL, 10 mmol, 6.25 M) was 
added to the suspension, and the reaction mixture was stirred for 30 min 
before a solution of benzhydryl bromide (2.47 g, 10 mmol) dissolved in CH3CN (10 mL) was 
added. The reaction mixture was heated under reflux overnight, following which it was 
filtered through Celite. The filtrate was dried over anhydrous Na2SO4, filtered, and all 
volatiles were removed under vacuum affording a beige oil. The crude product was purified 
by flash column chromatography (silica gel, ether) (1.45 g, 5.1 mmol, 51%). 1H NMR (300 
MHz, CDCl3): δ 7.84 (d, 1 H, Ar–H), 7.63 (s, 1 H, NCHN), 7.38–7.14 (m, 13 H, Ar–H), 6.76 
(s, 1 H, NCHPh2).
 13C{1H} NMR (75.5 MHz, CDCl3): δ 144.0 (Ar–C), 142.5 (NCHN), 138.0, 
134.0, 129.0, 128.5, 128.2, 123.0, 122.4, 120.3, 110.7 (Ar–C), 63.6 (NCHPh2). 
 
1-benzhydryl-3-isopropylbenzimidazolium bromide. 1-
benzhydrylbenzimidazole (1.42 g, 5.0 mmol) was suspended in CH3CN (2 
mL). Isopropyl bromide (0.5 mL, 5.3 mmol) was added to the suspension, 
and the reaction mixture was refluxed for 24 h. After cooling to ambient temperature, all 
volatiles were removed under vacuum. The crude product was washed several times with 
ethyl acetate and dried under vacuum to yield a white solid (1.58 g, 3.9 mmol, 78%). 1H NMR 
(300 MHz, CDCl3): δ 11.32 (s, 1 H, NCHN), 7.99 (s, 1 H, NCHPh2), 7.80–7.17 (m, 14 H, Ar–
H), 5.18–5.04 (m, 1 H, NCH(CH3)2), 1.83 (d, 6 H, CH3). 13C{1H} NMR (75.5 MHz, CDCl3): 
δ 147.9 (NCHN), 141.9, 135.6, 131.3, 131.0, 129.2, 129.1, 128.6, 126.82, 126.76, 115.8, 
113.7 (Ar–C), 66.5 (NCHPh2), 52.2 (NCH(CH3)2), 22.2 (CH3). MS (ESI): m/z = 327 [M – 
Br]+. 
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FPyrHBr (A). NaOH (77 mg, 1.93 mmol) was added to a solution of 
4,5,6,7-tetrahydro-1H-indazole (138 mg, 1.13 mmol) in acetonitrile (20 
mL) and the resulting mixture was stirred for 2 hours at ambient temperature. 1,4-
dibromobutane (240 μL, 2.01 mmol) was then added and the resulting mixture was stirred for 
a further 2 hours at ambient temperature. Subsequently, the reaction mixture was heated to 
reflux at 90 C for 24 hours. The solvent of the reaction mixture was removed under vacuum 
and the residue was suspended in CH2Cl2 (25 mL) and filtered. The solvent of the filtrate was 
removed under vacuum and the residue was washed with ethyl acetate (3  15 mL) and dried 
under vacuum. The product was obtained as a slightly hygroscopic off-white powder (194 mg, 
0.75 mmol, 67%). 1H NMR (500 MHz, CDCl3): δ 8.29 (s, 1 H, NCH), 4.56 (t, 2 H, 3J(H,H) = 
6.30 Hz, NCH2), 4.32 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 2.68 (t, 2 H, 
3J(H,H) = 6.30 Hz, 
CH2), 2.44 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.18 (m, 2 H, CH2), 2.11 (m, 2 H, CH2), 1.78 (m, 
2 H, CH2), 1.66 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 146.7 (NCH), 134.5 
(NCCH2), 118.7 (NCHC), 49.9, 47.1 (NCH2), 22.1, 21.5, 21.3, 20.2, 20.1, 20.0 (CH2). Anal. 
Calc. for C11H17N2Br: C, 51.37; H, 6.66; N, 10.89. Found: C, 51.60; H, 6.39; N, 10.76%. MS 
(ESI): m/z = 177 [M – Br]+. 
 
[PdBr2(FPyr)(iPr2-bimy)] (1). [PdBr2(
iPr2-bimy)]2 (99 mg, 0.11 
mmol) and salt A (54 mg, 0.21 mmol) were suspended in CH2Cl2 
(20 mL). Ag2O (29 mg, 0.13 mmol) was added to the mixture, and 
the resulting suspension was stirred for 12 h at ambient temperature, shielded from light. The 
reaction mixture was then filtered over Celite, and the solvent of the filtrate was removed 
under vacuum yielding the crude product. Recrystallization of the crude product from a 
solution in CH2Cl2 layered with toluene produced a yellow crystalline product (113 mg, 0.18 
mmol, 83%). 1H NMR (500 MHz, CDCl3): δ 7.52 (dd, 2 H, Ar–H), 7.16 (dd, 2 H, Ar–H), 6.31 
Experimental Section  93 
(m, 1 H, 3J(H,H) = 6.95 Hz, NCH), 6.13 (m, 1 H, 3J(H,H) = 6.95 Hz, NCH), 4.75 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 3.84 (t, 2 H, 
3J(H,H) = 5.65 Hz, NCH2), 2.93 (t, 2 H, 
3J(H,H) = 
5.65 Hz, CH2), 2.43 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.14 (m, 2 H, CH2), 2.08 (m, 2 H, CH2), 
1.84 (d, 6 H, 3J(H,H) = 6.95 Hz, CH3), 1.81 (d, 6 H, 
3J(H,H) = 6.95 Hz, CH3) (Signals due to 
another 2 CH2 groups of the FPyr ligand were overlapped with the signals due to the CH3 
groups of the iPr2-bimy ligand, in the 1.75–1.85 ppm region). 13C{1H} NMR (125.8 MHz, 
CDCl3): δ 184.0 (Ccarbene (iPr2-bimy)), 171.4 (Ccarbene (FPyr)), 142.5, 134.6, 134.3, 125.2, 
122.3, 113.0 (Ar–C), 54.1 (NCH), 53.9 (NCH), 51.2 (NCH2), 46.0 (NCH2), 23.6, 23.1, 22.8, 
22.7, 22.03, 21.99, 21.7, 21.4 (CH2 & CH3). Anal. Calc. for C24H34N4PdBr2·0.2C7H8: C, 
46.00; H, 5.41; N, 8.45. Found: C, 45.77; H, 5.08; N, 8.50%. MS (ESI): m/z = 565 [M – Br]+. 
 
[AuCl(FPyr)] (2). Ag2O (16 mg, 0.07 mmol) was added to a solution of B 
(29 mg, 0.11 mmol) in CH2Cl2 (15 mL), and the resulting mixture was 
stirred for 6 hours at ambient temperature, shielded from light. The reaction 
mixture was then filtered through Celite into a solution of [AuCl(SC4H8)] (37 mg, 0.12 mmol) 
in CH2Cl2 (10 mL) and the resulting mixture was stirred for 6 hours at ambient temperature. 
The reaction mixture was then filtered through Celite, and the solvent of the filtrate was 
removed under vacuum. The residue was subsequently washed with diethyl ether (3  15 mL) 
and dried under vacuum, affording the product as a white powder (38 mg, 0.09 mmol, 84%). 
1H NMR (500 MHz, CDCl3): δ 4.36 (t, 2 H, 3J(H,H) = 6.00 Hz, NCH2), 3.99 (t, 2 H, 3J(H,H) 
= 5.45 Hz, NCH2), 2.54 (t, 2 H, 
3J(H,H) = 6.00 Hz, CH2), 2.49 (t, 2 H, 
3J(H,H) = 6.00 Hz, 
CH2), 2.13 (m, 4 H, CH2), 1.84 (m, 2 H, CH2), 1.72 (m, 2 H, CH2). 
13C{1H} NMR (125.8 
MHz, CDCl3): δ 167.8 (Ccarbene), 144.4, 126.1 (Ar–C), 51.7, 46.4 (NCH2), 23.3, 23.1, 22.7, 
22.1, 21.50, 21.48 (CH2). Anal. Calc. for C11H16N2AuCl: C, 32.33; H, 3.95; N, 6.85. Found: 
C, 32.24; H, 3.96; N, 7.33%. MS (ESI): m/z = 549 [M – Cl + FPyr]+. 
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[AuBr(FPyr)] (3). LiBr (95 mg, 1.09 mmol) dissolved in acetone (15 mL) 
was added to a solution of 2 (45 mg, 0.11 mmol) in acetone (20 mL), and 
the resulting solution was stirred for 24 h at ambient temperature. The 
solvent of the reaction mixture was removed under vacuum, and the residue was dissolved 
(partially) in CH2Cl2 (25 mL). The suspension was subsequently filtered through Celite and a 
short plug of silica. The solvent of the filtrate was removed under vacuum, affording the 
product as a white powder (46 mg, 0.10 mmol, 92%). 1H NMR (500 MHz, CDCl3): δ 4.38 (t, 
2 H, 3J(H,H) = 5.95 Hz, NCH2), 3.98 (t, 2 H, 
3J(H,H) = 5.40 Hz, NCH2), 2.55 (t, 2 H, 
3J(H,H) 
= 6.35 Hz, CH2), 2.52 (t, 2 H, 
3J(H,H) = 6.15 Hz, CH2), 2.13 (m, 4 H, CH2), 1.85 (m, 2 H, 
CH2), 1.73 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 171.7 (Ccarbene), 144.4, 
126.0 (Ar–C), 51.7, 46.5 (NCH2), 23.3, 23.0, 22.7, 22.2, 21.6, 21.5 (CH2). Anal. Calc. for 
C11H16N2AuBr: C, 29.16; H, 3.56; N, 6.18. Found: C, 29.01; H, 3.74; N, 6.21%. MS (ESI): 
m/z = 549 [M – Br + FPyr]+. 
 
[AuI(FPyr)] (4). NaI (120 mg, 0.80 mmol) dissolved in acetone (30 mL) 
was added to a solution of 2 (64 mg, 0.16 mmol) in acetone (25 mL), and the 
resulting solution was stirred for 24 h at ambient temperature. The solvent of 
the reaction mixture was removed under vacuum, and the residue was dissolved (partially) in 
CH2Cl2 (30 mL), and subsequently filtered through Celite. The solvent of the filtrate was 
removed under vacuum, affording the product as a white powder (74 mg, 0.15 mmol, 95%). 
1H NMR (500 MHz, CDCl3): δ 4.38 (t, 2 H, 3J(H,H) = 6.05 Hz, NCH2), 3.99 (t, 2 H, 3J(H,H) 
= 5.45 Hz, NCH2), 2.57 (t, 2 H, 
3J(H,H) = 6.25 Hz, CH2), 2.53 (t, 2 H, 
3J(H,H) = 6.05 Hz, 
CH2), 2.13 (m, 4 H, CH2), 1.85 (m, 2 H, CH2), 1.73 (m, 2 H, CH2). 
13C{1H} NMR (125.8 
MHz, CDCl3): δ 178.7 (Ccarbene), 144.4, 125.7 (Ar–C), 51.4, 46.5 (NCH2), 23.3, 22.9, 22.7, 
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22.1, 21.6, 21.5 (CH2). Anal. Calc. for C11H16N2AuI: C, 26.42; H, 3.22; N, 5.60. Found: C, 
26.58; H, 3.28; N, 5.69%. MS (ESI): m/z = 549 [M – I + FPyr]+. 
 
General procedure for the synthesis of gold(I) hetero-bis(carbene) complexes 5–12 
Complex 2 (1 equiv) and the appropriate azolium hexafluorophosphate salt (1 equiv) were 
dissolved in acetone. K2CO3 (1.3 equiv) was added to the solution, and the resulting mixture 
was stirred for 24 h at ambient temperature. The solvent of the reaction mixture was then 
removed under vacuum. The residue was suspended in CH2Cl2 and filtered over Celite. The 
solvent of the filtrate was removed under vacuum, and the resulting residue was washed thrice 
with ethyl acetate or diethyl ether. The crude product was purified by crystallization via 
vapour diffusion of diethyl ether into a solution of the compound in CH3Cl or CH2Cl2. All 
complexes were obtained as colourless crystals. 
 
[Au(FPyr)(iPr2-bimy)]PF6 (5). Yield: 79%. 1H NMR (500 MHz, 
CDCl3): δ 7.66 (dd, 2 H, Ar–H), 7.41 (dd, 2 H, Ar–H), 5.33 (m, 2 
H, 3J(H,H) = 7.10 Hz, NCH), 4.44 (t, 2 H, 3J(H,H) = 5.15 Hz, 
NCH2), 4.10 (t, 2 H, 
3J(H,H) = 5.80 Hz, NCH2), 2.62 (br m, 4 H, CH2), 2.21 (br m, 4 H, CH2), 
1.88 (br m, 4 H, CH2), 1.83 (d, 12 H, 
3J(H,H) = 7.10 Hz, CH3). 
13C{1H} NMR (125.8 MHz, 
CDCl3): δ 192.5 (Ccarbene (iPr2-bimy)), 179.6 (Ccarbene (FPyr)), 144.4, 133.4, 126.6, 124.9, 
113.4 (Ar–C), 53.9 (NCH), 51.9, 46.7 (NCH2), 23.4 (CH3), 23.2, 23.1, 22.6, 22.0, 21.3, 21.1 
(CH2). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, 
CDCl3): δ 2.28 (d, PF6). Anal. Calc. for C24H34N4AuPF6: C, 40.01; H, 4.76; N, 7.78. Found: 
C, 39.78; H, 4.82; N, 8.06%. MS (ESI): m/z = 575 [M – PF6]+. 
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[Au((CHPh2)2-bimy)(FPyr)]PF6 (6). Yield: 82%. 1H NMR (500 
MHz, CDCl3): δ 7.66 (s, 2 H, NCH), 7.40–7.38 (m, 12 H, Ar–H), 
7.28–7.27 (m, 8 H, Ar–H), 7.17 (dd, 2 H, Ar–H), 7.05 (dd, 2 H, 
Ar–H), 4.02 (t, 2 H, 3J(H,H) = 5.70 Hz, NCH2), 3.88 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 2.56 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.34 (t, 2 H, 
3J(H,H) = 5.70 
Hz, CH2), 2.12 (m, 2 H, CH2), 2.01 (m, 2 H, CH2), 1.82 (m, 2 H, CH2), 1.70 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 197.8 (Ccarbene ((CHPh2)2-bimy)), 178.8 (Ccarbene 
(FPyr)), 144.4, 137.9, 134.5, 129.7, 129.5, 129.0, 126.3, 125.3, 114.6 (Ar–C), 68.8 (NCH), 
51.5, 46.5 (NCH2), 23.3, 22.9, 22.5, 21.9, 21.2, 21.0 (CH2). 
31P{1H} NMR (202.4 MHz, 
CDCl3): δ –143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 2.30 (d, PF6). Anal. Calc. 
for C44H42N4AuPF6: C, 54.55; H, 4.37; N, 5.78. Found: C, 54.54; H, 4.26; N, 5.61%. MS 
(ESI): m/z = 823 [M – PF6]+. 
 
[Au(FPyr)((iPr)(CHPh2)-bimy)]PF6 (7). Yield: 76%. 1H NMR 
(500 MHz, CDCl3): δ 7.73 (d, 1 H, Ar–H), 7.68 (s, 1 H, NCHPh2), 
7.42–7.28 (m, 11 H, Ar–H), 7.22 (t, 1 H, Ar–H), 7.03 (d, 1 H, Ar–
H), 5.40 (m, 1 H, 3J(H,H) = 6.30 Hz, NCH(CH3)2), 4.20 (br t, 2 H, 
NCH2), 4.09 (br t, 2 H, NCH2), 2.62 (br t, 2 H, CH2), 2.52 (br t, 2 H, CH2), 2.16 (br m, 4 H, 
CH2), 1.88 (d, 6 H, 
3J(H,H) = 6.30 Hz, CH3), 1.77 (br m, 2 H, CH2), 1.31 (br m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 195.1 (Ccarbene ((iPr)(CHPh2)-bimy)), 179.2 (Ccarbene 
(FPyr)), 144.4, 138.0, 134.2, 133.4, 129.7, 129.6, 129.3, 129.0, 126.4, 125.13, 125.07, 114.6, 
113.5 (Ar–C), 68.8 (NCHPh2), 54.0 (NCH(CH3)2), 51.7, 46.6 (NCH2), 23.31 (CH2), 23.29 
(CH3), 23.0, 22.5, 21.9, 21.2, 21.0 (CH2). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –143.8 (m, 
PF6). 
19F{1H} NMR (282.4 MHz, CDCl3): δ 2.34 (d, PF6). Anal. Calc. for 
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C34H38N4AuPF6·0.3CH2Cl2·0.6Et2O: C, 48.20; H, 4.92; N, 6.13. Found: C, 48.29; H, 4.71; N, 
6.01%. MS (ESI): m/z = 699 [M – PF6]+. 
 
[Au((CH2Ph)2-bimy)(FPyr)]PF6 (8). Yield: 80%. 1H NMR (500 
MHz, CDCl3): δ 7.44–7.31 (m, 14 H, Ar–H), 5.77 (s, 4 H, 
NCH2Ph), 4.22 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 4.03 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 2.57 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.50 (t, 2 H, 
3J(H,H) = 6.30 
Hz, CH2), 2.09 (m, 4 H, CH2), 1.83 (m, 2 H, CH2), 1.72 (m, 2 H, CH2). 
13C{1H} NMR (125.8 
MHz, CDCl3): δ 195.7 (Ccarbene ((CH2Ph)2-bimy)), 179.9 (Ccarbene (FPyr)), 144.4, 135.8, 134.2, 
129.8, 129.2, 127.9, 126.7, 125.6, 112.8 (Ar–C), 52.9 (NCH2Ph), 51.7, 46.6 (NCH2), 23.3, 
22.9, 22.5, 21.9, 21.3, 21.1 (CH2). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –143.7 (m, PF6). 
19F{1H} NMR (282.4 MHz, CDCl3): δ 2.59 (d, PF6). Anal. Calc. for C32H34N4AuPF6: C, 




[Au(FPyr)(iBu2-bimy)]PF6 (9). Yield: 74%. 1H NMR (500 MHz, 
CDCl3): δ 7.52 (dd, 2 H, Ar–H), 7.44 (dd, 2 H, Ar–H), 4.40 (br t, 2 
H, NCH2), 4.31 (d, 4 H, 
3J(H,H) = 7.55 Hz, NCH2CH(CH3)2), 4.10 
(br t, 2 H, NCH2), 2.62 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.59 (t, 2 
H, 3J(H,H) = 6.30 Hz, CH2), 2.44 (m, 2 H, NCH2CH(CH3)2), 2.19 (br t, 4 H, CH2), 1.87 (m, 2 
H, CH2), 1.79 (m, 2 H, CH2), 1.03 (d, 12 H, 
3J(H,H) = 6.30 Hz, CH3). 
13C{1H} NMR (125.8 
MHz, CDCl3): δ 194.8 (Ccarbene (iBu2-bimy)), 180.2 (Ccarbene (FPyr)), 144.5, 134.3, 126.6, 
125.3, 112.5 (Ar–C), 56.4 (NCH2CH(CH3)2), 51.8, 46.6 (NCH2), 30.2 (NCH2CH(CH3)2), 
23.4, 23.0, 22.5, 22.0, 21.3, 21.1 (CH2), 21.0 (CH3). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –
143.7 (m, PF6). 
19F{1H} NMR (282.4 MHz, CDCl3): δ 2.49 (d, PF6). Anal. Calc. for 
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C26H38N4AuPF6: C, 41.72; H, 5.12; N, 7.48. Found: C, 41.52; H, 5.10; N, 7.31%. MS (ESI): 
m/z = 603 [M – PF6]+. 
 
[Au(FPyr)(n-Pr2-bimy)]PF6 (10). Yield: 79%. 1H NMR (500 
MHz, CD3CN): δ 7.67 (dd, 2 H, Ar–H), 7.47 (dd, 2 H, Ar–H), 4.49 
(t, 4 H, 3J(H,H) = 6.90 Hz, NCH2CH2CH3), 4.41 (br t, 2 H, NCH2), 
4.04 (br t, 2 H, NCH2), 2.60 (m, 4 H, CH2), 2.10 (br t, 4 H, CH2), 1.99 (m, 4 H, CH2), 1.84 
(m, 2 H, CH2), 1.76 (m, 2 H, CH2), 0.98 (t, 6 H, 
3J(H,H) = 7.60 Hz, CH3). 
13C{1H} NMR 
(125.8 MHz, CD3CN): δ 194.8 (Ccarbene (n-Pr2-bimy)), 180.0 (Ccarbene (FPyr)), 144.5, 134.2, 
126.3, 125.1, 112.7 (Ar–C), 51.8 (NCH2), 50.6 (NCH2CH2CH3), 46.6 (NCH2), 24.2 
(NCH2CH2CH3), 23.4, 22.8, 22.5, 21.7, 21.1, 20.8 (CH2), 11.5 (CH3). 
31P{1H} NMR (202.4 
MHz, CD3CN): δ –143.2 (m, PF6). 19F{1H} NMR (282.4 MHz, CD3CN): δ 3.43 (d, PF6). 
Anal. Calc. for C24H34N4AuPF6: C, 40.01; H, 4.76; N, 7.78. Found: C, 40.04; H, 4.40; N, 
7.73%. MS (ESI): m/z = 575 [M – PF6]+. 
 
[Au(Et2-bimy)(FPyr)]PF6 (11). Yield: 72%. 1H NMR (500 MHz, 
CDCl3): δ 7.53 (dd, 2 H, Ar–H), 7.46 (dd, 2 H, Ar–H), 4.57 (m, 4 
H, 3J(H,H) = 7.55 Hz, NCH2CH3), 4.47 (t, 2 H, 
3J(H,H) = 5.65 Hz, 
NCH2), 4.09 (t, 2 H, 
3J(H,H) = 6.30 Hz, NCH2), 2.62 (t, 4 H, 
3J(H,H) = 6.30 Hz, CH2), 2.21 
(m, 4 H, CH2), 1.89 (m, 2 H, CH2), 1.80 (m, 2 H, CH2), 1.60 (t, 6 H, 
3J(H,H) = 7.60 Hz, CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 194.1 (Ccarbene (Et2-bimy)), 180.7 (Ccarbene (FPyr)), 
144.3, 133.7, 126.7, 125.3, 112.1 (Ar–C), 52.0, 46.7 (NCH2), 44.4 (NCH2CH3), 23.4, 23.0, 
22.6, 22.0, 21.4, 21.2 (CH2), 16.6 (CH3). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –143.8 (m, 
PF6). 
19F{1H} NMR (282.4 MHz, CDCl3): δ 2.27 (d, PF6). Anal. Calc. for C22H30N4AuPF6: C, 
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[Au(FPyr)((2-propenyl)2-bimy)]PF6 (12). Yield: 75%. 1H NMR 
(500 MHz, CD3CN): δ 7.63 (dd, 2 H, Ar–H), 7.47 (dd, 2 H, Ar–H), 
6.14 (m, 2 H, NCH2CH=CH2), 5.28 (dm, 2 H, 
3J(H,H) = 10.10 Hz, 
NCH2CH=CHHtrans), 5.16–5.19 (m, 6 H, NCH2CH=CH2 and NCH2CH=CHHcis), 4.39 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 4.04 (t, 2 H, 
3J(H,H) = 5.70 Hz, NCH2), 2.59 (m, 4 H, CH2), 2.09 
(br t, 4 H, CH2), 1.84 (m, 2 H, CH2), 1.76 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, 
CD3CN): δ 196.0 (Ccarbene ((2-propenyl)2-bimy)), 179.9 (Ccarbene (FPyr)), 144.7, 134.4, 133.7, 
126.5, 125.6, 118.6, 113.1 (Ar–C and vinylic–C), 52.0 (NCH2), 51.5 (NCH2CH=CH2), 46.8 
(NCH2), 23.6, 23.0, 22.7, 21.9, 21.3, 21.0 (CH2). 
31P{1H} NMR (202.4 MHz, CD3CN): δ –
144.0 (m, PF6). 
19F{1H} NMR (282.4 MHz, CD3CN): δ 3.46 (d, PF6). Anal. Calc. for 
C24H30N4AuPF6: C, 40.23; H, 4.22; N, 7.82. Found: C, 40.14; H, 4.36; N, 7.64%. MS (ESI): 
m/z = 571 [M – PF6]+. 
 
General procedure for the synthesis of gold(I) heteroleptic complexes 13–15 
Complex 2 (1 equiv) and the appropriate pro-ligand (1.2 equiv) were dissolved in acetone. 
KPF6 (3 equiv) dissolved in acetone was added to the solution, and the resulting mixture was 
stirred for 1 h at ambient temperature. The solvent of the reaction mixture was then removed 
under vacuum. The residue was suspended in CH2Cl2 and filtered over Celite. The solvent of 
the filtrate was removed under vacuum, and the resulting residue was washed thrice with 
diethyl ether. The crude product was purified by crystallization via vapour diffusion of diethyl 
ether into a solution of the compound in CH2Cl2. All complexes were obtained as colourless 
crystals. 
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[Au(FPyr)(PPh3)]PF6 (13). Yield: 94%. 1H NMR (500 MHz, CDCl3): 
δ 7.54–7.41 (m, 15 H, Ar–H), 4.41 (br t, 2 H, NCH2), 4.12 (br t, 2 H, 
NCH2), 2.60 (m, 4 H, CH2), 2.18 (br m, 4 H, CH2), 1.86 (br m, 2 H, 
CH2), 1.77 (br m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 
182.4 (Ccarbene), 144.7 (Ar–C), 134.6, 132.5, 130.1, 130.0 (d, Ar–C), 126.4 (Ar–C), 52.0, 46.7 
(NCH2), 23.2, 22.9, 22.5, 21.8, 21.2, 20.9 (CH2). 
31P{1H} NMR (202.4 MHz, CDCl3): δ 41.3 
(PPh3), –143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 2.32 (d, PF6). Anal. Calc. for 
C29H31N2AuP2F6: C, 44.63; H, 4.00; N, 3.59. Found: C, 44.88; H, 3.89; N, 3.40%. MS (ESI): 
m/z = 635 [M – PF6]+. 
 
[Au(FPyr)(P(OPh)3)]PF6 (14). Yield: 77%. 1H NMR (500 MHz, 
CDCl3): δ 7.48–7.27 (m, 15 H, Ar–H), 4.02 (t, 2 H, 3J(H,H) = 5.70 
Hz, NCH2), 3.79 (t, 2 H, 
3J(H,H) = 6.30 Hz, NCH2), 2.52 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.20 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.10 
(m, 2 H, CH2), 2.00 (m, 2 H, CH2), 1.78 (m, 2 H, CH2), 1.65 (m, 2 H, CH2). 
13C{1H} NMR 
(125.8 MHz, CDCl3): δ 179.6 (d, 2J(C,P) = 178 Hz, Ccarbene), 150.1, 144.6, 131.3, 127.5, 
126.6, 121.9 (d, Ar–C), 51.5, 46.6 (NCH2), 23.1, 22.4, 22.3, 21.4, 21.2, 20.7 (CH2). 31P{1H} 
NMR (202.4 MHz, CDCl3): δ 139.3 (P(OPh)3), –143.8 (m, PF6). 19F{1H} NMR (282.4 MHz, 
CDCl3): δ 2.35 (d, PF6). Anal. Calc. for C29H31N2O3AuP2F6: C, 42.04; H, 3.77; N, 3.38. 
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[Au(DMAP)(FPyr)]PF6 (15). Yield: 81%. 1H NMR (500 MHz, 
CD3CN): δ 7.99 (d, 2 H, Ar–H), 6.68 (d, 2 H, Ar–H), 4.37 (br t, 2 
H, NCH2), 4.00 (br t, 2 H, NCH2), 3.05 (s, 6 H, NCH3), 2.54 (m, 4 
H, CH2), 2.06 (m, 4 H, CH2), 1.82 (br m, 2 H, CH2), 1.73 (br m, 2 H, CH2). 
13C{1H} NMR 
(125.8 MHz, CD3CN): δ 161.0 (Ccarbene), 156.1, 150.4, 144.7, 125.9, 108.3 (Ar–C), 52.1, 46.7 
(NCH2), 39.5 (NCH3), 23.3, 23.0, 22.5, 21.7, 21.1, 20.9 (CH2). 
31P{1H} NMR (202.4 MHz, 
CD3CN): δ –143.1 (m, PF6). 19F{1H} NMR (282.4 MHz, CD3CN): δ 3.46 (d, PF6). Anal. 
Calc. for C18H26N4AuPF6: C, 33.76; H, 4.09; N, 8.75. Found: C, 33.85; H, 4.10; N, 8.51%. 
MS (ESI): m/z = 405 [M – PF6 – DMAP + CH3OH]+, 495 [M – PF6]+. 
 
[Au(FPyr)2]PF6 (16). Salt B (35 mg, 0.11 mmol), 
tetrabutylammonium bromide (35 mg, 0.11 mmol) and Ag2O (26 
mg, 0.11 mmol) were stirred in CH2Cl2 (20 mL) for 6 h at 
ambient temperature, shielded from light. [AuCl(SC4H8)] (18 mg, 0.06 mmol) was then added 
to the reaction mixture and stirring was continued for 6 h. The resulting mixture was filtered 
through Celite, and the solvent of the filtrate was removed under vacuum. The resulting 
residue was washed with ethyl acetate (3  5 mL) and dried under vacuum, affording the 
product as an off-white powder (24 mg, 0.03 mmol, 62%). 1H NMR (500 MHz, CDCl3): δ 
4.39 (br t, 2 H, NCH2), 4.01 (br t, 2 H, NCH2), 2.57 (t, 4 H, 
3J(H,H) = 5.65 Hz, CH2), 2.14 (br 
t, 4 H, CH2), 1.85 (br m, 2 H, CH2), 1.75 (br m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, 
CDCl3): δ 184.6 (Ccarbene), 144.2, 126.8 (Ar–C), 51.8, 46.6 (NCH2), 23.4, 23.0, 22.7, 22.2, 
21.4 ( 2) (CH2). 31P{1H} NMR (202.4 MHz, CDCl3): δ –143.9 (m, PF6). 19F{1H} NMR 
(282.4 MHz, CDCl3): δ 2.57 (d, PF6). Anal. Calc. for C22H32N4AuPF6: C, 38.05; H, 4.64; N, 
8.07. Found: C, 38.39; H, 4.63; N, 7.92%. MS (ESI): m/z = 549 [M – PF6]+. 
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General procedure for the syntheses of Au(III) complexes 17–19 
The precursor Au(I) complex (1 equiv) and PhICl2 (1.2 equiv) were dissolved in CH2Cl2 and 
stirred for 24 hours at ambient temperature, shielded from light. The solvent of the reaction 
mixture was then removed under vacuum, and the resulting residue was washed with hexane 
and diethyl ether several times, and dried under vacuum. 
 
[AuCl3(FPyr)] (17). Pale yellow powder, 90%. 1H NMR (500 MHz, 
DMSO-d6): δ 4.42 (br t, 2 H, NCH2), 4.28 (br t, 2 H, NCH2), 2.67 (t, 2 H, 
3J(H,H) = 5.65 Hz, CH2), 2.54 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.07 (m, 4 
H, CH2), 1.79 (m, 2 H, CH2), 1.72 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, DMSO-d6): δ 
145.3 (Ar–C), 134.9 (Ccarbene), 119.6 (Ar–C), 50.0, 46.2 (NCH2), 21.6, 20.9, 20.5, 20.1, 19.7, 
19.1 (CH2). Anal. Calc. for C11H16N2AuCl3: C, 27.55; H, 3.36; N, 5.84. Found: C, 27.67; H, 
3.21; N, 5.72%. MS (ESI): m/z = 905 [2M – 2Cl + OH]+. 
 
[AuCl2(FPyr)(iPr2-bimy)]PF6 (18). Pale yellow powder, 98%. 1H 
NMR (500 MHz, CDCl3): δ 7.77 (br m, 2 H, Ar–H), 7.46 (dd, 2 H, 
Ar–H), 5.34 (m, 2 H, 3J(H,H) = 6.95 Hz, NCH), 4.55 (t, 2 H, 
3J(H,H) = 5.65 Hz, NCH2), 4.23 (t, 2 H, 
3J(H,H) = 6.30 Hz, NCH2), 2.70 (m, 4 H, CH2), 2.32 
(br m, 2 H, CH2), 2.24 (br m, 2 H, CH2) 1.93 (br m, 4 H, CH2), 1.87 (d, 12 H, 
3J(H,H) = 6.95 
Hz, CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 168.5 (Ccarbene (iPr2-bimy)), 151.2 (Ccarbene 
(FPyr)), 146.0, 133.7, 125.6, 122.8, 114.8 (Ar–C), 51.4, 47.6 (NCH2), 22.9, 22.21 (CH2), 
22.18 (CH3), 21.8, 21.6, 21.5, 20.8 (CH2). 
31P{1H} NMR (202.4 MHz, CDCl3): δ –143.7 (m, 
PF6). 
19F{1H} NMR (282.4 MHz, CDCl3): δ 2.58 (d, PF6). Anal. Calc. for C24H34N4AuCl2PF6: 
C, 36.42; H, 4.33; N, 7.08. Found: C, 36.62; H, 4.32; N, 7.42%. MS (ESI): m/z = 645 [M – 
PF6]
+. 
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[AuCl2(FPyr)2]PF6 (19). Yellow powder, 95%. 1H NMR (500 
MHz, DMSO-d6): δ 4.45 (br t, 2 H, NCH2), 4.23 (br t, 2 H, 
NCH2), 2.67 (t, 2 H, 
3J(H,H) = 5.05 Hz, CH2), 2.62 (br t, 2 H, 
CH2), 2.08 (br m, 4 H, CH2), 1.80 (br m, 2 H, CH2), 1.73 (br m, 2 H, CH2). 
13C{1H} NMR 
(125.8 MHz, DMSO-d6): δ 155.4 (Ccarbene), 144.5, 121.1 (Ar–C), 49.7, 45.9 (NCH2), 22.0, 
21.2, 20.6, 20.2, 20.0, 19.4 (CH2). 
31P{1H} NMR (202.4 MHz, DMSO-d6): δ –143.0 (m, PF6). 
19F{1H} NMR (282.4 MHz, DMSO-d6): δ 5.80 (d, PF6). Anal. Calc. for C22H32N4AuCl2PF6: 




[Au(CN-Xyl)(iPr2-bimy)]BF4 (20). [AuCl(iPr2-bimy)] (98 
mg, 0.23 mmol) was dissolved in CH2Cl2 (25 mL), and 2,6-
dimethylphenylisocyanide (35 mg, 0.27 mmol) and AgBF4 
(53 mg, 0.27 mmol) were added to the solution. The resulting suspension was stirred at 
ambient temperature for 1 h, shielded from light. The reaction mixture was then filtered over 
Celite, and the filtrate was concentrated under vacuum to ~5 mL. Diethyl ether (30 mL) was 
added to precipitate the product, which was obtained as a white powder (132 mg, 0.21 mmol, 
95%). 1H NMR (500 MHz, CDCl3): δ 7.75 (dd, 2 H, Ar–H), 7.46 (dd, 2 H, Ar–H), 7.36 (t, 1 
H, Ar–H), 7.19 (d, 2 H, Ar–H), 5.38 (m, 2 H, 3J(H,H) = 6.95 Hz, NCH), 2.55 (s, 6 H, CH3), 
1.82 (d, 12 H, 3J(H,H) = 6.95 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 181.0 
(Ccarbene), 137.6, 133.1, 132.3, 129.2, 125.7, 114.3 (Ar–C), 55.5 (NCH), 23.1 (NCH(CH3)2), 
19.4 (CH3) (Signals due to the two carbon atoms in the CN–C moiety could not be detected 
despite extended analysis time). 19F{1H} NMR (282.4 MHz, CDCl3): δ –76.91 (10BF4), –
76.97 (11BF4). Anal. Calc. for C22H27N3AuBF4: C, 42.81; H, 4.41; N, 6.81. Found: C, 42.82; 
H, 4.24; N, 6.76%. MS (ESI): m/z = 530 [M – BF4]+. 
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[Au(ADC)(iPr2-bimy)]BF4 (21). Complex 20 (55 mg, 0.09 mmol) 
was dissolved in CH2Cl2 (25 mL), and HNEt2 (30 L, 0.29 mmol) 
was added. The resulting solution was stirred at ambient 
temperature for 1 h, shielded from light. The reaction mixture was 
then concentrated under vacuum to ~5 mL, and diethyl ether (30 mL) was added to precipitate 
the product as a white powder (60 mg, 0.09 mmol, 97%). 1H NMR (500 MHz, CDCl3): δ 8.30 
(br s, 1 H, NH), 7.57 (br s, 2 H, Ar–H), 7.34 (br s, 2 H, Ar–H), 7.14–7.07 (m, 3 H, Ar–H), 
4.69 (m, 2 H, 3J(H,H) = 6.95 Hz, NCH), 3.95 (br m, 2 H, NCH2), 3.68 (br m, 2 H, NCH2), 
2.29 (s, 6 H, CH3), 1.53 (d, 12 H, 
3J(H,H) = 6.95 Hz, NCH(CH3)2), 1.39 (br m, 6 H, 
NCH2CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 203.5 (Ccarbene (ADC)), 188.7 (Ccarbene 
(iPr2-bimy)), 139.0, 137.9, 133.0, 128.8, 128.7, 124.9, 113.8 (Ar–C), 54.2 (NCH), 53.0, 42.8 
(NCH2), 22.5 (NCH(CH3)2), 19.4 (CH3), 16.0, 13.0 (NCH2CH3). 
19F{1H} NMR (282.4 MHz, 
CDCl3): δ –77.16 (10BF4), –77.21 (11BF4). Anal. Calc. for C26H38N4AuBF4: C, 45.23; H, 5.55; 
N, 8.12. Found: C, 45.23; H, 5.29; N, 7.96%. MS (ESI): m/z = 603 [M – BF4]+. 
 
General procedure for the syntheses of gold(I) azido complexes 22–24. 
The appropriate chlorido precursor complex (1 equiv) was dissolved in a mixture of CH2Cl2 
and methanol. AgNO3 (1.2 equiv) dissolved in methanol was then added to the solution, and 
the resulting mixture was stirred for 30 mins at ambient temperature, shielded from light. The 
reaction mixture was then filtered over Celite into a solution of NaN3 (5 equiv) in methanol. 
The resulting mixture was stirred for 30 mins at ambient temperature, after which it was 
filtered over Celite. The solvent of the filtrate was removed under vacuum, and CH2Cl2 was 
added to partially dissolve the residue. The suspension was filtered over Celite, and the 
solvent of the filtrate was removed under vacuum, affording the product as a white powder in 
all three cases. 
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[Au(N3)(FPyr)] (22). Yield = 95%. 1H NMR (500 MHz, CDCl3): δ 4.34 
(br t, 2 H, NCH2), 3.99 (br t, 2 H, NCH2), 2.54 (t, 2 H, 
3J(H,H) = 6.35 Hz, 
CH2), 2.48 (t, 2 H, 
3J(H,H) = 5.65 Hz, CH2), 2.13 (br m, 4 H, CH2), 1.85 
(br m, 2 H, CH2), 1.74 (br m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 165.8 
(Ccarbene), 144.3, 126.3 (Ar–C), 51.8, 46.4 (NCH2), 23.3, 23.1, 22.7, 22.2, 21.5, 21.4 (CH2). 
Anal. Calc. for C11H16N5Au0.5CH3OH: C, 31.95; H, 4.08; N, 16.48. Found: C, 31.95; H, 
3.75; N, 16.20%. MS (ESI): m/z = 549 [M – N3 + FPyr]+. 
 
[Au(N3)(iPr2-bimy)] (23). Yield = 92%. 1H NMR (500 MHz, CDCl3): δ 
7.63 (dd, 2 H, Ar–H), 7.36 (dd, 2 H, Ar–H), 5.41 (m, 2 H, 3J(H,H) = 
6.90 Hz, NCH), 1.72 (d, 12 H, 3J(H,H) = 6.90 Hz, CH3). 
13C{1H} NMR 
(125.8 MHz, CDCl3): δ 174.7 (Ccarbene), 133.0, 124.5, 113.6 (Ar–C), 54.9 (NCH), 22.3 (CH3). 
Anal. Calc. for C13H18N5Au0.5CH3OH: C, 35.46; H, 4.41; N, 15.31. Found: C, 35.41; H, 
4.15; N, 15.10%. MS (ESI): m/z = 601 [M – N3 + iPr2-bimy]+. 
 
[Au(N3)(ADC)] (24). Yield = 94%. 1H NMR (500 MHz, CDCl3): δ 7.16 
(m, 2 H, Ar–H + NH), 7.07 (m, 2 H, Ar–H), 3.90 (q, 2 H, 3J(H,H) = 7.55 
Hz, NCH2), 3.46 (q, 2 H, 
3J(H,H) = 7.55 Hz, NCH2), 2.19 (s, 6 H, CH3), 
1.30 (m, 6 H, NCH2CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 191.2 
(Ccarbene), 138.1, 136.9, 129.2, 129.0 (Ar–C), 54.2, 42.0 (NCH2), 19.5, 15.5, 13.0 (CH3). Anal. 
Calc. for C13H20N5Au: C, 35.22; H, 4.55; N, 15.80. Found: C, 35.33; H, 4.18; N, 15.68%. MS 
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General procedure for the syntheses of gold(I) tetrazolato complexes 25–27. 
The appropriate azido precursor complex (22–24) (1 equiv) was dissolved in CH2Cl2. CN-tBu 
(10 equiv) was added to the solution, and the resulting mixture was allowed to stand unstirred 
overnight, shielded from light. The reaction mixture was then concentrated under vacuum, 
and hexane was added to precipitate the crude product. The precipitate was collected and 
washed with hexane and diethyl ether, and dried under vacuum, affording the product as a 
white powder in all three cases. 
 
[Au(CN4-tBu)(FPyr)] (25). Yield = 89%. 1H NMR (500 MHz, CDCl3): 
δ 4.48 (t, 2 H, 3J(H,H) = 5.70 Hz, NCH2), 3.99 (t, 2 H, 3J(H,H) = 5.70 
Hz, NCH2), 2.58 (t, 2 H, 
3J(H,H) = 6.30 Hz, CH2), 2.54 (t, 2 H, 
3J(H,H) 
= 6.30 Hz, CH2), 2.13 (br m, 4 H, CH2), 1.85 (br m, 11 H, CH2 and CH3), 1.76 (m, 2 H, CH2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 184.2 (Ccarbene), 182.4 (N=C–N), 144.0, 126.8 (Ar–C), 
58.9 (NC(CH3)3), 51.7, 46.5 (NCH2), 32.2 (NC(CH3)3), 23.4, 23.0, 22.7, 22.3, 21.53, 21.48 
(CH2). Anal. Calc. for C16H25N6Au0.15CH2Cl2: C, 37.95; H, 4.99; N, 16.44. Found: C, 
38.09; H, 4.73; N, 16.44%. MS (ESI): m/z = 499 [M + H]+, 997 [2M + H]+. 
 
[Au(CN4-tBu)(iPr2-bimy)] (26). Yield = 87%. 1H NMR (500 MHz, 
CDCl3): δ 7.66 (dd, 2 H, Ar–H), 7.38 (dd, 2 H, Ar–H), 5.55 (m, 2 H, 
3J(H,H) = 6.95 Hz, NCH), 1.87 (s, 9 H, NC(CH3)3), 1.77 (d, 12 H, 
3J(H,H) = 6.95 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 192.1 (Ccarbene), 
179.0 (N=C–N), 133.4, 124.5, 113.8 (Ar–C), 58.7 (NC(CH3)3), 54.5 (NCH), 32.2 
(NC(CH3)3), 22.6 (NCH(CH3)2). Anal. Calc. for C18H27N6Au0.1CH2Cl2: C, 40.79; H, 5.14; 
N, 15.77. Found: C, 41.05; H, 5.14; N, 15.43%. MS (ESI): m/z = 525 [M + H]+, 1049 [2M + 
H]+. 
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[Au(CN4-tBu)(ADC)] (27). Yield = 84%. 1H NMR (500 MHz, CDCl3): 
δ 8.53 (br s, 1 H, NH), 6.97–7.04 (m, 3 H, Ar–H), 3.99 (m, 2 H, 3J(H,H) 
= 6.95 Hz, NCH2CH3), 3.60 (m, 2 H, 
3J(H,H) = 6.90 Hz, NCH2CH3), 
2.24 (s, 6 H, CH3), 1.32 (s, 9 H, NC(CH3)3), 1.28 (m, 6 H, NCH2CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 206.2 (Ccarbene), 178.9 (N=C–N), 139.0, 137.4, 129.0, 
128.4 (Ar–C), 58.5 (NC(CH3)3), 53.0, 42.4 (NCH2CH3), 31.6 (NC(CH3)3), 19.6 (CH3), 15.8, 
13.2 (NCH2CH3). Anal. Calc. for C18H29N6Au: C, 41.07; H, 5.55; N, 15.96. Found: C, 41.00; 
H, 5.57; N, 15.83%. MS (ESI): m/z = 527 [M + H]+, 549 [M + Na]+, 1053 [2M + H]+. 
 
General procedure for the syntheses of gold(I) tetrazolin-5-ylidene complexes 28 and 29. 
The appropriate precursor complex (26 or 27) (1 equiv) was dissolved in a mixture of CH2Cl2 
and acetonitrile. HBF4 (~54% in diethyl ether) (1.2 equiv) was added to the solution, and the 
resulting mixture was stirred at ambient temperature for 30 mins. The reaction mixture was 
then concentrated under vacuum, and hexane was added to precipitate the products, which 
was obtained as a white powder in both cases. 
 
[Au(iPr2-bimy)(tBu-tzy)]BF4 (28). Yield = 93%. 1H NMR (500 
MHz, CDCl3): δ 14.85 (s, 1 H, NH), 7.72 (dd, 2 H, Ar–H), 7.42 
(dd, 2 H, Ar–H), 5.48 (m, 2 H, 3J(H,H) = 6.95 Hz, NCH), 1.96 (s, 
9 H, NC(CH3)3), 1.80 (d, 12 H, 
3J(H,H) = 6.95 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, 
CDCl3): δ 185.6 (Ccarbene (iPr2-bimy)), 177.9 (Ccarbene (tBu-tzy)), 133.2, 125.1, 114.2 (Ar–C), 
63.4 (NC(CH3)3), 55.5 (NCH), 31.6 (NC(CH3)3), 22.6 (NCH(CH3)2). 
19F{1H} NMR (282.4 
MHz, CDCl3): δ –74.81 (10BF4), –74.87 (11BF4). Anal. Calc. for C18H28N6AuBF40.1CH2Cl2: 
C, 35.02; H, 4.58; N, 13.54. Found: C, 35.16; H, 4.84; N, 13.15%. MS (ESI): m/z = 525 [M – 
BF4]
+. 
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[Au(ADC)(tBu-tzy)]BF4 (29). Yield = 97%. 1H NMR (300 MHz, 
CDCl3): δ 14.52 (br s, 1 H, NH), 7.57 (br s, 1 H, NH), 7.15–7.05 (m, 
3 H, Ar–H), 4.04 (m, 2 H, 3J(H,H) = 7.05 Hz, NCH2CH3), 3.58 (m, 2 
H, 3J(H,H) = 6.90 Hz, NCH2CH3), 2.25 (s, 6 H, CH3), 1.40–1.34 (m, 
15 H, NC(CH3)3) and NCH2CH3). 
13C{1H} NMR (75.5 MHz, CDCl3): δ 201.3 (Ccarbene 
(ADC)), 177.7 (Ccarbene (
tBu-tzy)), 138.5, 137.7, 129.3, 129.1 (Ar–C), 62.8 (NC(CH3)3), 54.1, 
42.4 (NCH2CH3), 31.1 (NC(CH3)3), 19.4 (CH3), 15.8, 12.9 (NCH2CH3). 
19F{1H} NMR (282.4 
MHz, CDCl3): δ –74.68 (10BF4), –74.74 (11BF4). Anal. Calc. for C18H30N6Au: C, 35.20; H, 
4.92; N, 13.68. Found: C, 35.23; H, 4.93; N, 13.69%. MS (ESI): m/z = 527 [M – BF4]+. 
 
General procedure for the syntheses of Au(I)/Pd(II) hetero-bimetallic complexes 30–32. 
The appropriate tetrazolato complex (25–27) (1 equiv) was dissolved in CH2Cl2. [PdBr2(iPr2-
bimy)]2 (0.5 equiv) was added to the solution, and the resulting suspension was stirred for 2 h 
at ambient temperature. The reaction mixture was then concentrated under vacuum to ~5 mL, 
and diethyl ether was added to precipitate the product, which was obtained as a yellow 
powder in all three cases. 
 
[(FPyr)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (30). 
Yield = 84%. 1H NMR (500 MHz, CDCl3): δ 7.50 (br m, 2 H, 
Ar–H), 7.13 (br m, 2 H, Ar–H), 6.59 (br m, 2 H, NCH), 4.64 (br 
t, 2 H, NCH2), 3.99 (br t, 2 H, NCH2), 2.69 (br t, 2 H, CH2), 
2.60 (br t, 2 H, CH2), 2.05 (br m, 4 H, CH2), 1.82 (br m, 13 H, 
CH2 and CH3), 1.63 (d, 12 H, 
3J(H,H) = 6.30 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, 
CDCl3): δ 183.7, (Ccarbene (FPyr)), 182.7 (N=C–N), 165.4 (Ccarbene (iPr2-bimy)), 143.8, 134.2, 
126.9, 122.4, 113.0 (Ar–C), 59.7 (NC(CH3)3), 54.7 (NCH), 52.0, 46.6 (NCH2), 31.9 
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(NC(CH3)3), 23.5, 23.3, 22.8, 22.2, 21.5( 2) (CH2), 21.2 (NCH(CH3)2). Anal. Calc. for 
C29H43N8AuPdBr2: C, 36.02; H, 4.48; N, 11.59. Found: C, 36.36; H, 4.35; N, 11.69%. MS 
(ESI): m/z = 887 [M – Br]+. 
 
[(iPr2-bimy)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (31). 
Yield = 90%. 1H NMR (500 MHz, CDCl3): δ 7.71 (dd, 2 H, Ar–
H), 7.49 (dd, 2 H, Ar–H), 7.40 (dd, 2 H, Ar–H), 7.13 (dd, 2 H, 
Ar–H), 6.54 (m, 2 H, 3J(H,H) = 6.90 Hz, NCH(CH3)2), 5.78 (m, 
2 H, 3J(H,H) = 6.90 Hz, NCH(CH3)2), 1.84 (s, 9 H, NC(CH3)3), 
1.77 (d, 12 H, 3J(H,H) = 7.55 Hz, NCH(CH3)2), 1.68 (d, 12 H, 
3J(H,H) = 6.90 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 190.5 (Ccarbene (iPr2-
bimy (Au))), 180.9 (N=C–N), 164.8 (Ccarbene (iPr2-bimy (Pd))), 134.2, 133.4, 124.5, 122.5, 
114.0, 113.0 (Ar–C), 59.9 (NC(CH3)3), 54.73, 54.69 (NCH(CH3)2), 31.9 (NC(CH3)3), 22.6, 
21.3 (NCH(CH3)2). Anal. Calc. for C31H45N8AuPdBr2: C, 37.50; H, 4.57; N, 11.29. Found: C, 
37.83; H, 4.79; N, 11.10%. MS (ESI): m/z = 913 [M – Br]+, 993 [M + H]+. 
 
[(ADC)Au(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] (32). 
Yield = 82%. 1H NMR (500 MHz, CDCl3): δ 7.55 (dd, 2 H, Ar–
H), 7.38 (s, 1 H, NH), 7.17 (dd, 2 H, Ar–H), 7.03–7.06 (m, 3 H, 
Ar–H), 6.54 (m, 3J(H,H) = 6.90 Hz, NCH(CH3)2), 4.29 (m, 2 H, 
3J(H,H) = 6.90 Hz, NCH2CH3), 3.61 (m, 2 H, 
3J(H,H) = 6.95 
Hz, NCH2CH3), 2.35 (s, 6 H, CH3), 1.76 (d, 12 H, 
3J(H,H) = 
6.90 Hz, NCH(CH3)2), 1.41 (m, 6 H, NCH2CH3), 1.37 (s, 9 H, NC(CH3)3). 
13C{1H} NMR 
(125.8 MHz, CDCl3): δ 206.0 (Ccarbene (ADC)), 180.4 (N=C–N), 165.3 (Ccarbene (iPr2-bimy)), 
138.3, 137.2, 134.2, 129.3, 128.8, 122.5, 113.1 (Ar–C), 59.4 (NC(CH3)3), 54.8 (NCH(CH3)2), 
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53.8 (NCH2CH3), 42.1 (NCH2CH3), 31.5 (NC(CH3)3), 21.4 (NCH(CH3)2), 19.7 (CH3), 16.2 
(NCH2CH3), 13.3 (NCH2CH3). Anal. Calc. for C31H47N8AuPdBr2: C, 37.42; H, 4.76; N, 
11.26. Found: C, 37.28; H, 4.66; N, 11.32%. MS (ESI): m/z = 914 [M – Br]+, 993 [M – H]–. 
 
[AuBr2(CN4-tBu)(iPr2-bimy) (33). Complex 26 (63 mg, 0.12 mmol) 
was dissolved in CH2Cl2 (20 mL). Elemental bromine (7.5 L, 0.15 
mmol) was added to the solution, and the resulting mixture was 
stirred for 1 h at ambient temperature. The reaction mixture was then concentrated under 
vacuum to ~ 5 mL. Hexane was added to precipitate the product, which was obtained as a 
yellow powder (75 mg, 0.11 mmol, 91 %). 1H NMR (500 MHz, CDCl3): δ 7.77 (br m, 2 H, 
Ar–H), 7.43 (dd, 2 H, Ar–H), 5.56 (br m, 1 H, NCH), 5.39 (br m, 1 H, NCH), 1.91 (s, 9 H, 
NC(CH3)3), 1.80 (br m, 12 H, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 165.8 
(Ccarbene), 149.2 (N=C–N), 134.0, 133.5, 125.1, 115.1, 114.8 (Ar–C), 60.2 (NC(CH3)3), 55.5 
(NCH), 31.9 (NC(CH3)3), 21.6, 21.4 (NCH(CH3)2). Anal. Calc. for 
C18H27N6AuBr20.75CH2Cl20.25C6H14: C, 31.61; H, 4.19; N, 10.92. Found: C, 31.65; H, 
4.24; N, 10.87%. MS (ESI): m/z = 685 [M + H]+. 
 
[(iPr2-bimy)AuBr2(µ-η1C:η1N-(CN4-tBu))PdBr2(iPr2-bimy)] 
(34). Method 1: Complex 33 (45 mg, 0.07 mmol) was dissolved 
in CH2Cl2 (20 mL), and [PdBr2(
iPr2-bimy)]2 (31 mg, 0.03 mmol) 
was added to the solution. The resulting mixture was stirred for 
2 h at ambient temperature. The reaction mixture was 
concentrated under vacuum to ~ 5 mL, and diethyl ether was 
added to precipitate the product. The product was obtained as a yellow powder (64 mg, 0.06 
mmol, 84%). 
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Method 2: Complex 31 (86 mg, 0.09 mmol) was dissolved in CH2Cl2 (25 mL), and elemental 
bromine (5.4 L, 0.11 mmol) was added. The resulting mixture was stirred for 1 h at ambient 
temperature. The reaction mixture was then concentrated to ~ 5 mL under vacuum. Diethyl 
ether was added to precipitate the product, which was obtained as a yellow powder (92 mg, 
0.08 mmol, 92%). 
1H NMR (500 MHz, CDCl3): δ 7.80 (br m, 2 H, Ar–H), 7.57 (br m, 2 H, Ar–H), 7.43 (br m, 2 
H, Ar–H), 7.17 (br m, 2 H, Ar–H), 6.62 (m, 2 H, 3J(H,H) = 6.95 Hz, NCH(CH3)2), 6.39 (m, 1 
H, 3J(H,H) = 6.95 Hz, NCH(CH3)2), 5.58 (br m, 1 H, NCH(CH3)2), 1.96 (s, 9 H, NC(CH3)3), 
1.81 (d, 6 H, 3J(H,H) = 6.90 Hz, NCH(CH3)2), 1.76 (d, 12 H, 
3J(H,H) = 6.90 Hz, 
NCH(CH3)2), 1.72 (d, 6 H, 
3J(H,H) = 6.95 Hz, NCH(CH3)2). 
13C{1H} NMR (125.8 MHz, 
CDCl3): δ 162.5 (Ccarbene (iPr2-bimy (Pd))), 161.8 (Ccarbene (iPr2-bimy (Au))), 152.6 (N=C–N), 
134.2, 134.1, 133.6, 125.02, 124.95, 122.5, 115.5, 114.9, 113.2 (Ar–C), 62.4 (NC(CH3)3), 
55.13, 55.07, 54.9 (NCH(CH3)2), 32.0 (NC(CH3)3), 21.9, 21.5, 21.4 (NCH(CH3)2). Anal. 
Calc. for C31H45N8AuPdBr4: C, 32.30; H, 3.93; N, 9.72. Found: C, 32.31; H, 3.86; N, 9.55%. 
MS (ESI): m/z = 685 [M – [PdBr2(iPr2-bimy)] + H]+, 1071 [M – Br]+. 
 
[IrCl(COD)(iPr2-bimy)] (35). 1,3-diisopropylbenzimidazolium bromide 
(258 mg, 0.91 mmol) was dissolved in CH2Cl2 (30 mL), and Ag2O (127 
mg, 0.55 mmol) was added to the solution. The resulting mixture was 
stirred for 4 h at ambient temperature, shielded from light. The reaction mixture was then 
filtered over Celite into a solution of [Ir(µ-Cl)(COD)]2 (306 mg, 0.46 mmol) in CH2Cl2 (50 
mL). The resulting mixture was stirred overnight at ambient temperature, shielded from light. 
The reaction mixture was then filtered over Celite, and the filtrate was collected and 
concentrated to ~ 10 mL under vacuum. The crude product was purified by column 
chromatography on silica, with diethyl ether as the eluent. The bright yellow band was 
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collected, and the solvent was removed under vacuum. The product was obtained as a bright 
yellow powder (309 mg, 0.57 mmol, 63%). 1H NMR (300 MHz, CDCl3): δ 7.51 (dd, 2 H, Ar–
H), 7.15 (dd, 2 H, Ar–H), 6.19 (m, 2 H, 3J(H,H) = 7.08 Hz, NCH), 4.67 (br m, 2 H, CH 
(COD)), 3.10 (br m, 2 H, CH (COD)), 2.26 (br m, 4 H, CH2 (COD)), 1.77 (d, 6 H, 
3J(H,H) = 
7.08 Hz, CH3), 1.64 (d, 6 H, 
3J(H,H) = 7.08 Hz, CH3) (Signals from the other 2 CH2 groups of 
the COD ligand are overlapped with the CH3 signals in the 1.85–1.60 ppm region). 13C{1H} 
NMR (75.5 MHz, CDCl3): δ 190.3 (Ccarbene), 134.4, 122.3, 113.0 (Ar–C), 86.0 (COD), 54.2 
(NCH), 52.2, 34.2, 30.0 (COD), 22.2, 21.3 (CH3). Anal. Calc. for C21H30N2IrCl: C, 46.87; H, 
5.62; N, 5.21. Found: C, 46.64; H, 5.37; N, 5.12%. MS (ESI): m/z = 544 [M – Cl + CH3CN]+. 
 
[Ir(COD)(iPr2-bimy)(PPh3)]PF6 (36). Complex 35 (83 mg, 0.15 
mmol) and PPh3 (49 mg, 0.19 mmol) were dissolved in acetone (30 
mL). KPF6 (85 mg, 0.46 mmol) dissolved in acetone (10 mL) was 
then added to the solution. The resulting mixture was stirred for 1 h 
at ambient temperature. Subsequently, the solvent of the reaction mixture was removed under 
vacuum. The resulting residue was suspended in CH2Cl2 and filtered. The solvent of the 
filtrate was removed under vacuum, and the resulting residue was washed with diethyl ether 
(3  20 mL). After drying under vacuum, the product was obtained as a bright reddish-orange 
powder (127 mg, 0.14 mmol, 91%). 1H NMR (300 MHz, CDCl3): δ 7.52 (dd, 2 H, Ar–H), 
7.41 (m, 3 H, Ar–H), 7.29 (m, 8 H, Ar–H), 7.17 (m, 6 H, Ar–H), 5.65 (m, 2 H, 3J(H,H) = 6.90 
Hz, NCH), 4.57 (br m, 2 H, CH (COD)), 3.79 (br m, 2 H, CH (COD)), 2.46 (br m, 4 H, CH2), 
2.20–2.09 (br m, 4 H, CH2), 1.74 (d, 6 H, 3J(H,H) = 6.90 Hz, CH3), 0.85 (d, 6 H, 3J(H,H) = 
6.90 Hz, CH3). 
13C{1H} NMR (75.5 MHz, CDCl3): δ 183.9 (d, 2J(C,P) = 9.3 Hz, Ccarbene), 
134.5 (Ar–C), 134.4, 132.1 (d, Ar–C), 131.1, 130.4 (Ar–C), 129.8 (d, Ar–C), 123.6, 113.6 
(Ar–C), 86.3 (d, COD), 82.2 (COD), 55.2 (NCH), 31.6, 30.9 (d, COD), 22.9, 19.4 (CH3). 
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31P{1H} NMR (121.5 MHz, CDCl3): δ 17.8 (PPh3), –143.6 (m, PF6). 19F{1H} NMR (282.4 
MHz, CDCl3): δ 2.43 (d, PF6). Anal. Calc. for C39H45N2IrP2F6: C, 51.48; H, 4.98; N, 3.08. 
Found: C, 51.82; H, 4.81; N, 3.03%. MS (ESI): m/z = 765 [M – PF6]+. 
 
[IrCl(CO)2(iPr2-bimy)] (37). Complex 35 (55 mg, 0.10 mmol) was 
dissolved in CH2Cl2 (20 mL). Carbon monoxide was bubbled into the 
solution for 3 mins with stirring, at ambient temperature. The reaction 
mixture was concentrated to ~ 5 mL under vacuum, and hexane was added to precipitate the 
product, which was obtained as a pale yellow powder (46 mg, 0.09 mmol, 92%). 1H NMR 
(500 MHz, CDCl3): δ 7.65 (dd, 2 H, Ar–H), 7.31 (dd, 2 H, Ar–H), 5.84 (m, 2 H, 3J(H,H) = 
6.95 Hz, NCH), 1.70 (m, 12 H, CH3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 181.9 (CO), 
181.0 (Ccarbene), 168.7 (CO), 133.9, 123.9, 114.1 (Ar–C), 55.3 (NCH), 21.7, 21.3 (CH3). Anal. 
Calc. for C15H18N2IrClO2: C, 37.07; H, 3.73; N, 5.76. Found: C, 37.08; H, 3.71; N, 5.81%. 
MS (ESI): m/z = 423 [M – Cl – CO]+. 
 
[Ir(CN-tBu)3(iPr2-bimy)]PF6 (38). CN-tBu (41 µL, 0.36 mmol) 
and a solution of KPF6 (55 mg, 0.30 mmol) in acetone (10 mL) 
were sequentially added to a solution of 35 (55 mg, 0.10 mmol) in 
acetone (30 mL). The resulting suspension was stirred for 1 h at ambient temperature, 
following which the solvent of the reaction mixture was removed under vacuum. The residue 
was suspended in CH2Cl2 (25 mL) and filtered over Celite. The solvent of the filtrate was 
concentrated to ~ 5 mL under vacuum, and a mixture of hexane and diethyl ether was added. 
The resulting precipitate was collected, washed with hexane (3  15 mL), and dried under 
vacuum. The product was obtained as a yellowish-brown powder (50 mg, 0.06 mmol, 62%). 
1H NMR (500 MHz, CDCl3): δ 7.62 (dd, 2 H, Ar–H), 7.30 (dd, 2 H, Ar–H), 5.78 (m, 2 H, 
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3J(H,H) = 6.95 Hz, NCH), 1.62 (d, 12 H, 3J(H,H) = 6.95 Hz, NCH(CH3)2), 1.54 (s, 9 H, 
CNC(CH3)3), 1.40 (s, 18 H, CNC(CH3)3). 
13C{1H} NMR (125.8 MHz, CDCl3): δ 179.1 
(Ccarbene), 133.9, 123.6, 113.4 (Ar–C), 58.5, 58.1 (CNC(CH3)3), 54.9 (NCH), 31.1, 30.9 
(CNC(CH3)3), 21.5 (CH3) (Signals due to the isocyanide carbon atoms attached to the iridium 
center could not be detected despite extended analysis time). 31P{1H} NMR (202.4 MHz, 
CDCl3): –143.7 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 2.40 (d, PF6). Anal. Calc. for 
C28H45N5IrPF6·0.1CH2Cl2: C, 42.33; H, 5.71; N, 8.78. Found: C, 42.20; H, 5.76; N, 9.00%. 
MS (ESI): m/z = 644 [M – PF6]+. 
 
[Ir(CHCl2)Cl(CN-tBu)3(iPr2-
bimy)]PF6 (39). Complex 38 
(80 mg, 0.10 mmol) was 
dissolved in CHCl3 (25 mL). 
The resulting solution was allowed to stand at ambient temperature for 48 h, following which 
the solvent of the reaction mixture was removed under vacuum. The product was obtained as 
a white powder (88 mg, 0.10 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ 7.82 (br m, 2 H, 
Ar–H), 7.37 (br m, 2 H, Ar–H), 6.27 (s, 1 H, CHCl2), 5.49 (br m, 2 H, NCH), 1.85 (d, 6 H, 
3J(H,H) = 6.90 Hz, NCH(CH3)2), 1.78 (d, 6 H, 
3J(H,H) = 6.72 Hz, NCH(CH3)2), 1.73 (s, 9 H, 
CNC(CH3)3), 1.63 (s, 18 H, CNC(CH3)3). 
13C{1H} NMR (75.5 MHz, CDCl3): δ 154.1 
(Ccarbene), 133.6, 124.6, 115.0 (Ar–C), 61.6, 60.9 (CNC(CH3)3), 54.3 (NCH), 30.8, 30.5 
(CNC(CH3)3), 22.9, 22.3 (CH3) (Signals due to the isocyanide carbon atoms attached to the 
iridium center, and the CHCl2 ligand could not be detected despite extended analysis time). 
31P{1H} NMR (121.5 MHz, CDCl3): –143.7 (m, PF6). 19F{1H} NMR (282.4 MHz, CDCl3): δ 
3.08 (d, PF6). Anal. Calc. for C29H46N5IrCl3PF6: C, 38.35; H, 5.11; N, 7.71. Found: C, 38.26; 
H, 4.89; N, 7.56%. MS (ESI): m/z = 762 [M – PF6]+. 
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X-ray Diffraction Studies 
X-ray data were collected with a Bruker AXS SMART APEX diffractometer, using Mo K 
radiation at 100(2) K (4, 5, 8·CHCl3, 9, 12–14, 21–24, 26, 27, 29, 32·2CCl4·CH2Cl2, 35, and 
36·CHCl3), 125(2) K (31), or 223(2) K (2 and 3) with the SMART suite of programs.
68 Data 
were processed and corrected for Lorentz and polarization effects with SAINT69 and for 
absorption effects with SADABS.70 Structural solution and refinement were carried out with 
the SHELXTL suite of programs.71 The structures were solved by direct methods to locate the 
heavy atoms, followed by difference maps for the light, non-hydrogen atoms. Hydrogen 
atoms were placed in calculated positions, except in cases where they could be located on 
difference maps. All non-hydrogen atoms were generally given anisotropic displacement 
parameters in the final model. A summary of the most important crystallographic data is 
provided in the following section (see Selected X-ray Crystallographic Data). 
 
Cytotoxicity Studies 
In vitro toxicities of 2, 5–19, and cisplatin were determined by CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay (MTS). NCI-H1666 cells were maintained in complete 
RPMI medium with 10% FBS and 1% PenStrep. Standard DMSO solutions of the compounds 
were diluted with complete RPMI medium, with the final concentration of DMSO in each 
diluted solution being less than 0.5%. The cells were seeded in 96-well plates at a density of 
2000 cells/well in 100 μL of complete RPMI medium without antibiotics and cultured 
overnight at 37 °C in a humidified atmosphere containing 5% CO2. A 100 μL portion of 
media containing different concentrations of the compounds was added in the wells to a final 
concentration from 0.0005 to 50 μM. Compound-free solvent controls were also included. 
After a 72-hour incubation period, 20 μL of CellTiter 96 AQueous One Reagent containing 
the tetrazolium compound MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
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2-(4-sulfophenyl)-2H-tetrazolium, inner salt) was added to each well. After incubation for 
about 3 h, the absorbance was measured at 490 nm using a Tecan Infinite M200 plate reader. 
Nonlinear regression analysis was performed using GraphPad Prism version 5.00 for 
Windows to calculate the IC50 value of each compound. 
 
Computational Studies 
Geometry optimization for complex 25 was performed using the Gaussian 09 program72 at the 
B3LYP level,73 and analysis of the vibrational frequencies confirms the optimized structure to 
represent a minima on the potential energy surface. Single-point energy calculations were 
carried out with the Gaussian 09 program at the same level of theory, using either the 
molecular structure obtained from single-crystal X-ray diffraction experiments (26, 27, 31, 35, 
and 36), or the optimized structure (25). Hydrogen, carbon and nitrogen atoms were described 
with a cc-pVDZ basis set74, and the Stuttgart/Köln ECP60MDF pseudopotential75 was used in 
combination with the adapted basis set cc-pVDZ-PP for the description of bromine, 
palladium, iridium, and gold.76 All basis sets were retrieved from the EMSL Basis Set 
Library.77 Natural bond orbital (NBO) analysis78 was performed to obtain a localized form of 
the wavefunction. Natural atomic orbitals (NAOs) are used to express natural localized 




Cyclic voltammetry experiments were conducted using a Metrohm AUTOLABIII 
potentiostat equipped with a standard three-electrode cell, controlled by a computer through 
the NOVA 1.8 software. All experiments were carried out with a Metrohm glassy carbon (3 
mm) working electrode, a Metrohm platinum (2 mm) counter electrode, and a Metrohm 
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Ag/AgCl (3M KCl) reference electrode. The ferrocenium/ferrocene (Fc+/Fc) redox couple 
was used as an internal reference. 
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Selected X-ray Crystallographic Data 
 2 3 4 5 
formula C11H16N2AuCl C11H16N2AuBr C11H16N2AuI C24H34N4AuPF6 
fw 408.67 453.13 500.12 720.49 
colour, habit colourless, block colourless, block yellow, block colourless, block 
crystal size (mm) 0.52 × 0.30 × 0.30 0.44 × 0.30 × 0.20 0.36 × 0.20 × 0.20 0.40 × 0.20 × 0.10 
temp (K) 223(2) 223(2) 100(2) 100(2) 
cryst syst monoclinic monoclinic monoclinic monoclinic 
space group P21/n P21/n P21/n P21/c 
a (Å) 10.5789(8) 10.6918(12) 11.1860(17) 10.6027(13) 
b (Å) 8.7778(7) 8.7944(9) 8.4161(12) 13.8516(16) 
c (Å) 12.9485(10) 13.1485(14) 13.456(2) 18.185(2) 
 () 90 90 90 90 
 () 91.434(2) 91.423(2) 90.756(3) 102.706(2) 
 () 90 90 90 90 
V (Å3) 1202.01(16) 1235.9(2) 1266.6(3) 2605.3(5) 
Z 4 4 4 4 
Dc (g cm
-3) 2.258 2.435 2.623 1.837 
radiation used Mo K Mo K Mo K Mo K 
 (mm-1) 12.430 15.106 14.023 5.772 
 () 2.46–27.49 2.43–27.49 2.35–27.49 1.87–27.50 
no. of unique data 2757 2822 2898 5976 
max, min transmission 0.1181, 0.0597 0.1521, 0.0576 0.1658, 0.0811 0.4305, 0.2906 
final R indices  
[I > 2(I)] 
R1 = 0.0447,  
wR2 = 0.1151 
R1 = 0.0384,  
wR2 = 0.0852 
R1 = 0.0373,  
wR2 = 0.0895 
R1 = 0.0349,  
wR2 = 0.0854 
R indices (all data) 
R1 = 0.0527,  
wR2 = 0.1194 
R1 = 0.0515,  
wR2 = 0.0899 
R1 = 0.0437,  
wR2 = 0.0919 
R1 = 0.0426,  
wR2 = 0.0999 
goodness-of-fit on F2 1.052 1.029 1.113 1.137 
peak/hole (e Å-3) 2.577/–1.587 1.604/–1.009 2.566/–1.154 1.983/–1.146 
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Continued… 
 8·CHCl3 9 12 13 
formula C33H35N4AuCl3PF6 C26H38N4AuPF6 C24H30N4AuPF6 C29H31N2AuP2F6 
fw 935.94 748.54 716.46 780.46 
colour, habit colourless, block colourless, block colourless, block colourless, block 
crystal size (mm) 0.13 × 0.11 × 0.04 0.27 × 0.11 × 0.05 0.36 × 0.26 × 0.10 0.28 × 0.08 × 0.06 
temp (K) 100(2) 100(2) 100(2) 100(2) 
cryst syst triclinic triclinic triclinic orthorhombic 
space group P-1 P-1 P-1 Pna21 
a (Å) 8.5921(10) 11.000(3) 9.7407(7) 20.319(4) 
b (Å) 11.9088(14) 12.126(3) 12.5859(9) 13.683(3) 
c (Å) 17.348(2) 12.426(3) 12.8314(9) 10.2795(19) 
 () 87.324(2) 109.051(5) 60.9630(10) 90 
 () 87.300(2) 98.373(5) 73.3970(10) 90 
 () 80.596(2) 108.802(5) 68.0160(10) 90 
V (Å3) 1747.9(4) 1423.7(6) 1264.80(16) 2857.9(9) 
Z 2 2 2 4 
Dc (g cm
-3) 1.778 1.746 1.881 1.814 
radiation used Mo K Mo K Mo K Mo K 
 (mm-1) 4.546 5.285 5.944 5.321 
 () 1.18–27.50 2.04–27.49 1.83–27.50 2.48–27.50 
no. of unique data 8012 6505 5813 6506 
max, min transmission 0.8391, 0.5895 0.7780, 0.3295 0.5879, 0.2234 0.7407, 0.3173 
final R indices  
[I > 2(I)] 
R1 = 0.0400,  
wR2 = 0.0890 
R1 = 0.0384,  
wR2 = 0.0850 
R1 = 0.0244,  
wR2 = 0.0622 
R1 = 0.0373,  
wR2 = 0.0764 
R indices (all data) 
R1 = 0.0469,  
wR2 = 0.1057 
R1 = 0.0449,  
wR2 = 0.0873 
R1 = 0.0263,  
wR2 = 0.0703 
R1 = 0.0494,  
wR2 = 0.0816 
goodness-of-fit on F2 1.132 1.068 1.266 0.973 
peak/hole (e Å-3) 1.687/–2.077 2.285/–2.254 1.227/–0.647 2.555/–0.638 
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Continued… 
 14 21 22 23 
formula C29H31N2AuO3P2F6 C26H38N4AuBF4 C11H16N5Au C13H18N5Au 
fw 828.46 690.38 415.25 441.29 
colour, habit colourless, block pale yellow, block colourless, block colourless, thin plate 
crystal size (mm) 0.17 × 0.11 × 0.08 0.40 × 0.26 × 0.24 0.40 × 0.30 × 0.30 0.30 × 0.10 × 0.06 
temp (K) 100(2) 100(2) 100(2) 100(2) 
cryst syst orthorhombic orthorhombic monoclinic monoclinic 
space group P212121 Pbca P21/c P21/m 
a (Å) 10.5523(6) 11.6941(8) 8.4014(6) 10.2665(8) 
b (Å) 14.9858(8) 19.2402(13) 16.5697(11) 6.8280(5) 
c (Å) 19.0095(10) 24.2721(17) 8.7780(6) 11.2119(9) 
 () 90 90 90 90 
 () 90 90 94.1970(10) 115.5090(10) 
 () 90 90 90 90 
V (Å3) 3006.1(3) 5461.1(6) 1218.70(15) 709.33(9) 
Z 4 8 4 2 
Dc (g cm
-3) 1.831 1.679 2.263 2.066 
radiation used Mo K Mo K Mo K Mo K 
 (mm-1) 5.072 5.437 12.057 10.364 
 () 2.14–27.50 2.12–25.00 2.43–27.47 2.01–27.47 
no. of unique data 6905 4796 2790 1752 
max, min transmission 0.6871, 0.4793 0.3553, 0.2197 0.1226, 0.0859 0.5752, 0.1470 
final R indices  
[I > 2(I)] 
R1 = 0.0452,  
wR2 = 0.0847 
R1 = 0.0407,  
wR2 = 0.0922 
R1 = 0.0319,  
wR2 = 0.0780 
R1 = 0.0435,  
wR2 = 0.0954 
R indices (all data) 
R1 = 0.0514,  
wR2 = 0.0869 
R1 = 0.0483,  
wR2 = 0.0955 
R1 = 0.0345,  
wR2 = 0.0792 
R1 = 0.0459,  
wR2 = 0.0969 
goodness-of-fit on F2 1.004 1.063 1.106 1.220 
peak/hole (e Å-3) 2.037/–1.176 2.645/–1.837 2.502/–1.541 6.994/–3.464 
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Continued… 
 24 26 27 29 
formula C13H20N5Au C18H27N6Au C18H29N6Au C18H30N6AuBF4 
fw 443.31 524.42 526.44 614.26 
colour, habit colourless, thin plate colourless, block colourless, block colourless, block 
crystal size (mm) 0.48 × 0.37 × 0.05 0.50 × 0.50 × 0.40 0.44 × 0.31 × 0.19 0.33 × 0.22 × 0.19 
temp (K) 100(2) 100(2) 100(2) 100(2) 
cryst syst monoclinic monoclinic monoclinic monoclinic 
space group P21/c P21/n P21/n P21/c 
a (Å) 8.865(3) 9.6480(8) 13.982(2) 23.985(3) 
b (Å) 26.316(8) 19.9096(17) 10.6446(16) 13.2607(16) 
c (Å) 13.216(4) 11.3954(10) 28.082(4) 21.712(3) 
 () 90 90 90 90 
 () 106.766(6) 111.5070(10) 101.651(3) 96.618(3) 
 () 90 90 90 90 
V (Å3) 2952.0(15) 2036.5(3) 4093.5(11) 6859.7(14) 
Z 8 4 8 12 
Dc (g cm
-3) 1.995 1.710 1.708 1.784 
radiation used Mo K Mo K Mo K Mo K 
 (mm-1) 9.962 7.236 7.200 6.482 
 () 1.55–27.48 2.05–27.50 1.48–27.50 0.85–27.50 
no. of unique data 6741 4685 9374 15741 
max, min transmission 0.6357, 0.0868 0.1599, 0.1226 0.3416, 0.1438 0.4305, 0.3301 
final R indices  
[I > 2(I)] 
R1 = 0.0354,  
wR2 = 0.0890 
R1 = 0.0323,  
wR2 = 0.0751 
R1 = 0.0431,  
wR2 = 0.0983 
R1 = 0.0456,  
wR2 = 0.0985 
R indices (all data) 
R1 = 0.0410,  
wR2 = 0.0927 
R1 = 0.0362,  
wR2 = 0.0768 
R1 = 0.0588,  
wR2 = 0.1079 
R1 = 0.0649,  
wR2 = 0.1103 
goodness-of-fit on F2 1.032 1.081 1.128 1.106 
peak/hole (e Å-3) 2.924/–2.172 3.131/–1.443 3.003/–2.350 2.387/–1.069 
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 31 32·2CCl4·CH2Cl2 35 36·CHCl3 
formula C31H45N8AuPdBr2 C34H49N8AuPdBr2Cl10 C21H30N2IrCl C40H46N2IrCl3P2F6 
fw 992.94 1387.50 538.12 1029.28 
colour, habit yellow, block colourless, thin plate orange, block red, block 
crystal size (mm) 0.45 × 0.23 × 0.20 0.19 × 0.10 × 0.07 0.24 × 0.14 × 0.06 0.34 × 0.24 × 0.18 
temp (K) 125(2) 100(2) 100(2) 100(2) 
cryst syst orthorhombic triclinic monoclinic monoclinic 
space group P212121 P-1 P21/n P21/c 
a (Å) 13.6702(16) 10.0922(14) 9.7449(11) 10.3521(13) 
b (Å) 14.9318(18) 13.1673(18) 15.3635(17) 20.877(3) 
c (Å) 17.808(2) 19.950(3) 13.3649(14) 18.725(2) 
 () 90 106.490(3) 90 90 
 () 90 90.463(3) 97.621(2) 95.059(2) 
 () 90 102.654(3) 90 90 
V (Å3) 3634.9(7) 2473.3(6) 1983.3(4) 4031.1(9) 
Z 4 2 4 4 
Dc (g cm
-3) 1.814 1.863 1.802 1.696 
radiation used Mo K Mo K Mo K Mo K 
 (mm-1) 6.757 5.516 6.873 3.651 
 () 1.78–27.50 1.66–27.50 2.44–27.50 1.95–27.50 
no. of unique data 8306 11328 4554 9261 
max, min transmission 0.3451, 0.1510 0.6987, 0.4204 0.6832, 0.2893 0.5595, 0.3700 
final R indices  
[I > 2(I)] 
R1 = 0.0277,  
wR2 = 0.0562 
R1 = 0.0703,  
wR2 = 0.1795 
R1 = 0.0324,  
wR2 = 0.0683 
R1 = 0.0339,  
wR2 = 0.0757 
R indices (all data) 
R1 = 0.0323,  
wR2 = 0.0569 
R1 = 0.1005,  
wR2 = 0.1970 
R1 = 0.0457,  
wR2 = 0.0733 
R1 = 0.0415,  
wR2 = 0.0789 
goodness-of-fit on F2 0.898 1.045 0.985 1.023 
peak/hole (e Å-3) 2.096/–0.959 5.078/–2.304 1.705/–0.937 1.906/–0.990 
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Appendix 
Dose-response curves for complexes 2, 5–19, and cisplatin on the NCI-H1666 cell line 
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